KOL | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
KOL简历 Harry Roger Büller
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Harry Roger Büller：影响统计
运行报告
| Concept | World rank |
|---|---|
| failure cip | #1 |
| uesvt uedvt | #1 |
| clinically suspected uedvt | #1 |
| clinical decision rule | #1 |
| enoxaparin tb402 | #1 |
| frequency venous thromboembolism | #1 |
| death category | #1 |
| apixaban conventional therapy | #1 |
| 50 rivaroxaban | #1 |
| tb402 enoxaparin | #1 |
| malignancy achieved inr | #1 |
| test venography | #1 |
| cancer patients uedvt | #1 |
| heparin org 10172 | #1 |
| doacs anatomical extent | #1 |
| dvt anticoagulants | #1 |
| aged nadroparin | #1 |
| vte difference | #1 |
| nadroparin aspirin | #1 |
| patients normal tests | #1 |
| ddimer test combination | #1 |
| cdr dimer | #1 |
| leg veins patients | #1 |
| presentation category | #1 |
| levels procoagulant factors | #1 |
| idraparinux months | #1 |
| 3633 patients edoxabantreated | #1 |
| absolute annual incidences | #1 |
| enoxaparin initial treatment | #1 |
| pulmonary embolism fondaparinux | #1 |
| anticoagulants chemotherapy | #1 |
| annual incidence patients | #1 |
| hokusai vte cancer | #1 |
| heparins data | #1 |
| quantitative ddimer test | #1 |
| phase doacs | #1 |
| matisse trials | #1 |
| sensitivity 100 percent | #1 |
| year prophylaxis | #1 |
| diagnostic strategy primary | #1 |
| ctscan qscan | #1 |
| uesvt recurrent vte | #1 |
| daily dalteparin treatment | #1 |
| calfvein thrombi | #1 |
| patients laalleles | #1 |
| wells simplified | #1 |
| gogh dvt trial | #1 |
| anticoagulant treatment vte | #1 |
| individuals air travel | #1 |
| time recombinant | #1 |
| vte risk day | #1 |
| conventional therapy enoxaparin | #1 |
| tb402 prevention | #1 |
| treatment experimental thrombosis | #1 |
| acute treatment lmwh | #1 |
| beta thromboglobulin org | #1 |
| doac recipients | #1 |
| rivaroxaban acute dvt | #1 |
| heparins vitamin antagonists | #1 |
| thromboembolism 3 | #1 |
| ddimer test result | #1 |
| ultrasonography dvt | #1 |
| aptt org 10172 | #1 |
| submassive incidence | #1 |
| fviii normal levels | #1 |
| calf dvt ultrasound | #1 |
| lmwh edoxaban | #1 |
| failure diagnostic management | #1 |
| enoxaparin vkas | #1 |
| mutation arg506 | #1 |
| distal clots | #1 |
| 0·2 3633 patients | #1 |
| combination nonhigh cdr | #1 |
| subsequent diagnosis malignancy | #1 |
| ldf cus | #1 |
| cdr ddimer test | #1 |
| simplified rule proportion | #1 |
| pulmonary angiography study | #1 |
| p0001 saline | #1 |
| therapeutic doses lmwh | #1 |
| extended anticoagulation apixaban | #1 |
| unexplained dvt | #1 |
| recurrence major bleeding | #1 |
| preference doacs | #1 |
| compression ultrasonography detection | #1 |
| venography tests | #1 |
| embolism suspected | #1 |
| elevated cardiac troponins | #1 |
| pulmonary embolism basis | #1 |
| venography feasibility | #1 |
| initial treatment dvt | #1 |
| venous thrombus growth | #1 |
| departments orthopedic surgery | #1 |
| elderly outpatients combination | #1 |
| superficial thrombophlebitis incidence | #1 |
| intestinal microbiota coagulation | #1 |
| falsenormal | #1 |
| avidin idrabiotaparinux | #1 |
| lmprovement | #1 |
| lmwh users incidence | #1 |
| platelets iqr | #1 |
| —brachial | #1 |
| 547253 | #1 |
| heparin initial | #1 |
| probability normal | #1 |
| controlledstudy | #1 |
| factual hemorrhage heparin | #1 |
| treatment idraparinux | #1 |
| original wells | #1 |
| relative risks carriers | #1 |
| feasibility venography | #1 |
| orthopedic surgery netherlands | #1 |
| nadroparin therapeutic dose | #1 |
| practiceassistants | #1 |
| ankle brachial prevalence | #1 |
| cancer patients patients | #1 |
| fxainhibitors | #1 |
| patients initial heparin | #1 |
| 8h flight | #1 |
| age∗10μg | #1 |
| presenting location women | #1 |
| limited screening 95 | #1 |
| evaluable patients apixaban | #1 |
| normal levels fviii | #1 |
| elevated fviii age | #1 |
| heparin survival | #1 |
| standardintensity vkas | #1 |
| fibrinolysis levels | #1 |
| 9 incidence | #1 |
| age multiple comorbidities | #1 |
| scores occult cancer | #1 |
| efficiency subgroups | #1 |
| protein resistance control | #1 |
| vkas efficacy | #1 |
| doacs cirrhosis patients | #1 |
| rfviia 3 | #1 |
| study centre duration | #1 |
| reduceddose noacs stroke | #1 |
| patients idraparinux | #1 |
| ufh grade 1a | #1 |
| einstein dvt patients | #1 |
| major bleeding cancer | #1 |
| synthetic selective factor | #1 |
| obstetric complications relatives | #1 |
| easier monitoring | #1 |
| ultrasonography diagnostic | #1 |
| pvoq | #1 |
| 2 diagnostic management | #1 |
| cdr normal | #1 |
| rtap lmwh | #1 |
| prolactin venous thrombosis | #1 |
| cus strategies | #1 |
| patients wells rule | #1 |
| 750 μg l1 | #1 |
| thromboembolism relatives | #1 |
| noacs prevention | #1 |
| hyperhomocysteinemia relatives | #1 |
| undvt | #1 |
| patients examiner | #1 |
| treatment cumulative incidence | #1 |
| rfviia fondaparinux | #1 |
| compression ultrasonography patients | #1 |
| standardintensity vkas doacs | #1 |
| elevated biomarkers hospital | #1 |
| suspected perfusion scan | #1 |
| symptomatic legs dvt | #1 |
| patients clinical probability | #1 |
| false normal | #1 |
| botticelli dvt dose‐ranging | #1 |
| analysis hokusai | #1 |
| compression ultrasound dvt | #1 |
| protein levels mortality | #1 |
| ddimer test patients | #1 |
| khorana | #1 |
| wellsrule | #1 |
| wells cdr | #1 |
| matisse dvt | #1 |
| apc resistance tests | #1 |
| treatment venous | #1 |
| anticoagulant fondaparinux | #1 |
| 95ci tb402 | #1 |
| perelated death category | #1 |
| clinical presentation category | #1 |
| cancer cdr | #1 |
| apixaban randomized patients | #1 |
| current comprehensions | #1 |
| nadroparin patients | #1 |
| warfarin cstatistic | #1 |
| quantitative dimer | #1 |
| 2630 pilots | #1 |
| 500 org | #1 |
| inherited thrombophilia patients | #1 |
| studies ttr | #1 |
| patients deep | #1 |
| anticoagulants probability | #1 |
| association protein levels | #1 |
| excluding pulmonary | #1 |
| unexplained dvt patients | #1 |
| polyethylenglycolhirudin | #1 |
| cstatistic major bleeding | #1 |
| pulmonary embolism role | #1 |
| 3633 patients edoxaban | #1 |
| patients protein deficiencies | #1 |
| safety outcome | #1 |
| bmi fondaparinux | #1 |
| studies doac treatment | #1 |
| cvc crt | #1 |
| deep vein thrombosis | #1 |
| uedvt clinical | #1 |
| ecq ankle brachial | #1 |
| cancer patients ufh | #1 |
| treated vka | #1 |
| pulmonary embolism tests | #1 |
| vitamin antagonists treatment | #1 |
| early time recurrence | #1 |
| dimer clinical | #1 |
| 97 compression ultrasonography | #1 |
| fviii vte | #1 |
| patients malignancy | #1 |
| older patients cdr | #1 |
| qscan 3 weeks | #1 |
| hemorrhage heparin | #1 |
| timerequirement | #1 |
| procoagulant factors levels | #1 |
| intravenous injections lmwh | #1 |
| ddimer levels cdr | #1 |
| somittrial | #1 |
| idraparinux placebo | #1 |
| wellscdrscore | #1 |
| p0424 | #1 |
| heparins inhibition | #1 |
| patients reduceddose noacs | #1 |
| embolism radionuclide | #1 |
| proportion pulmonary embolism | #1 |
| xageneration | #1 |
| bleeding clinically | #1 |
| relatives normal fviii | #1 |
| rnapc2 united states | #1 |
| weight heparinoid | #1 |
| risk percentage points | #1 |
| acenocoumarol efficacy | #1 |
| survival lmwh | #1 |
| 378 patients edoxaban | #1 |
| longhaul flight | #1 |
| risk pulmonary embolism | #1 |
| cdrs patients | #1 |
| age recurrent vte | #1 |
| oral apixaban treatment | #1 |
| outcome recurrent | #1 |
| risk homozygous women | #1 |
| elevated fviii | #1 |
| patients tests prevalence | #1 |
| orthopedic thromboprophylaxis | #1 |
| symptomatic pts | #1 |
| carriers recurrence | #1 |
| dimer result | #1 |
| hokusaivte trial patients | #1 |
| fviii women | #1 |
| vitamin antagonists time | #1 |
| graft patency patency | #1 |
| included patients study | #1 |
| strategy abdominal pelvic | #1 |
| fviii venous thromboembolism | #1 |
| edoxabantreated | #1 |
| 95 elevated ctni | #1 |
| extended anticoagulation doacs | #1 |
| months standard therapy | #1 |
| selective ddimer thresholds | #1 |
| chest perfusion scintigraphy | #1 |
| netherlands lmwh | #1 |
| prescriptionbased | #1 |
| heparins cancer patients | #1 |
| anticoagulation period | #1 |
| influenza case patients | #1 |
| relatives mutation | #1 |
| replacement vka | #1 |
| uedvt terms | #1 |
| long haul flights | #1 |
| ivte clinical practice | #1 |
| uesvt mortality | #1 |
| impedance thrombophlebitis | #1 |
| travel venous thromboembolism | #1 |
| combination cdr | #1 |
| 95 3633 patients | #1 |
| 7268 patients suspected | #1 |
| doacs factor | #1 |
| probability categories | #1 |
| oral rivaroxaban treatment | #1 |
| pulmonary embolism studies | #1 |
| thrombosis vitamin | #1 |
| thrombophilia late loss | #1 |
| severity clinical presentation | #1 |
| wells rules | #1 |
| prothrombin individuals | #1 |
| presenting vte location | #1 |
| placebo 25mg apixaban | #1 |
| safety idraparinux | #1 |
| doacs initial heparin | #1 |
| 2479 relatives | #1 |
| mdct expert radiologist | #1 |
| nonhigh cdr | #1 |
| ddimer test | #1 |
| idraparinux vte | #1 |
| heparins cancer spread | #1 |
| symptomatic recurrent | #1 |
| baseline characteristics duration | #1 |
| suspected symptomatic | #1 |
| dvt 56 | #1 |
| reported incidence vte | #1 |
| patients acute recurrent | #1 |
| rfviia idraparinux | #1 |
| leg ultrasonography patients | #1 |
| exclusion pulmonary | #1 |
| dimer test | #1 |
| idraparinux standard therapy | #1 |
| ldfr symptomatic legs | #1 |
| perelated death classification | #1 |
| compression ultrasonography | #1 |
| vka treatment treatment | #1 |
| 023 relatives | #1 |
| cstatistic model discrimination | #1 |
| prospective management study | #1 |
| proximal location ipe | #1 |
| atherosclerosis hemophilia patients | #1 |
| fetal loss miscarriage | #1 |
| positive vte | #1 |
| presentation major | #1 |
| org heparin | #1 |
| diagnosis deepvein thrombosis | #1 |
| bleeding einstein | #1 |
| dvt 3 | #1 |
| segmental subsegmental | #1 |
| rnapc2 groups placebo | #1 |
| 393 patients warfarin | #1 |
| ft4 level patients | #1 |
| patients tb402 | #1 |
| normal dimer | #1 |
| single dose tb402 | #1 |
| cancer patients cdr | #1 |
| severe presentation patients | #1 |
| presenting location vte | #1 |
| dvt impedance plethysmography | #1 |
| heparin initial treatment | #1 |
| abelacimab | #1 |
| dose response apixaban | #1 |
| oral edoxaban dose | #1 |
| lowmolecularweight heparin treatment | #1 |
| scan pulmonary embolism | #1 |
| ufh grade | #1 |
| 3 rfviia | #1 |
| local radiologist | #1 |
| members symptomatic carriers | #1 |
| thiazoles venous | #1 |
| lmwh immobilization | #1 |
| ml1 ctpa | #1 |
| current practise | #1 |
| sspe proximal | #1 |
| factor viii relatives | #1 |
| 36 papers | #1 |
| embolism wells | #1 |
| placebo rnapc2 | #1 |
| plasma concentration fviii | #1 |
| idraparinux versus | #1 |
| oral administration bsf | #1 |
| vte study | #1 |
| recurrent vte immobilization | #1 |
| pulmonary embolism cdr | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| bleeding risk lmwh | #1 |
| referral basis | #1 |
| absolute thrombotic risk | #1 |
| clinically suspected cancer | #1 |
| crt cvc | #1 |
| subcutaneous nadroparin placebo | #1 |
| vte trial | #1 |
| warfarin cancer patients | #1 |
| coagulation clinical | #1 |
| lmwhs 95 | #1 |
| pulmonary embolism life | #1 |
| 5 avidin infusion | #1 |
| heparin vitamin antagonist | #1 |
| elevated fviii patients | #1 |
| alternative diagnoses patients | #1 |
| avws prevalence | #1 |
| progression svt | #1 |
| extensive screening cancer | #1 |
| venous thrombosis vwf | #1 |
| 65±9years | #1 |
| studies 3 months | #1 |
| aged venous | #1 |
| simplified geneva score | #1 |
| 5 years lmwh | #1 |
| dose rnapc2 | #1 |
| 12 months edoxaban | #1 |
| ccus 4 | #1 |
| vitamin anticoagulants | #1 |
| diagnostic management patients | #1 |
| elevated levels fviii | #1 |
| cdrscore | #1 |
| 15 lmwh | #1 |
| equinox study | #1 |
| proportion 75 years | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| elderly patients dvt | #1 |
| category death | #1 |
| riskstroponin | #1 |
| lmwh plasma levels | #1 |
| quantitative ddimer tests | #1 |
| deepvein thrombosis incidence | #1 |
| strategies abdominal pelvic | #1 |
| carriers thrombophilic defects | #1 |
| recurrent thrombosis pts | #1 |
| 7268 patients | #1 |
| administration lmwh | #1 |
| ventilation lung scanning | #1 |
| svt lmwh | #1 |
| heparinoid | #1 |
| control anticardiolipin antibodies | #1 |
| guideline adherence justification | #1 |
| diagnostic strategies patients | #1 |
| protecht shr | #1 |
| puerperium diagnostic suspicion | #1 |
| major bleeds vka | #1 |
| netherlands 5 years | #1 |
| clinical uedvt | #1 |
| selective beta‐blocker treatment | #1 |
| management study | #1 |
| idrabiotaparinux idraparinux | #1 |
| rule cdr | #1 |
| death vte studies | #1 |
| fxainhibitors vka recipients | #1 |
| pharmacological methods prophylaxis | #1 |
| progression vte | #1 |
| fondaparinux rfviia injection | #1 |
| carriers relative risks | #1 |
| 3 idraparinux | #1 |
| reduceddose noacs | #1 |
| amplify trial | #1 |
| patients advanced malignancy | #1 |
| randomized studies efficacy | #1 |
| org aptt | #1 |
| acenocoumarol initial treatment | #1 |
| anticoagulant treatment patients | #1 |
| pregnancyrelated complications relatives | #1 |
| recurrence bleeding risk | #1 |
| d‐dimer test | #1 |
| previous surveys netherlands | #1 |
| category fxainhibitors | #1 |
| edoxaban dalteparin | #1 |
| uesvt median | #1 |
| rule exclusion | #1 |
| 00515 | #1 |
| inr range ttr | #1 |
| 5‐snp scores | #1 |
| vte risk coc | #1 |
| association travel | #1 |
| ventricular dysfunction edoxaban | #1 |
| heparin vitamin | #1 |
| isolated deficiencies proteins | #1 |
| clinical probability exclusion | #1 |
| respondents lmwh | #1 |
| protein mortality | #1 |
| diagnostic strategies strategies | #1 |
| anticoagulants double | #1 |
| ambulatory computers | #1 |
| venous thromboembolism edoxaban | #1 |
| upper extremity uedvt | #1 |
| cart lower levels | #1 |
| combination cdrs | #1 |
| rabinovpaulin | #1 |
| pulmonary embolism idraparinux | #1 |
| tomography angiography vte | #1 |
| standalone ddimer testing | #1 |
| safety 60 dose | #1 |
| hokusai‐vte cancer study | #1 |
| laalleles platelets | #1 |
| rnapc2 inhibition | #1 |
| mortality postthrombotic symptoms | #1 |
| aptt org | #1 |
| hellp syndrome mutations | #1 |
| ctscanreading | #1 |
| heparin acenocoumarol | #1 |
| adjunct thrombolysis | #1 |
| withheld | #1 |
| relevant major | #1 |
| types major bleeding | #1 |
| fxiaso enoxaparin | #1 |
| threemonth incidence | #1 |
| 208791 | #1 |
| idraparinux 25 | #1 |
| 5395 patients | #1 |
| ili score | #1 |
| relatives tafi levels | #1 |
| thrombo‐embolic events | #1 |
| neoplasms heparin | #1 |
| duration heparin treatment | #1 |
| prophylaxis idraparinux | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| plateletactivating antibodies risk | #1 |
| specificity pulmonary embolism | #1 |
| wells clinical | #1 |
| idraparinux vitamin antagonist | #1 |
| vkas lmwh | #1 |
| study ecq | #1 |
| patients mismatched scan | #1 |
| excluded pulmonary | #1 |
| extra hospital visits | #1 |
| fviii homocysteine | #1 |
| einsteindvt | #1 |
| low levels ft4 | #1 |
| prediction models recurrence | #1 |
| netherlands vka | #1 |
| extended treatment edoxaban | #1 |
| doses 75 microg | #1 |
| international thrombosis experts | #1 |
| vte airline pilots | #1 |
| rivaroxaban replacement | #1 |
| intrinsic coagulation vivo | #1 |
| dvt symptomatic | #1 |
| elevated ctni patients | #1 |
| edoxaban warfarin groups | #1 |
| smoking patency | #1 |
| lmwh rtap | #1 |
| patients retropubic prostatectomy | #1 |
| intracranial clinical presentation | #1 |
| 6 months avidin | #1 |
| lmwh departments | #1 |
| local radiologist experts | #1 |
| wound haematoma | #1 |
| clinical probability patients | #1 |
| uesvt patients | #1 |
| hokusaivte trial | #1 |
| cip diagnostic management | #1 |
| avidin vte | #1 |
| rule dimer | #1 |
| dvt costs | #1 |
| patients uedvt uesvt | #1 |
| suspected cdr | #1 |
| d‐dimer level | #1 |
| strategies diagnostic management | #1 |
| venous thromboembolism episode | #1 |
| symptomatic recurrent vte | #1 |
| vte addition | #1 |
| vivo coagulation factor | #1 |
| single‐detector row | #1 |
| 50 years combination | #1 |
| 12 kg1 enoxaparin | #1 |
| controlled trials thrombophilia | #1 |
| presence venous thrombosis | #1 |
| desogestrelcontaining coagulation factors | #1 |
| patency smokers | #1 |
| prevalence coagulation | #1 |
| efficacy outcome | #1 |
| crp test patients | #1 |
| rnapc2 groups | #1 |
| symptomatic venous | #1 |
| lmwh replacement | #1 |
| thrombosis vte | #1 |
| treat thrombosis | #1 |
| relatives normal levels | #1 |
| presentation 1 week | #1 |
| rivaroxaban lmwh vka | #1 |
| clinical probability risk | #1 |
| rhir lmwh | #1 |
| pulmonary embolism metaanalysis | #1 |
| cancer patients cvcs | #1 |
| carriers pulmonary embolism | #1 |
| incidence venous | #1 |
| lmwh venous thrombosis | #1 |
| edoxaban cancer patients | #1 |
| xainhibitors | #1 |
| ifngamma pselectin | #1 |
| hokusaivte study | #1 |
| travel‐related venous thrombosis | #1 |
| infections gentamicin | #1 |
| enoxaparin heparin treatment | #1 |
| coagulationinhibiting | #1 |
| 123362 | #1 |
| subcutaneous idraparinux | #1 |
| realtime bmode ultrasonography | #1 |
| rnapc2 patients | #1 |
| vte arterial | #1 |
| residual thrombotic mass | #1 |
| messages justification | #1 |
| quantitative ddimer testing | #1 |
| standard therapy months | #1 |
| outcome clinically | #1 |
| patients inherited thrombophilia | #1 |
| ldf diagnosis | #1 |
| antithrombotic prescriptions adherence | #1 |
| pulmonary angiography ultrasonography | #1 |
| probability cdr | #1 |
| ddimer result | #1 |
| abnormal ipg | #1 |
| tests pulmonary embolism | #1 |
| adjusted dose ufh | #1 |
| obese hemophilic patients | #1 |
| efficacy heparin therapy | #1 |
| idraparinux patients | #1 |
| patients treatment duration | #1 |
| clinically suspected dvt | #1 |
| prophylaxis crt | #1 |
| wellscdr | #1 |
| incidental symptomatic vte | #1 |
| incidence ctni | #1 |
| deficiency proteins | #1 |
| enoxaparin primary efficacy | #1 |
| coagulation factors markers | #1 |
| subcutaneous length life | #1 |
| patients advanced prostate | #1 |
| initial heparin patients | #1 |
| fetal loss stillbirth | #1 |
| death venous thromboembolism | #1 |
| predefined outcomes vte | #1 |
| poc test patients | #1 |
| pvo ctscan | #1 |
| survival fondaparinux | #1 |
| smoking graft patency | #1 |
| bleeding rates quality | #1 |
| screening carriers | #1 |
| intensity vkas doacs | #1 |
| rabinov | #1 |
| ultrasonography leg veins | #1 |
| sgs pretest probability | #1 |
| 250 patients cancer | #1 |
| thrombophilia patients doacs | #1 |
| idraparinux | #1 |
| avidin placebo | #1 |
| milliliter enoxaparin | #1 |
| probabilityscan | #1 |
| clinically relevant disease | #1 |
| lowmolecularweight heparin category | #1 |
| constans score | #1 |
| axa activity 5 | #1 |
| rate recurrent | #1 |
| standard therapy rivaroxaban | #1 |
| ultrasound compression ultrasound | #1 |
| successful attenuation | #1 |
| followup overt cancer | #1 |
| advanced malignancy | #1 |
| lmwh delivery | #1 |
| recurrent vte doacs | #1 |
| revascularisation procedures patients | #1 |
| individualized duration | #1 |
| 53 amputations | #1 |
| simple diagnostic strategy | #1 |
| idraparinux 6 months | #1 |
| gentamicin patients netilmicin | #1 |
| embolism randomized | #1 |
| thrombophlebitis tomography | #1 |
| lmwh acute treatment | #1 |
| women elevated levels | #1 |
| patients artificial graft | #1 |
| departments pharmacological prophylaxis | #1 |
| ipe expert radiologists | #1 |
| obese controls difference | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| monoclonal antibodies apc | #1 |
| decisions duration | #1 |
| fetal loss carriers | #1 |
| pulmonary embolism carriers | #1 |
| cancer edoxaban | #1 |
| intravenous unfractionated | #1 |
| tests prevalence abi | #1 |
| acquired atiii deficiency | #1 |
| 95 intracranial | #1 |
| pioped study study | #1 |
| recommendations dvt | #1 |
| guidelines abi | #1 |
| echocardiography normotensive patients | #1 |
| predefined outcomes | #1 |
| qscan | #1 |
| nondiagnostic lung scan | #1 |
| patients antithrombotic prescriptions | #1 |
| vka recipients | #1 |
| 5mg apixaban | #1 |
| normotensive patients studies | #1 |
| cdr physicians | #1 |
| animal female heparin | #1 |
| tinaquant assay comparison | #1 |
| principal safety | #1 |
| tb402 50 | #1 |
| baseline pvo | #1 |
| vte location | #1 |
| wells rule primary | #1 |
| mutation relatives | #1 |
| laalleles | #1 |
| pyridines recurrence | #1 |
| 560 pharmacies | #1 |
| dvt 69 | #1 |
| vka netherlands | #1 |
| vte fatal | #1 |
| safety clinical utility | #1 |
| popliteal veins sensitivity | #1 |
| amplify trial apixaban | #1 |
| doubleheterozygotes | #1 |
| vte occurred | #1 |
| edoxaban east asian | #1 |
| outpatients symptomatic dvt | #1 |
| relatives elevated levels | #1 |
| ventilation scan chest | #1 |
| chromogenic endotoxin | #1 |
| tsh antitpo | #1 |
| travellers thrombosis | #1 |
| normal ddimer result | #1 |
| asymptomatic extension | #1 |
| silent dvt | #1 |
| vte procoagulant activity | #1 |
| patients khorana | #1 |
| matisse clinical trials | #1 |
| chest perfusion scan | #1 |
| initial heparin edoxaban | #1 |
| perfusion scan | #1 |
| ultrasound strategies patients | #1 |
| uedvt recurrent vte | #1 |
| venous thromboembolism idraparinux | #1 |
| 0·620·74 | #1 |
| patients compression ultrasonography | #1 |
| combination ddimer testing | #1 |
| embolism sensitivity | #1 |
| preferred oral anticoagulant | #1 |
| noncarriers annual incidence | #1 |
| bleeding risk treatment | #1 |
| ivte | #1 |
| subsequent symptomatic cancer | #1 |
| fondaparinux unfractionated | #1 |
| pulmonary angiography strategies | #1 |
| probability ventilation | #1 |
| postthrombotic symptoms patients | #1 |
| dalteparin major bleeding | #1 |
| lowmolecularweight heparin 95 | #1 |
| edoxaban risk factors | #1 |
| apixaban extended treatment | #1 |
| patients enoxaparin vkas | #1 |
| oral anticoagulants phase | #1 |
| probability lung scan | #1 |
| method factor | #1 |
| factor viii homocysteine | #1 |
| women factor leiden | #1 |
| sustained antithrombotic effects | #1 |
| level loss patency | #1 |
| increasing levels ft4 | #1 |
| efficacy vte | #1 |
| 20210a mutation | #1 |
| double heterozygous carriers | #1 |
| idraparinux recurrent thromboembolism | #1 |
| combination cdrscore | #1 |
| venous thrombosis hyperglycemia | #1 |
| relatives antithrombin | #1 |
| total vte patients | #1 |
| standard treatment idraparinux | #1 |
| 25mg apixaban | #1 |
| efficacy conventional treatment | #1 |
| rivaroxaban standard therapy | #1 |
| initial treatment patients | #1 |
| respondents 60 | #1 |
| systematic search cteph | #1 |
| prothrombin 20210a mutation | #1 |
| antidote vitamin | #1 |
| acute recurrent patients | #1 |
| vitamin antagonist patients | #1 |
| vte day | #1 |
| pulmonary embolism | #1 |
| lmwhmediated | #1 |
| combined training gps | #1 |
| normal lung scan | #1 |
| dalteparin 6 months | #1 |
| early discharge strategies | #1 |
| tb402 12 kg1 | #1 |
| comparison vidas assay | #1 |
| dose daily edoxaban | #1 |
| recurrent dvt dvt | #1 |
| crptest | #1 |
| uesvt | #1 |
| loss subsequent pregnancy | #1 |
| cdrscore combination | #1 |
| patients ivte | #1 |
| fviii hyperhomocysteinemia | #1 |
| einsteinextension | #1 |
| failure rate efficiency | #1 |
| tests venography | #1 |
| cancer clinical presentation | #1 |
| questionnaires thrombosis | #1 |
| non‐invasive diagnostic work‐up | #1 |
| abdominal pelvic strategies | #1 |
| cancer patients cancer | #1 |
| enoxaparin vkas treatment | #1 |
| apc resistance factor | #1 |
| s1p1activation | #1 |
| achieved inr patients | #1 |
| variable d‐dimer thresholds | #1 |
| scenarioanalysis | #1 |
| relevant bleeding | #1 |
| consensus strategy strategy | #1 |
| united states rnapc2 | #1 |
| reocclusion antithrombotic drug | #1 |
| vka share | #1 |
| endotoxemia tests | #1 |
| inr studies | #1 |
| 0·2 edoxabantreated | #1 |
| pvo qscan | #1 |
| recurrent vte statin | #1 |
| normal venogram | #1 |
| cdr ddimer levels | #1 |
| acenocoumarol heparin | #1 |
| rivaroxaban dvt treatment | #1 |
| flebography | #1 |
| category perelated death | #1 |
| prevention topic guidelines | #1 |
| proximal extent ipe | #1 |
| hokusai‐vte trial | #1 |
| 69 conclusions | #1 |
| suspected deep | #1 |
| topic thrombophlebitis | #1 |
| abnormal vaginal bleeding | #1 |
| activecontrol placebo | #1 |
| women edoxaban | #1 |
| wells rule exclusion | #1 |
| coagulation fibrinolytic proteins | #1 |
| dalteparin vte treatment | #1 |
| timeperiod | #1 |
| venous thrombosis recurrence | #1 |
| scores riete score | #1 |
| evaluable patients 95 | #1 |
| fviii concentration | #1 |
| double reports | #1 |
| patients unexplained dvt | #1 |
| normal ddimer concentration | #1 |
| compression ultrasonography presentation | #1 |
| reduceddose noacs warfarin | #1 |
| submassive elevated ctni | #1 |
| iii plg | #1 |
| beneficial lmwh | #1 |
| role exclusion | #1 |
| thromboembolism treated | #1 |
| venous thrombosis pregnancy | #1 |
| strategies ultrasonography | #1 |
| cancer 145 patients | #1 |
| molecular weight fondaparinux | #1 |
| casedescription | #1 |
| gastrointestinal cancer edoxaban | #1 |
| thrice daily gentamicin | #1 |
| simplified wells rule | #1 |
| models development studies | #1 |
| venous thrombosis mutations | #1 |
| thromboinflammation cardiovascular disease | #2 |
| death vte | #2 |
| pulmonary embolism purpose | #2 |
| graft occlusion patients | #2 |
| uptake noacs | #2 |
| 8292 patients | #2 |
| safety pravastatin therapy | #2 |
| levothyroxine exposure | #2 |
| n832 | #2 |
| cdr variables cdr | #2 |
| vein compressibility | #2 |
| composite scores area | #2 |
| rnapc2 | #2 |
| primary hospitalbased strategies | #2 |
| years 36 | #2 |
| protein rnapc2 | #2 |
| central localization | #2 |
| exclude pulmonary | #2 |
| failure rate strategy | #2 |
| heparin treatment influenza | #2 |
| impedance plethysmography patients | #2 |
| vte svt | #2 |
| rnapc2 doses | #2 |
| rivaroxaban thiazoles | #2 |
| thyroid hormone coagulation | #2 |
| amuse strategy | #2 |
| patients khorana score | #2 |
| simplified wells | #2 |
| vitamin antagonists quality | #2 |
| venous thrombophlebitis | #2 |
| recombinant hirudin cgp | #2 |
| sr34006 | #2 |
| sspe patients patients | #2 |
| efficiency diagnostic strategies | #2 |
| amadeus study | #2 |
| relation coagulation factors | #2 |
| medscape | #2 |
| influenza prothrombotic state | #2 |
| primary efficacy outcome | #2 |
| patients oral factor | #2 |
| endotoxininduced activation coagulation | #2 |
| gauge plethysmography | #2 |
| clinical prediction model | #2 |
| uedvt cancer patients | #2 |
| pregnancy coc | #2 |
| ddimer determination | #2 |
| thrombophilic disorders | #2 |
| patients peripheral graft | #2 |
| uedvt performance | #2 |
| intrinsic cascade | #2 |
| recurrence thromboembolism | #2 |
| cancer addition | #2 |
| thrombosis normal | #2 |
| bleeding complications treatment | #2 |
| n1423 | #2 |
| diagnostic lung | #2 |
| received edoxaban | #2 |
| duration anticoagulant | #2 |
| adapted ddimer thresholds | #2 |
| heparin compounds | #2 |
| heparin nadroparin | #2 |
| rule proportion | #2 |
| wells cdr patients | #2 |
| thrombophilic defects risk | #2 |
| exposure flights | #2 |
| normohomocysteinemic relatives | #2 |
| 95 dvt | #2 |
| c1173t dimorphism | #2 |
| risk khorana | #2 |
| brain metastases doacs | #2 |
| single administration tb402 | #2 |
| hemorr2hages atria scores | #2 |
| months 25 | #2 |
| deficiencies proteins | #2 |
| simplired test | #2 |
| age‐adjusted d‐dimer testing | #2 |
| vte 1000 personyears | #2 |
| alife study | #2 |
| endogenous activated protein | #2 |
| common alternative diagnoses | #2 |
| coagulation factors prolactin | #2 |
| comparator individuals 95 | #2 |
| ufh survival | #2 |
| factor iia | #2 |
| primary healthcare secondary | #2 |
| treated anticoagulants | #2 |
| intermediate phenotype vte | #2 |
| nct00633893 | #2 |
| risk deep | #2 |
| dimer thresholds | #2 |
| incidental vte | #2 |
| pregnancy venous thrombosis | #2 |
| hokusai vte | #2 |
| nematode anticoagulant | #2 |
| efficiency original score | #2 |
| vte 12 | #2 |
| travel venous | #2 |
| blood coagulation inhibition | #2 |
| vte elevated fviii | #2 |
| standardised time intervals | #2 |
| ventilation scanning | #2 |
| clinical pretest probability | #2 |
| fvl carriers carriers | #2 |
| fibrinolysis influenza | #2 |
| absolute incidence | #2 |
| rule combined | #2 |
| pravastatin therapy children | #2 |
| idraparinux vitamin | #2 |
| oral direct inhibitors | #2 |
| normal ddimer test | #2 |
| test cancer | #2 |
| mild risk factor | #2 |
| limits cancer | #2 |
| suspected upper | #2 |
| lower clinical utility | #2 |
| patients abi measurement | #2 |
| patients hemorr2hages | #2 |
| undiagnosed malignancy | #2 |
| 95 0·2 | #2 |
| decision rule | #2 |
| beta‐receptor blockade | #2 |
| 95 cancer patients | #2 |
| crnm bleeds | #2 |
| incidence recurrent | #2 |
| vitamin antagonist rivaroxaban | #2 |
| fibrinolytic proteins | #2 |
| bleeding edoxaban | #2 |
| compression doppler | #2 |
| biomarkers casecontrol studies | #2 |
| heparin effective | #2 |
| annual incidences | #2 |
| plasmin activity inhibition | #2 |
| warfarintreated | #2 |
| women therapeutic doses | #2 |
| ufh 6 months | #2 |
| patients prior vte | #2 |
| plasma concentrations endotoxin | #2 |
| fviii increased risk | #2 |
| clinical probability estimate | #2 |
| exclusion pulmonary embolism | #2 |
| bleeding occurred | #2 |
| coagulation fibrinolytic | #2 |
| life treatment duration | #2 |
| ageadjusted ddimer testing | #2 |
| administration rviia | #2 |
| regression pravastatin | #2 |
| mutation 35 | #2 |
| clinically suspected | #2 |
| hellp syndrome prevalence | #2 |
| uedvt efficiency | #2 |
| angioplasty clopidogrel | #2 |
| pharmacological strategies | #2 |
| presentation dvt | #2 |
| subsegmental emboli | #2 |
| lmwh users | #2 |
| subcutaneous length | #2 |
| major bleeding cindexes | #2 |
| principal safety outcome | #2 |
| treated edoxaban | #2 |
| employees longhaul flight | #2 |
| mutations cleavage sites | #2 |
| vte orthopedic surgery | #2 |
| prolactin relation | #2 |
| healthcare settings findings | #2 |
| impedance plethysmography diagnosis | #2 |
| resource utilisation treatment | #2 |
| global public awareness | #2 |
| venographically | #2 |
| serum tnf activity | #2 |
| treatment ttr | #2 |
| cdr wells cdr | #2 |
| levels coagulation factors | #2 |
| duration anticoagulant treatment | #2 |
| efficiency strategy | #2 |
| referred patients secondary | #2 |
| performance constans rule | #2 |
| hasbled score hemorr2hages | #2 |
| major bleeding recurrent | #2 |
| major clinically | #2 |
| recombinant nematode | #2 |
| blood coagulation rnapc2 | #2 |
| cancer recurrent vte | #2 |
| statins recurrent vte | #2 |
| hmb primary outcome | #2 |
| mdct reference standard | #2 |
| 3306 patients | #2 |
| pulmonary embolism efficacy | #2 |
| apixaban lmwh vka | #2 |
| risk anticoagulation therapy | #2 |
| wells cdr cdr | #2 |
| khorana protecht | #2 |
| hospitalbased strategies | #2 |
| major bleeding intermediate | #2 |
| extended constans score | #2 |
| enoxaparin warfarin | #2 |
| recurrent deep | #2 |
| measurement ankle brachial | #2 |
| euro138 | #2 |
| gcpg | #2 |
| quality warfarin treatment | #2 |
| suspected pulmonary embolism | #2 |
| embolism deep | #2 |
| sustained antithrombotic | #2 |
| concomitant thrombophilic | #2 |
| major bleeding edoxaban | #2 |
| surgical casts | #2 |
| recurrent vte risk | #2 |
| negative ageadjusted ddimer | #2 |
| acquired antithrombin | #2 |
| coumarin sensitivity | #2 |
| scan normal | #2 |
| symptomatic outpatients | #2 |
| antagonists vka | #2 |
| embolism safely | #2 |
| apixaban enoxaparin warfarin | #2 |
| ultrasonography patients | #2 |
| patients low probability | #2 |
| f5 r506q | #2 |
| mutations propeptide | #2 |
| 8 wk risk | #2 |
| pentasaccharide fondaparinux | #2 |
| 6 months scores | #2 |
| thromboembolism thrombophilia | #2 |
| nonpermanent heart failure | #2 |
| treatment deep | #2 |
| ate cancer patients | #2 |
| analysis venous | #2 |
| plasma d‐dimer concentration | #2 |
| fibrinolysis pentoxifylline | #2 |
| anticoagulated patients permanent | #2 |
| influenza coagulation | #2 |
| 17 apixaban | #2 |
| lowmolecularweight heparin women | #2 |
| hyperglycemia diagnosis | #2 |
| relevant patient subgroups | #2 |
| crd42017056309 | #2 |
| tinaquant vidas | #2 |
| screening fvl | #2 |
| secondary strategies | #2 |
| lmwh efficacy | #2 |
| inflammation neutrophils thrombosis | #2 |
| 20210a mutations | #2 |
| rivaroxaban 30 bid | #2 |
| vidas assay | #2 |
| computerized impedance | #2 |
| cha2ds2vasc nri | #2 |
| model cancer patients | #2 |
| interleukin‐10 response | #2 |
| ddimer assay | #2 |
| suspected pulmonary | #2 |
| venous thromboembolism enoxaparin | #2 |
| hokusai vtecancer study | #2 |
| bleeding rate patients | #2 |
| 95 comparator individuals | #2 |
| pulmonary embolism asthma | #2 |
| venous | #2 |
| raskob | #2 |
| computed venous | #2 |
| current clinical challenges | #2 |
| arterial thrombotic disease | #2 |
| outcome symptomatic | #2 |
| score dimer | #2 |
| heparin administered | #2 |
| rfviia injection rfviia | #2 |
| prothrombin pulmonary embolism | #2 |
| secondary efficiency | #2 |
| low‐molecular‐weight heparin | #2 |
| incidental venous | #2 |
| events severe | #2 |
| embolism primary | #2 |
| enoxaparin difference | #2 |
| venous thrombosis travel | #3 |
| activecontrol | #3 |
| 6575 years | #3 |
| travel venous thrombosis | #3 |
| discontinuation ufh | #3 |
| dvt einstein | #3 |
| pulmonary embolism primary | #3 |
| presenting location | #3 |
| factors prothrombin | #3 |
| fxiaso | #3 |
| primary rule | #3 |
| low probability models | #3 |
| patients venography | #3 |
| dalteparin difference | #3 |
| cancer randomised trials | #3 |
| einstein studies | #3 |
| baseline values placebo | #3 |
| safely | #3 |
| bleeding major | #3 |
| approaches primary | #3 |
| tb‐402 | #3 |
| treatment vitamin antagonists | #3 |
| healthy donor fmt | #3 |
| influence heparins | #3 |
| oral hormonal cross | #3 |
| composite stroke | #3 |
| subcutaneous lmwh | #3 |
| heparin heparin | #3 |
| revised geneva efficiency | #3 |
| heparins cancer | #3 |
| pulmonary embolism models | #3 |
| gestalt 95 | #3 |
| outcome venous | #3 |
| dvt hip | #3 |
| antithrombin iii concentrate | #3 |
| subcutaneous fondaparinux | #3 |
| einstein dvt | #3 |
| patients ultrasonography | #3 |
| stable acute | #3 |
| ventilation scan | #3 |
| pad smokers | #3 |
| venous thromboembolism thrombophilia | #3 |
| monoclonal replacement | #3 |
| venous arterial | #3 |
| dvt systematic differences | #3 |
| cardiac troponine | #3 |
| cancer patients ipe | #3 |
| treatment vka | #3 |
| endogenous apc | #3 |
| tfindependent | #3 |
| older children vte | #3 |
| vte 3 | #3 |
| safely excluded | #3 |
| strategies efficiency | #3 |
| idrabiotaparinux | #3 |
| placebo n4 | #3 |
| treatment low | #3 |
| inhibition blood coagulation | #3 |
| lmwh pph | #3 |
| favour lmwh | #3 |
| thrombophilic defect | #3 |
| axa activity | #3 |
| rnapc2 fviia | #3 |
| patients proximalvein thrombosis | #3 |
| efficacy heparin | #3 |
| therapy venous | #3 |
| prolactin controls | #3 |
| patients wells | #3 |
| sensitivity compression | #3 |
| ft4 risk | #3 |
| hf severity risk | #3 |
| coagulation influence | #3 |
| treatment vte recurrence | #3 |
| venous thrombosis positive | #3 |
| wells rule dvt | #3 |
| recurrent thromboembolic | #3 |
| venous thrombosis cancer | #3 |
| topic heparin heparin | #3 |
| introduction mdct | #3 |
| incidence enoxaparin | #3 |
| definition perelated death | #3 |
| proximalvein thrombosis | #3 |
| prevalence avws | #3 |
| warfarin subgroup | #3 |
| female hemorrhage humans | #3 |
| negative predictive proportion | #3 |
| coagulation air travel | #3 |
| 95 wells rule | #3 |
| safely exclude | #3 |
| svt vte | #3 |
| cancer active cancer | #3 |
| normal ctnt presentation | #3 |
| idrabiotaparinux warfarin | #3 |
| impedance predictive | #3 |
| compensated dic | #3 |
| age annual incidence | #3 |
| atria hemorr2hages | #3 |
| studies cus strategies | #3 |
| venous thromboembolism | #3 |
| cdr combination | #3 |
| hokusai‐vte | #3 |
| venous thromboembolism apixaban | #3 |
| protein thrombophilia | #3 |
| ddimer assays | #3 |
| gestalt probability | #3 |
| thromboembolism low | #3 |
| dimer blood | #3 |
| 3month incidence | #3 |
| heparin edoxaban | #3 |
| wells rule gestalt | #3 |
| vte denmark | #3 |
| 12month study period | #3 |
| crt cancer patients | #3 |
| mechanisms heparin | #3 |
| female humans inhibitors | #3 |
| safety acenocoumarol | #3 |
| lowmolecularweight heparin placebo | #3 |
| detection dvt | #3 |
| death clinical studies | #3 |
| nct00643201 | #3 |
| diagnosis pulmonary | #3 |
| plethysmography impedance | #3 |
| apc protective | #3 |
| knee factor | #3 |
| simplified wells specificity | #3 |
| ctnt risk stratification | #3 |
| patients venous | #3 |
| idiopathic venous | #3 |
| probability dimer | #3 |
| normal result | #3 |
| diagnosis pulmonary embolism | #3 |
| adult patients vte | #3 |
| desogestrelcontaining | #3 |
| tinaquant assay | #3 |
| 02011 | #3 |
| thiophenes venous | #3 |
| lowmolecularweight humans length | #3 |
| treatment lowmolecularweight heparin | #3 |
| 3month vte incidence | #3 |
| ipe cancer patients | #3 |
| combination wells score | #3 |
| intravenous loading dose | #3 |
| diagnosis deep | #3 |
| capillary blood sample | #3 |
| embolism‐related | #3 |
| cancer patients ate | #3 |
| chemotherapy prophylaxis | #3 |
| thombosis | #3 |
| incidental pulmonary embolism | #3 |
| multiple comorbidities polypharmacy | #3 |
| pulmonary embolism‐related death | #3 |
| recurrence thrombophlebitis | #3 |
| enoxaparin follow | #3 |
| patients gastrointestinal cancer | #3 |
| single diagnostic | #3 |
| incidence total vte | #3 |
| primary wells rule | #3 |
| products follow | #3 |
| patients ft4 level | #3 |
| prevalence hemostatic abnormalities | #3 |
| dvt major | #3 |
| platelet agents | #3 |
| einstein patients | #3 |
| factor viiic | #3 |
| mutation venous | #3 |
| patients 6575 years | #3 |
| predictable pharmacokinetics | #3 |
| vte performance | #3 |
| studies hemorrhage | #3 |
| alternative diagnoses | #3 |
| vte major burden | #3 |
| bleeding 3 | #3 |
| lmwh | #3 |
| patients 6 months | #3 |
| pph lmwh | #3 |
| iii deficiency | #3 |
| vte low | #3 |
| hasbled | #3 |
| ultrasonography strategies | #3 |
| outpatients dvt | #3 |
| 20210ga | #3 |
| 3633 patients | #3 |
| failurerate | #3 |
| dip placebo | #3 |
| ddimer threshold | #3 |
| extensive screening | #3 |
| patients incidental vte | #3 |
| clinical models patients | #3 |
| vein thrombosis | #3 |
| pulmonary embolism gestalt | #3 |
| thrombophlebitis treatment | #3 |
| standard therapy treatment | #3 |
| nadroparin placebo | #3 |
| deep vein | #3 |
| dose reduction edoxaban | #3 |
| cohort study employees | #3 |
| selectine | #3 |
| users incidence | #3 |
| administration rnapc2 | #3 |
| “gestalt | #3 |
| dvt primary | #3 |
| thromboembolism background | #3 |
| vte venous thrombosis | #3 |
| outpatient treatment dvt | #3 |
| time venous thrombosis | #3 |
| 100 years year | #3 |
| recombinant hirudin rhir | #3 |
| population rivaroxaban | #4 |
| predilution postdilution | #4 |
| ultrasonography venous | #4 |
| thromboembolism systematic | #4 |
| vte global | #4 |
| amadeus trial | #4 |
| global burden vte | #4 |
| warfarin 3 months | #4 |
| oral rivaroxaban | #4 |
| thrombosis deep | #4 |
| patients edoxaban | #4 |
| procoagulant factors | #4 |
| vte treatment patients | #4 |
| disease vte | #4 |
| travel thrombosis | #4 |
| leiden carriers | #4 |
| patients fondaparinux | #4 |
| impedance plethysmography | #4 |
| cancer vwf | #4 |
| thromboembolism occurred | #4 |
| chads2 p0001 | #4 |
| patients clinically | #4 |
| embolism tomography | #4 |
| thrombosis uedvt | #4 |
| doac studies | #4 |
| patients crcl 60 | #4 |
| diagnostic management strategies | #4 |
| serial impedance | #4 |
| diagnostic prediction models | #4 |
| apixaban efficacy | #4 |
| control anticoagulation | #4 |
| ddimer assay patients | #4 |
| risk vkas | #4 |
| 6 months prophylaxis | #4 |
| symptomatic deep | #4 |
| enoxaparin female humans | #4 |
| criteria dose reduction | #4 |
| “reversal | #4 |
| vte highincome countries | #4 |
| cleavage sites apc | #4 |
| thromboembolism study | #4 |
| patients venous thromboembolism | #4 |
| daily netilmicin | #4 |
| patients submassive | #4 |
| coagulation factors risk | #4 |
| abdomen relationship | #4 |
| chromogenic compounds | #4 |
| patient category | #4 |
| thrombophilia 95 | #4 |
| embolism dimer | #4 |
| hemostatic profile | #4 |
| postthrombotic symptoms | #4 |
| coagulation endotoxin | #4 |
| dutch orthopedic | #4 |
| vitamin antagonists | #4 |
| primary failure rate | #4 |
| primary pulmonary embolism | #4 |
| venous thrombosis levels | #4 |
| lmwh female heparin | #4 |
| lmwh cancer patients | #4 |
| hyperhomocysteinemic relatives | #4 |
| 35±4 | #4 |
| safety pravastatin | #4 |
| patient education treatment | #4 |
| thromboembolism arterial | #4 |
| treatment unfractionated heparin | #4 |
| women normal levels | #4 |
| prophylaxis lmwh | #4 |
| diagnostic management | #4 |
| global disease burden | #4 |
| 3587 | #4 |
| thrombosis symptomatic | #4 |
| received warfarin | #4 |
| preexisting heparin | #4 |
| lmwhs standard heparin | #4 |
| questionnaires venous | #4 |
| vka treatment | #4 |
| chemotherapy vte prophylaxis | #4 |
| lowmolecularweight heparin | #4 |
| total vte | #4 |
| thrombophilic families | #4 |
| thrombosis air | #4 |
| contraindications treatment | #4 |
| refuted | #4 |
| negative point | #4 |
| 335 patients | #4 |
| chinese korean ethnicity | #4 |
| pregnancies carriers | #4 |
| venous thromboembolism patients | #4 |
| thromboembolism factor | #4 |
| bleeding anticoagulants | #4 |
| advanced cancer 95 | #4 |
| noacs netherlands | #4 |
| patients alternative diagnosis | #4 |
| embolism background | #4 |
| extended treatment | #4 |
| probability prospective | #4 |
| vte total | #4 |
| activation fibrinolytic | #4 |
| proximal patients | #4 |
| noacs cancer patients | #4 |
| estrogen therapy patients | #4 |
| clot resolution | #4 |
| mbe patients | #4 |
| vitamin antagonist treatment | #4 |
| hemorr2hages | #4 |
| idiopathic venous thrombosis | #4 |
| thrombosis ischemic stroke | #4 |
| point dimer | #4 |
| enoxaparin day | #4 |
| vte netherlands | #4 |
| vte global burden | #4 |
| nct00571649 | #4 |
| 150 microg desogestrel | #4 |
| measurement abi | #4 |
| recurrent vte months | #4 |
| episode venous | #4 |
| women apc resistance | #4 |
| clot lysis patients | #4 |
| clinically relevant bleeding | #4 |
| embolism roc | #4 |
| ageadjusted cutoff patients | #4 |
| rule pulmonary | #4 |
| sankyo | #4 |
| thromboembolism treatment | #4 |
| rfviia injection | #4 |
| fibrin generation test | #4 |
| levels ft4 | #4 |
| netherlands pulmonary | #4 |
| vitamin antagonists patients | #4 |
| patients nonpermanent | #4 |
| rivaroxaban 20 | #4 |
| tinaquant | #4 |
| life duration | #4 |
| gramnegative bacteria humans | #4 |
| chemotherapy shr | #4 |
| serial impedance plethysmography | #4 |
| edoxaban patients | #4 |
| dimer assays | #4 |
| venography patients | #4 |
| patients dimer | #4 |
| thromboembolism vitamin | #4 |
| 0651 | #4 |
| 10172 | #4 |
| disease burden vte | #4 |
| diagnosis uedvt | #4 |
| 150 microg levonorgestrel | #4 |
| death survey | #4 |
| risk occult cancer | #4 |
| arterial thrombotic | #4 |
| dose noacs | #4 |
| rviia thrombin generation | #4 |
| series venograms | #4 |
| lowmolecular weight heparins | #4 |
| patients primary healthcare | #4 |
| protecht | #4 |
| outpatients hospital | #5 |
| elevated plasma level | #5 |
| predilution | #5 |
| vte 6 | #5 |
| vte patients cancer | #5 |
| outcome major | #5 |
| 8491 | #5 |
| 2 rules | #5 |
| risk prediction scores | #5 |
| endotoxin chimpanzees | #5 |
| secondary venous thrombosis | #5 |
| recurrent dvt patients | #5 |
| burden vte | #5 |
| patients wells score | #5 |
| inhibition plasminogen activation | #5 |
| isolated calfvein thrombosis | #5 |
| fviia rnapc2 | #5 |
| ft4 level | #5 |
| bleeding cancer | #5 |
| suspected uedvt | #5 |
| factor leiden 95 | #5 |
| antithrombotic drug treatment | #5 |
| patients subtherapeutic | #5 |
| treatment acute dvt | #5 |
| pulmonary embolism patients | #5 |
| thromboembolism idraparinux | #5 |
| panwards | #5 |
| hokusai | #5 |
| patients parenteral anticoagulants | #5 |
| clinical presentation clinical | #5 |
| previous venous thromboembolism | #5 |
| lmwh incidence | #5 |
| specificity thrombophlebitis | #5 |
| thromboembolism thrombosis | #5 |
| upper extremity thrombosis | #5 |
| netilmicin patients | #5 |
| consensus strategy | #5 |
| gestalt | #5 |
| diagnosis questionnaire | #5 |
| treatment fondaparinux | #5 |
| coc pregnancy | #5 |
| compression ultrasound | #5 |
| daiichi sankyo | #5 |
| low molecularweight humans | #5 |
| exclusion venous thromboembolism | #5 |
| endogenous activated | #5 |
| day rivaroxaban | #5 |
| thrombosis upper | #5 |
| ventricular dysfunction echocardiography | #5 |
| thrombosis primary | #5 |
| efficiency patients | #5 |
| patients recurrent dvt | #5 |
| endotoxin testing | #5 |
| patients superficial thrombophlebitis | #5 |
| asymptomatic carriers mutation | #5 |
| 8292 | #5 |
| low‐molecular‐weight | #5 |
| pad smoking | #5 |
| iii plasminogen | #5 |
| heparin compared | #5 |
| southern latin america | #5 |
| fviii families | #5 |
| lmwh recommended | #5 |
| vka patients | #5 |
| vte factor | #5 |
| venous thromboembolism studies | #5 |
| thrombosis leg | #5 |
| rivaroxaban enoxaparin vka | #5 |
| hirudin treatment | #5 |
| adjusted dimer | #5 |
| severe pph women | #5 |
| pregnancy pph | #5 |
| women warfarin | #5 |
| cdr patients | #5 |
| medea study | #5 |
| thrombophlebitis ultrasonography | #5 |
| fh patients cvd | #5 |
| repeated ultrasonography | #5 |
| secondary dvt | #5 |
| deepvein thrombosis | #5 |
| cgp 39393 | #5 |
| patients pulmonary embolism | #5 |
| normal ctpa | #5 |
| preschool contraceptives | #5 |
| clinical probability | #5 |
| clinical probability assessment | #5 |
| phlebography plethysmography | #5 |
| incidence prognostic significance | #5 |
| diagnostic strategies | #5 |
| molecularweight heparin | #5 |
| dvt prevalence | #5 |
| transfusion blood loss | #5 |
| dimer combination | #5 |
| embolism reproducibility | #5 |
| cancer strategy | #5 |
| thromboembolism studies | #5 |
| thromboembolism | #5 |
| sensitivity negative predictive | #5 |
| coronary angioplasty angioplasty | #5 |
| effects levonorgestrel | #6 |
| dimer cut | #6 |
| 39393 | #6 |
| elisapositive | #6 |
| grade 1a ufh | #6 |
| 393 patients | #6 |
| incidence recurrence | #6 |
| embolism pulmonary | #6 |
| compression stockings patients | #6 |
| dabigatran etexilate dabigatran | #6 |
| embolism ventricular | #6 |
| patients iohexol | #6 |
| funding bayer | #6 |
| 10±4 | #6 |
| oral anticoagulants dabigatran | #6 |
| vte anticoagulant treatment | #6 |
| wells rule | #6 |
| lmwh users users | #6 |
| amplify | #6 |
| vte controls | #6 |
| endotoxininduced activation | #6 |
| cancer primary patients | #6 |
| vka | #6 |
| subcutaneous nadroparin | #6 |
| patients tests | #6 |
| severe antithrombin | #6 |
| patients factor mutation | #6 |
| initial heparin treatment | #6 |
| factor leiden carriers | #6 |
| assay fibrin | #6 |
| warfarin venous thromboembolism | #6 |
| prevalence vte | #6 |
| synthetic pentasaccharides | #6 |
| diagnostic workup | #6 |
| oral edoxaban | #6 |
| enoxaparin incidence | #6 |
| dalteparin dose | #6 |
| d‐dimer testing | #6 |
| anticoagulants hemorrhage | #6 |
| myocardial infarction ctni | #6 |
| selective beta | #6 |
| effects ufh | #6 |
| recurrent pulmonary | #6 |
| standardized morbidity ratio | #6 |
| repeatedly normal | #6 |
| severe dic | #6 |
| neoplasms pulmonary embolism | #6 |
| pulmonary embolism presence | #6 |
| risk increasing levels | #6 |
| venograms | #6 |
| endotoxin assays | #6 |
| combined utility | #6 |
| 049 95 | #6 |
| treatment svt | #6 |
| daily gentamicin | #6 |
| risk khorana score | #6 |
| efficiency proportion | #6 |
| thrombophilic defects | #6 |
| treatment intermittent claudication | #6 |
| thromboembolism bleeding | #6 |
| patients suspected | #6 |
| simplired dimer | #6 |
| vte cancer | #6 |
| pembqol questionnaire | #6 |
| symptoms intermittent claudication | #6 |
| apixaban treatment dose | #6 |
| ultrasonography normal | #6 |
| edoxaban efficacy | #6 |
| c1173 | #6 |
| patients pulmonary angiography | #6 |
| patients proximal | #6 |
| patients anticoagulation clinic | #6 |
| 12month cumulative incidence | #6 |
| antagonists treatment | #6 |
| low absolute risk | #6 |
| isolated deficiencies | #6 |
| levonorgestrel desogestrel | #6 |
| subjects vte | #6 |
| outcome occurred | #6 |
| subcutaneous low | #6 |
| arterial cardiovascular | #6 |
| treatment pulmonary embolism | #6 |
| thrombosis guidelines | #6 |
| svt extension | #6 |
| anticoagulants female | #6 |
| conventional therapy treatment | #6 |
| lmwh cancer | #6 |
| probability pulmonary | #6 |
| patients diagnostic | #6 |
| ft4 patients | #6 |
| perioperative blood loss | #6 |
| fixeddose regimen | #6 |
| rate major bleeding | #6 |
| leiden | #6 |
| dvt trial | #6 |
| proportion cancer patients | #6 |
| patients uedvt | #6 |
| women hyperhomocysteinemia | #6 |
| stressinduced hyperglycaemia | #6 |
| patients lowmolecularweight heparin | #6 |
| treatment ufh | #6 |
| clinically relevant subgroups | #6 |
| blood coagulation mechanism | #6 |
| symptomatic legs | #6 |
| anticoagulant treatment | #6 |
| fviia inhibition | #6 |
| duration rivaroxaban | #6 |
| recurrent dvt | #7 |
| incidence recurrent vte | #7 |
| ottawa score | #7 |
| proportion older patients | #7 |
| diagnostic suspicion | #7 |
| thromboembolism total | #7 |
| aspirin combined | #7 |
| carriers venous thromboembolism | #7 |
| inhibitor apixaban | #7 |
| primary efficacy | #7 |
| embolism prospective | #7 |
| vte cancer diagnosis | #7 |
| factor female humans | #7 |
| thromboembolism adult | #7 |
| protein protein deficiencies | #7 |
| noncompressibility | #7 |
| leg ultrasonography | #7 |
| day initial treatment | #7 |
| mpc1609 | #7 |
| 597939 | #7 |
| vka therapy | #7 |
| plasma levels ifngamma | #7 |
| mutations factor viii | #7 |
| doppler skin | #7 |
| lung scan | #7 |
| pulmonary embolism sensitivity | #7 |
| rivaroxaban 10 | #7 |
| arterial cardiovascular disease | #7 |
| placebo rivaroxaban | #7 |
| primary dvt | #7 |
| prothrombin risk | #7 |
| combination ipg | #7 |
| spiral sensitivity | #7 |
| heparin org | #7 |
| negative predictive npv | #7 |
| silent pulmonary embolism | #7 |
| neoplasms pulmonary | #7 |
| thrombophilia pregnancy loss | #7 |
| relation levels | #7 |
| thrombophlebitis adolescent | #7 |
| venous thrombosis treatment | #7 |
| blood coagulation humans | #7 |
| perelated death | #7 |
| thromboembolism vte | #7 |
| major bleeding | #7 |
| treatment doac | #7 |
| levels factor viii | #7 |
| specific antidotes | #7 |
| anticoagulant parameters | #7 |
| phenprocoumon polymorphism | #7 |
| relation prolactin levels | #7 |
| major bleeding rate | #7 |
| 680 | #7 |
| statin treatment risk | #7 |
| negative ddimer test | #7 |
| nondiagnostic lung scans | #7 |
| administration bsf | #7 |
| antithrombin protein | #7 |
| tb402 | #7 |
| major bleeding vkas | #7 |
| stockings control | #7 |
| coagulation humans | #7 |
| rates edoxaban | #7 |
| etexilate oral | #7 |
| presence cteph | #7 |
| tnf injection | #7 |
| 220 dabigatran | #7 |
| carriers defects | #7 |
| patients standard heparin | #7 |
| vitamin antagonists vka | #7 |
| ufh treatment | #7 |
| dvt ipg | #7 |
| diagnosis venous thrombosis | #7 |
| unselected women | #7 |
| general practitioners guideline | #7 |
| deepvein thrombosis patients | #7 |
| anticoagulants antineoplastic | #8 |
| acute symptomatic vte | #8 |
| inr determination | #8 |
| thrombosis adolescent | #8 |
| structured algorithm | #8 |
| risks dvt | #8 |
| inherited thrombophilic | #8 |
| homocysteine markers | #8 |
| p0001 hasbled score | #8 |
| vascular endothelial barrier | #8 |
| apixaban enoxaparin | #8 |
| carriers fvl | #8 |
| risk employees | #8 |
| dimer tests | #8 |
| wells scores | #8 |
| products humans | #8 |
| cancer pulmonary embolism | #8 |
| vte score | #8 |
| oral apixaban | #8 |
| proximal deep | #8 |
| vka lmwh | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| physicians stockings | #8 |
| arg506 factor | #8 |
| years cumulative incidence | #8 |
| 150 enoxaparin | #8 |
| aged phlebography | #8 |
| thrombosis prophylaxis | #8 |
| v617f jak2 | #8 |
| initial heparin | #8 |
| funding daiichi | #8 |
| 0·2 | #8 |
| overt cancer | #8 |
| testing rule | #8 |
| consecutive outpatients | #8 |
| prevention vte | #8 |
| patients extended anticoagulation | #8 |
| discontinuation anticoagulant treatment | #8 |
| occult cancer patients | #8 |
| administration low | #8 |
| anticoagulation unprovoked vte | #8 |
| pvoct | #8 |
| patients symptomatic vte | #8 |
| recurrent vte bleeding | #8 |
| tests pulmonary | #8 |
| persistent risk factors | #8 |
| low clinical probability | #8 |
| agnelli | #8 |
| bnp ctnt | #8 |
| vitamin antagonists vkas | #8 |
| current approach | #8 |
| severe preeclampsia patients | #8 |
| dimer concentration | #8 |
| recurrent vte mb | #8 |
| oral glucocorticoids risk | #8 |
| oac adherence | #8 |
| unprovoked vte patients | #8 |
| chemotherapy low risk | #8 |
| objectively confirmed | #8 |
| optimal intensity | #8 |
| contrast venography | #8 |
| normal computed | #8 |
| ageadjusted ddimer cutoff | #8 |
| euro55 | #8 |
| inr values patients | #8 |
| ufh initial treatment | #8 |
| increased fibrinolytic | #8 |
| 97 95 | #8 |
| nondiagnostic scan | #8 |
| international organisations | #8 |
| fxi aso | #8 |
| warfarin hazard ratio | #8 |
| symptomatic deepvein thrombosis | #8 |
| probability lung | #8 |
| lmwh grade 1a | #8 |
| deficiency antithrombin | #8 |
| nafronyl | #8 |
| 1599 patients | #8 |
| point ultrasonography | #8 |
| prospective management | #8 |
| enoxaparin vka | #8 |
| comorbidity polypharmacy | #8 |
| compression surveys | #8 |
| treatment venous thrombosis | #8 |
| leiden prothrombin | #8 |
| xii deficient | #8 |
| heparin vitamin antagonists | #8 |
| analysis apixaban | #8 |
| patients excluded | #8 |
| levonorgestrelcontaining | #8 |
| duration treatment | #8 |
| proximal deepvein thrombosis | #8 |
| prothrombin 20210a | #9 |
| generation pill | #9 |
| oral antithrombins | #9 |
| placebo plasma levels | #9 |
| homocysteine women | #9 |
| factors thrombophlebitis | #9 |
| vte relatives | #9 |
| heparin therapy patients | #9 |
| strategies dimer | #9 |
| enoxaparin factor | #9 |
| oral contraceptive pregnancy | #9 |
| characteristics severity | #9 |
| thrombosis thromboinflammation | #9 |
| vte rcts | #9 |
| incidence postthrombotic syndrome | #9 |
| anticoagulant pathways | #9 |
| discontinuing anticoagulation | #9 |
| acute medical illnesses | #9 |
| comorbidities polypharmacy | #9 |
| major bleeding treatment | #9 |
| normal ddimer | #9 |
| therapeutic dose patients | #9 |
| thromboembolism cancer | #9 |
| tafi levels | #9 |
| bled bleeding | #9 |
| independent committee | #9 |
| postdilution | #9 |
| fondaparinux cancer patients | #9 |
| diagnosis mdct | #9 |
| hemorr2hages atria | #9 |
| diagnostic prediction model | #9 |
| daiichisankyo | #9 |
| longterm treatment vte | #9 |
| fxa inhibitor | #9 |
| cofact | #9 |
| serotonin platelet | #9 |
| compression stockings prevention | #9 |
| months efficacy | #9 |
| embolism venous | #9 |
| edoxaban major bleeding | #9 |
| ultrasonogram | #9 |
| abnormal vaginal | #9 |
| weight heparin | #9 |
| method enoxaparin | #9 |
| cancer cell extravasation | #9 |
| büller | #9 |
| combination stroke | #9 |
| apixaban oral factor | #9 |
| crcl 60 | #9 |
| incidental pulmonary | #9 |
| patients active cancer | #9 |
| cancer episode | #9 |
| atiii concentrates | #9 |
| patients fxa inhibitors | #9 |
| lipoproteina women | #9 |
| lmwh mortality | #9 |
| treatment edoxaban | #9 |
| thrombosis venous thromboembolism | #9 |
| concomitant cancer | #9 |
| carriers factor leiden | #9 |
| thrombosis compared | #9 |
| treatment prophylaxis | #9 |
| iii concentrate | #9 |
| male oligosaccharides | #9 |
| nonpermanent | #9 |
| cancer factor | #9 |
| probability pulmonary embolism | #10 |
| patients endotoxemia | #10 |
| leg veins | #10 |
| 598 patients | #10 |
| inherited thrombophilic factors | #10 |
| major bleeding crnmb | #10 |
| lmwh studies | #10 |
| subcutaneous metaanalysis | #10 |
| pregnancy carriers | #10 |
| hypocoagulable state | #10 |
| gramnegative septicemia | #10 |
| oral thrombin inhibitor | #10 |
| simplified geneva | #10 |
| cvd fh patients | #10 |
| anticoagulants | #10 |
| thr incidence | #10 |
| injection avidin | #10 |
| magellan trial | #10 |
| schedule heparin | #10 |
| rates recurrent vte | #10 |
| snp scores | #10 |
| oral administration dabigatran | #10 |
| protein dic | #10 |
| cancer patients vte | #10 |
| embolism patients | #10 |
| deficiencies antithrombin | #10 |
| crp test | #10 |
| magellan study | #10 |
| venous thrombosis | #10 |
| aged antithrombin | #10 |
| retrospective study efficacy | #10 |
| single loss | #10 |
| extremity deep | #10 |
| patients venous thrombosis | #10 |
| fii mutation | #10 |
| dvt lower extremity | #10 |
| normohomocysteinemic | #10 |
| fondaparinux risk | #10 |
| 1215 patients | #10 |
| vnv | #10 |
| embolism clinical | #10 |
| induced coagulation | #10 |
| incidence 1000 personyears | #10 |
| cancer patients lmwh | #10 |
| asymptomatic pulmonary embolism | #10 |
| ddimer concentration | #10 |
| 100 years discontinuation | #10 |
| venous thromboembolic event | #10 |
| incidence major bleeding | #10 |
| 4470 | #10 |
| wells | #10 |
| bled scores | #10 |
| treatment uedvt | #10 |
| thrombosis background | #10 |
| treatment vitamin | #10 |
| treatment aprotinin | #10 |
| nadroparine | #10 |
| ageadjusted cutoff | #10 |
| rabbits administration | #10 |
| severity clinical | #10 |
| heparin nomogram | #10 |
| inr cases | #10 |
| year years | #10 |
| factor levels patients | #10 |
| animal heparin | #10 |
| intimamedia thickness imt | #10 |
| cus diagnosis | #10 |
| vte efficacy | #10 |
| factor prevention | #10 |
| rfviia blood loss | #10 |
| thrombophlebitis adult | #10 |
| edoxaban | #11 |
| oral dabigatran | #11 |
| mutations prevalence | #11 |
| pyridines thiazoles | #11 |
| medical conferences | #11 |
| lmwh pregnancies | #11 |
| patients cancer vte | #11 |
| pregnancyrelated complications | #11 |
| variation inr | #11 |
| inhibitors hemorrhage | #11 |
| carriers factor | #11 |
| reference testing | #11 |
| hospital lmwh | #11 |
| recombinant human tnf | #11 |
| intensity anticoagulation | #11 |
| gps training | #11 |
| heparinoid org | #11 |
| pcc dabigatran | #11 |
| endotoxin pentoxifylline | #11 |
| cancer patients dvt | #11 |
| vte vwf | #11 |
| 750 μg | #11 |
| pulmonary angiography venography | #11 |
| fondaparinux hemorrhage | #11 |
| haemophilia vwd | #11 |
| weight humans | #11 |
| endotoxin assay | #11 |
| crnmb 95 | #11 |
| pulmonary embolism incidence | #11 |
| knee clinical trials | #11 |
| 880 patients | #11 |
| patients probability | #11 |
| dvt | #11 |
| factor venous | #11 |
| lmwh pregnancy | #11 |
| embolism prevalence | #11 |
| sulfates dermatan | #11 |
| dabigatran enoxaparin | #11 |
| incidence major | #11 |
| patients cvcs | #11 |
| thromboembolism major | #11 |
| org 10172 | #11 |
| 30 microg ethinylestradiol | #11 |
| air travel | #11 |
| ufh studies | #11 |
| combination dimer | #11 |
| previous venous | #11 |
| adult anticoagulants | #11 |
| screening cancer | #11 |
| ldfr | #11 |
| levels prolactin | #11 |
| cancer patients evidence | #11 |
| embolism recurrence | #11 |
| patients anticoagulant treatment | #11 |
| gentamicin treatment patients | #11 |
| clinical pretest | #11 |
| d‐dimer levels | #11 |
| subsegmental pulmonary emboli | #12 |
| fondaparinux unfractionated heparin | #12 |
| hemodynamically stable | #12 |
| bayer schering pharma | #12 |
| anticoagulation unprovoked | #12 |
| thrombophilic | #12 |
| perelated | #12 |
| dvt treatment | #12 |
| observation risk | #12 |
| 9702 | #12 |
| doseadjustment | #12 |
| noacs vka | #12 |
| stopping anticoagulation | #12 |
| recurrent vte anticoagulation | #12 |
| proximal veins | #12 |
| event recurrence | #12 |
| bnp cardiac troponin | #12 |
| months primary | #12 |
| recurrent vte | #12 |
| vte recurrence risk | #12 |
| nephro | #12 |
| outcomes venous thromboembolism | #12 |
| ageadjusted ddimer | #12 |
| control metaanalysis | #12 |
| warfarin therapy inr | #12 |
| treatment crt | #12 |
| venous thromboembolism incidence | #12 |
| annual incidence vte | #12 |
| crd42013003526 | #12 |
| geneva score | #12 |
| prevention venous thrombosis | #12 |
| proximal vein | #12 |
| peghirudin | #12 |
| paulin | #12 |
| humanized arthroplasty | #12 |
| topic venous | #12 |
| patients lupus anticoagulant | #12 |
| patients lmwhs | #12 |
| outpatient management patients | #12 |
| thrombin generation fibrinolysis | #12 |
| safety efficiency | #12 |
| factor leiden prothrombin | #12 |
| women factor | #12 |
| risk venous | #12 |
| livebirth rate | #12 |
| anticoagulant factor | #12 |
| warfarin treated | #12 |
| 72 children | #12 |
| concomitant disorders | #12 |
| pioped study | #12 |
| thrombosis dvt | #12 |
| warfarin recurrent vte | #12 |
| hirulog1 | #12 |
| deficient women | #12 |
| female heparin humans | #12 |
| vka noacs | #12 |
| patients incidental | #12 |
| 9295 | #12 |
| groups inr | #13 |
| safety oral | #13 |
| patients anticoagulant | #13 |
| plethysmograms | #13 |
| 95 carriers | #13 |
| major hip | #13 |
| strain gauge plethysmography | #13 |
| treatment venous thromboembolism | #13 |
| uedvt | #13 |
| category studies | #13 |
| dabigatran vte | #13 |
| obesity haemophilia patients | #13 |
| inhibition tnf | #13 |
| vte 64 | #13 |
| prevention venous thromboembolism | #13 |
| vte major | #13 |
| randomized cross | #13 |
| levels factor | #13 |
| arixtra | #13 |
| time prothrombin | #13 |
| patients thrombophilia | #13 |
| vte female humans | #13 |
| hematologic pregnancy trimester | #13 |
| association venous thrombosis | #13 |
| dimer threshold | #13 |
| vte groups | #13 |
| daily subcutaneous | #13 |
| conventional anticoagulants | #13 |
| pselectin patients | #13 |
| concomitant antiplatelet therapy | #13 |
| safety doacs | #13 |
| inferiority efficacy | #13 |
| arterial thromboembolism ate | #13 |
| vte recurrence 95 | #13 |
| ufh dalteparin | #13 |
| continuous intravenous heparin | #13 |
| dvt lower | #13 |
| factor viii apc | #13 |
| recombinant hirudin rhirudin | #13 |
| nct00986154 | #13 |
| selective testing | #13 |
| thrombosis young | #13 |
| deepvein thrombosis dvt | #13 |
| dabigatran 220 | #13 |
| marder score | #13 |
| rivaroxaban thiophenes | #13 |
| superficial thrombophlebitis | #13 |
| bayer healthcare | #13 |
| indication anticoagulation | #13 |
| bleeding events edoxaban | #13 |
| plethysmography | #13 |
| thrombosis acute | #13 |
| antithrombin iii activity | #13 |
| clinical decision rules | #13 |
| vte | #13 |
| factor leiden mutation | #13 |
| dimer testing | #13 |
| 86 percent | #13 |
| spiral computed tomography | #13 |
| heparin low | #13 |
| occult cancer | #13 |
| plasminogen apoa | #14 |
| low molecular | #14 |
| recurrent venous thromboembolism | #14 |
| 12 kg1 | #14 |
| patients dvt | #14 |
| effects hyperthyroidism | #14 |
| pregnancy venous | #14 |
| anticoagulant rivaroxaban | #14 |
| aspirin women | #14 |
| obstetric complications women | #14 |
| dvt lower extremities | #14 |
| patients vka therapy | #14 |
| limited screening | #14 |
| thromboembolism age | #14 |
| cadherins endothelium | #14 |
| doseranging study | #14 |
| lmwh vka | #14 |
| gastrointestinal bleeding patients | #14 |
| treatment duration patients | #14 |
| vte months | #14 |
| loss women | #14 |
| experimental endotoxaemia | #14 |
| patients outpatients | #14 |
| factor viii levels | #14 |
| conventionaltherapy | #14 |
| riete score | #14 |
| crnm | #14 |
| safety edoxaban | #14 |
| costs dvt | #14 |
| fvl carriers | #14 |
| symptomatic pulmonary | #14 |
| patients acute vte | #14 |
| edoxaban warfarin | #14 |
| awareness pad | #14 |
| placebo rfviia | #14 |
| edoxaban oral factor | #14 |
| standard heparin | #14 |
| thrombophilia patients | #14 |
| higher ddimer levels | #14 |
| incidence severe pph | #14 |
| atiii deficiency | #14 |
| unprovoked vte vte | #14 |
| aged plethysmography | #14 |
| recurrent venous | #14 |
| female fibrin | #14 |
| acute deep | #14 |
| thrombosis | #14 |
| vte statin | #14 |
| treated lmwh | #14 |
| cancer patients anticoagulation | #14 |
| revised geneva | #14 |
| bolus intravenous injection | #14 |
| ultrasound strategies | #14 |
| 17 placebo | #14 |
| aged anticoagulants | #14 |
| treatment 12 months | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| symptomatic events | #15 |
| activation contact | #15 |
| cteph incidence | #15 |
| oral direct factor | #15 |
| inr range | #15 |
| khorana score | #15 |
| lmwh ufh | #15 |
| doacs aspirin | #15 |
| control subjects prevalence | #15 |
| 500 pg | #15 |
| established vte | #15 |
| probability assessment | #15 |
| subcutaneous regimen | #15 |
| thyroid hormone excess | #15 |
| generation oral | #15 |
| enoxaparin vte | #15 |
| diagnosis venous | #15 |
| lomoparan | #15 |
| patients ctpa | #15 |
| edoxaban treatment | #15 |
| studies pulmonary | #15 |
| recombinant factor viia | #15 |
| thrombosis diagnosis | #15 |
| cardiovascular diseases thrombosis | #15 |
| primary safety outcome | #15 |
| subcutaneous enoxaparin | #15 |
| antagonist vka | #15 |
| coc vte | #15 |
| prior venous thromboembolism | #15 |
| clinically relevant endpoints | #15 |
| arg506 | #15 |
| thrombus growth | #15 |
| abdominal pelvic | #15 |
| prophylaxis venous thromboembolism | #15 |
| pregnancy outcome pregnancy | #15 |
| inr patient | #15 |
| fondaparinux efficacy | #15 |
| patients vitamin antagonists | #15 |
| coagulation | #15 |
| arg562 | #15 |
| vitaminkantagonists | #15 |
| experimental thrombosis | #15 |
| thrombinography | #15 |
| factor leiden | #15 |
| anticoagulants patients | #15 |
| viia activity | #16 |
| abdomino | #16 |
| bleeding aged | #16 |
| major bleeding events | #16 |
| cancer screening patients | #16 |
| positivity threshold | #16 |
| major bleeding anticoagulation | #16 |
| occult cancer detection | #16 |
| thrombosis low | #16 |
| test clinical | #16 |
| risk clinically | #16 |
| ddimer levels patients | #16 |
| deep venous thrombosis | #16 |
| patients acenocoumarol | #16 |
| netilmicin gentamicin | #16 |
| cancer cancer patients | #16 |
| factors major | #16 |
| vte khorana score | #16 |
| 6 months placebo | #16 |
| thrombosis haemostasis | #16 |
| warfarin acenocoumarol | #16 |
| analysis rivaroxaban | #16 |
| thromboembolism time | #16 |
| impaired fibrinolysis | #16 |
| postthrombotic syndrome children | #16 |
| factor inhibitor | #16 |
| recurrent symptomatic | #16 |
| venous thrombosis warfarin | #16 |
| women unexplained | #16 |
| 100 95 | #16 |
| vterelated death | #16 |
| thrombosis association | #16 |
| arterial vascular events | #16 |
| combination clinical | #16 |
| thrombosis adult | #16 |
| dvt lmwh | #16 |
| avws patients | #16 |
| subsequent pregnancy loss | #16 |
| prohemostatic | #17 |
| dimer assay | #17 |
| mutation women | #17 |
| recurrent vte events | #17 |
| thrombosis clinical | #17 |
| lmwhs patients | #17 |
| permanent patients | #17 |
| factors venous | #17 |
| 12 months patients | #17 |
| scan classification | #17 |
| compared enoxaparin | #17 |
| excessive blood loss | #17 |
| factor monoclonal | #17 |
| incidence pts | #17 |
| female humans vte | #17 |
| dvt prevention | #17 |
| 2688 | #17 |
| anticoagulants clinical | #17 |
| vte edoxaban | #17 |
| diagnosis svt | #17 |
| lower specificity | #17 |
| vkorc1 gene | #17 |
| fragment f1 | #17 |
| gentamicin netilmicin | #17 |
| topic hemorrhage humans | #17 |
| rivaroxaban oral factor | #17 |
| anticoagulant therapy patients | #17 |
| patients overt hypothyroidism | #17 |
| patients impedance | #17 |
| hematoma heparin | #17 |
| ctscans | #17 |
| women mutation | #17 |
| thromboembolism patients | #17 |
| pharmo record linkage | #17 |
| management crt | #17 |
| fibrinolysis treatment | #17 |
| 516 patients | #17 |
| endotoxemia bacteremia | #17 |
| anticoagulants drug | #17 |
| poc test | #18 |
| stable anticoagulation | #18 |
| patients strategy | #18 |
| combined form | #18 |
| thromboembolism venous | #18 |
| annual incidence | #18 |
| hivinfected patients cart | #18 |
| simplired | #18 |
| cancer vte | #18 |
| commercial airline pilots | #18 |
| sanofi aventis | #18 |
| proximal vein thrombosis | #18 |
| treatment vkas | #18 |
| vka edoxaban | #18 |
| intravenous heparin therapy | #18 |
| diagnostic strategy | #18 |
| favor lmwh | #18 |
| outcome events | #18 |
| 023 | #18 |
| edoxaban vte | #18 |
| 4 clinical | #18 |
| prothrombin g20210a | #18 |
| thrombosis pulmonary | #18 |
| weight adjusted | #18 |
| women pregnancy loss | #18 |
| flight hours | #18 |
| lmwh doacs | #18 |
| aptt heparin | #18 |
| venous thromboembolism rivaroxaban | #18 |
| warfarin hazard | #18 |
| thrombosis total | #18 |
| relevant nonmajor | #18 |
| apc thrombin generation | #18 |
| vka vte | #18 |
| antithrombotic treatment patients | #18 |
| systemic activation coagulation | #19 |
| prognostic echocardiography | #19 |
| vitamin antagonist | #19 |
| oral dabigatran enoxaparin | #19 |
| fondaparinux enoxaparin | #19 |
| extended oral | #19 |
| fibrinolytic response | #19 |
| versions version | #19 |
| active search | #19 |
| studies factor | #19 |
| patients sspe | #19 |
| subcutaneous dalteparin | #19 |
| recurrent venous thrombosis | #19 |
| edoxaban dose | #19 |
| objective testing | #19 |
| retropubic prostatectomy | #19 |
| abnormal ultrasound | #19 |
| increased fibrinolytic activity | #19 |
| ipdma | #19 |
| acute recurrent | #19 |
| lmwh patients | #19 |
| antibodynegative | #19 |
| patients derivation | #19 |
| coagulation studies | #19 |
| ufh lmwh | #19 |
| ddimer tests | #19 |
| 56 95 | #19 |
| symptomatic dvt | #19 |
| local angiogenesis | #19 |
| recurrence vte | #19 |
| venography sensitivity | #19 |
| venous thromboembolism relatives | #19 |
| vwf vte | #19 |
| dvt rivaroxaban | #19 |
| patients major bleeding | #19 |
| 35 women | #19 |
| increased risk relatives | #19 |
| patients prevalence | #19 |
| patients elevated biomarkers | #19 |
| low platelets | #19 |
| adjusted dose | #19 |
| treatment heparin | #19 |
| thromboembolism administration | #19 |
| endogenous fibrinolysis | #19 |
| doubleblinding | #19 |
| antagonists vkas | #20 |
| diagnostic workup patients | #20 |
| thrombophilia vte | #20 |
| patients ddimer testing | #20 |
| recurrence bleeding | #20 |
| dabigatran 150 | #20 |
| incidences death | #20 |
| ctnt bnp | #20 |
| standardtherapy hazard ratio | #20 |
| absolute risk | #20 |
| guidance ssc | #20 |
| distance treatment | #20 |
| warfarin edoxaban | #20 |
| antitpo | #20 |
| calf veins | #20 |
| symptomatic venous thrombosis | #20 |
| proteins thrombin | #20 |
| compared ufh | #20 |
| impedance plethysmography ipg | #20 |
| cancer severity | #20 |
| excluded patients | #20 |
| carriers prothrombin | #20 |
| intravenous injections | #20 |
| single criterion | #20 |
| new agent | #20 |
| prothrombin mutation | #20 |
| blindly | #20 |
| anticoagulation clinic | #20 |
| malignancy time | #20 |
| control situation | #20 |
| life venous thrombosis | #20 |
| risk thrombophilia | #20 |
| therapy rivaroxaban | #20 |
| thrombosis ultrasonography | #20 |
| treatment vte | #20 |
| synthetic cross | #20 |
| subsegmental | #20 |
| shr 95 | #20 |
| abi measurement | #20 |
| versions questionnaire | #20 |
| nadroparin | #20 |
| residual venous | #20 |
| portola | #20 |
| pregnancyrelated vte | #20 |
| injections subcutaneous | #20 |
| statin vte | #20 |
| established atherosclerosis | #20 |
| abi risk factors | #20 |
| hemodynamically stable patients | #21 |
| fibrinolysis inflammation | #21 |
| treatment acenocoumarol | #21 |
| ddimer concentrations | #21 |
| venogram | #21 |
| patients 3 months | #21 |
| thromb | #21 |
| thrombosis anticoagulants | #21 |
| occult malignancy | #21 |
| treatment apixaban | #21 |
| current standard treatment | #21 |
| doacs lmwhs | #21 |
| d‐dimer | #21 |
| disease ischemic | #21 |
| risk cohort study | #21 |
| deep venous | #21 |
| major bleeding patients | #21 |
| hemostatic abnormalities | #21 |
| prothrombin 20210 | #21 |
| internists cardiologists | #21 |
| distance quality | #21 |
| discriminatory performance | #21 |
| vte patients | #21 |
| carriers noncarriers | #21 |
| concomitant anti | #21 |
| outcome incidence | #21 |
| anticoagulants heparin | #22 |
| treatment dvt | #22 |
| cttr | #22 |
| time inr | #22 |
| daily enoxaparin | #22 |
| dose subcutaneous | #22 |
| bleeding treatment | #22 |
| hormonal cross | #22 |
| riskbenefit ratio | #22 |
| patients immobilization | #22 |
| patientyears | #22 |
| dichotomously | #22 |
| cmax ctrough | #22 |
| patients severe hf | #22 |
| ttr inr | #22 |
| patients recurrent symptoms | #22 |
| lpa plasminogen | #22 |
| host defense response | #22 |
| anticoagulants humans | #22 |
| public awareness | #22 |
| venous thromboembolic | #22 |
| acute vte | #22 |
| vascular endotoxins | #22 |
| doppler venous thrombosis | #22 |
| recurrent thromboembolism | #22 |
| safety treatment | #22 |
| alternative anticoagulation | #22 |
| dimer age | #22 |
| thrombophilia screening | #22 |
| time platelet | #23 |
| n1157 | #23 |
| cancer patients risk | #23 |
| kakkar | #23 |
| enoxaparin 40 | #23 |
| elevated ctni | #23 |
| bidirectional relation | #23 |
| development dic | #23 |
| fondaparinux | #23 |
| thromboembolism anticoagulants | #23 |
| direct factor inhibitors | #23 |
| life pulmonary embolism | #23 |
| rivaroxaban dosing | #23 |
| lower extremity amputation | #23 |
| recurrence venous | #23 |
| patients coagulation disorders | #23 |
| 5392 | #23 |
| 2 investigators | #23 |
| hasbled score | #23 |
| standardduration | #23 |
| ambulatory cancer patients | #23 |
| normal angiogram | #23 |
| prevalence venous thromboembolism | #23 |
| 011 | #23 |
| clotbound thrombin | #23 |
| odis | #23 |
| venous arterial thrombosis | #23 |
| vte studies | #23 |
| percentage increase | #23 |
| gentamicin patients | #23 |
| years episode | #24 |
| viiic | #24 |
| thrombosis carriers | #24 |
| overt hyperthyroidism | #24 |
| therapy heparin | #24 |
| patients severe bleeding | #24 |
| levels fviii | #24 |
| recurrent pulmonary embolism | #24 |
| month incidence | #24 |
| specific antidote | #24 |
| rates venous thromboembolism | #24 |
| patients abnormal perfusion | #24 |
| independent external validation | #24 |
| predefined criteria | #24 |
| desogestrel levonorgestrel | #24 |
| ddimer testing | #24 |
| recurrent thromboembolism patients | #24 |
| bleeding complication | #24 |
| food drugs | #24 |
| 049 | #24 |
| a21gly | #24 |
| lowmolecularweight humans | #24 |
| prevalence deficiencies | #24 |
| parameters fibrinolysis | #24 |
| followup incidence | #24 |
| safety fondaparinux | #24 |
| subtherapeutic | #24 |
| fondaparinux placebo | #24 |
| presence dvt | #24 |
| patients acute treatment | #24 |
| ufh patients | #24 |
| expert radiologists | #25 |
| fatima | #25 |
| xii activity | #25 |
| thromboembolism acute | #25 |
| perfusion lung scan | #25 |
| middeldorp | #25 |
| patients gastrointestinal bleeding | #25 |
| studies lmwh | #25 |
| factors anticoagulants | #25 |
| amadeus | #25 |
| vte clinical | #25 |
| sepsis intravascular coagulation | #25 |
| willebrand factor adamts13 | #25 |
| cha2ds2vasc chads2 | #25 |
| lmwh treatment | #25 |
| f1 2 levels | #25 |
| specificity efficiency | #25 |
| treatment symptomatic | #25 |
| anatomical extent | #25 |
| suggestions improvement | #25 |
| fibrinogen degradation | #25 |
| influence smoking | #25 |
| parameters risk | #26 |
| treatment lmwh | #26 |
| venous thromboemboli | #26 |
| edoxaban vka | #26 |
| viia complex | #26 |
| failure rate | #26 |
| miscarriage stillbirth | #26 |
| patients cdr | #26 |
| major bleeding bleeding | #26 |
| ecq | #26 |
| doacs vitamin antagonists | #26 |
| events year | #26 |
| 9715 | #26 |
| patients symptomatic dvt | #26 |
| rate recurrent vte | #26 |
| hormonal manipulation | #26 |
| asymptomatic carriers | #26 |
| dalteparin ufh | #26 |
| homozygous carriers | #26 |
| edoxaban versus | #26 |
| patients essential thrombocythaemia | #26 |
| specificity negative predictive | #26 |
| rethoracotomy | #26 |
| unprovoked vte | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| nonmajor | #27 |
| thrombophlebitis | #27 |
| treating physician | #27 |
| patients major hemorrhage | #27 |
| combined training | #27 |
| training gps | #27 |
| lowmolecularweight heparin patients | #27 |
| perfusion lung | #27 |
| venous thromboembolism carriers | #27 |
| airline pilots | #27 |
| 0·63 | #27 |
| day 35 | #27 |
| thrombocytopenia antibodies | #27 |
| thrombosis venous | #27 |
| anticoagulants factor | #27 |
| unprovoked venous | #27 |
| vte thr | #27 |
| anticoagulants blood | #27 |
| cancer spread | #27 |
| current guidance | #27 |
| lmwh prophylaxis | #27 |
| enoxaparin female | #27 |
| noncarriers 95 | #27 |
| patients 50 | #27 |
| low molecularweight heparin | #27 |
| vte doacs | #27 |
| female heterozygote | #27 |
| extremity venous | #27 |
| patients elevated levels | #27 |
| months studies | #27 |
| npv patients | #27 |
| cancer venous thromboembolism | #28 |
| presentation followup | #28 |
| apc plasma | #28 |
| anticoagulation women | #28 |
| vte 6 months | #28 |
| factors recurrent | #28 |
| patients unprovoked | #28 |
| pembqol | #28 |
| receiving rivaroxaban | #28 |
| coagulation tissue factor | #28 |
| specific reversal agent | #28 |
| therapeutic doses | #28 |
| tests diagnostic | #28 |
| objective tests | #28 |
| pph severe pph | #28 |
| anticoagulants compared | #28 |
| acutely medical patients | #28 |
| embolism retrospective | #28 |
| monitoring therapy | #28 |
| 4650 | #28 |
| vitamin aged | #28 |
| 2½ | #28 |
| unexplained | #28 |
| rfviia placebo | #28 |
| hirudin therapy | #28 |
| dvt pulmonary embolism | #29 |
| thrombo | #29 |
| prediction scores | #29 |
| aminoglycoside therapy | #29 |
| 1000 individuals | #29 |
| pbac score | #29 |
| patients standard therapy | #29 |
| plateletactivating antibodies | #29 |
| blind trials | #29 |
| pulmonary angiography | #29 |
| oral glucocorticoids | #29 |
| g20210a mutation | #29 |
| direct oral anticoagulants | #29 |
| recurrence svt | #29 |
| acenocoumarol patients | #29 |
| septicemia | #29 |
| thrombosis treatment | #29 |
| thrombosis 95 | #29 |
| spread cancer | #29 |
| 8240 | #29 |
| aspirin placebo | #29 |
| heparin versus | #29 |
| pulmonary embolism recurrence | #29 |
| cindexes | #29 |
| bleeding increased | #29 |
| dutch famine | #29 |
| dabigatran pcc | #29 |
| resistance activated protein | #29 |
| major bleeding rivaroxaban | #29 |
| patients avws | #29 |
| diagnosis dvt | #29 |
| authors incidence | #29 |
| sex‐specific differences | #29 |
| pulmonary embolism death | #29 |
| years year | #29 |
| aged morpholines | #29 |
| current management strategies | #29 |
| ufh vte | #30 |
| vte coc | #30 |
| embolism risk | #30 |
| xii factor | #30 |
| 1000 personyears incidence | #30 |
| subcutaneous heparin | #30 |
| cancer venous | #30 |
| prevention venous | #30 |
| administration pentoxifylline | #30 |
| f1 2 | #30 |
| patients vte | #30 |
| markers coagulation activation | #30 |
| doac vka | #30 |
| direct oral factor | #30 |
| rule patients | #30 |
| support techniques | #30 |
| costs diagnosis | #30 |
| 95 risk | #30 |
| residual thrombosis | #30 |
| thromboembolism warfarin | #30 |
| new anticoagulants | #30 |
| imaging sensitivity specificity | #31 |
| standardtherapy | #31 |
| extended prophylaxis | #31 |
| thromboprophylaxis risk | #31 |
| prevalence probability | #31 |
| apixaban placebo | #31 |
| term risk | #31 |
| rhir | #31 |
| thromboembolism adolescent | #31 |
| 8755 | #31 |
| iii activity | #31 |
| recurrent patients | #31 |
| bled | #31 |
| 2 antiplasmin | #31 |
| rfviia novoseven | #31 |
| pharmacological prophylaxis | #31 |
| incidence cteph | #31 |
| inhibitor edoxaban | #31 |
| experimental endotoxemia | #31 |
| recurrent vte patients | #31 |
| antithrombotic therapies | #31 |
| incidence pph | #31 |
| activation blood coagulation | #31 |
| dvt pulmonary | #31 |
| dimer cutoff | #31 |
| events 95 | #31 |
| patients deepvein thrombosis | #31 |
| women recurrent miscarriage | #31 |
| ventilation scintigraphy | #31 |
| ufh fondaparinux | #31 |
| analysis reviewers | #31 |
| vte ufh | #31 |
| placebo observation | #31 |
| 0206 | #31 |
| recurrent episode | #31 |
| leiden mutation | #32 |
| treatment anticoagulants | #32 |
| factor female | #32 |
| negative dimer | #32 |
| year 95 | #32 |
| varicosis | #32 |
| negative septicemia | #32 |
| warfarin vte | #32 |
| netherlands predictive | #32 |
| ufh | #32 |
| parenteral anticoagulation | #32 |
| international society thrombosis | #32 |
| low clinical | #32 |
| resistance activated | #32 |
| generation patients | #32 |
| normal genotype | #32 |
| factors thrombolytic | #32 |
| age adjusted | #32 |
| parenteral anticoagulants | #32 |
| suspected patients | #32 |
| khorana score patients | #32 |
| nephrotoxicity gentamicin | #33 |
| factor viii patients | #33 |
| mega study | #33 |
| anticoagulant protein | #33 |
| data meta | #33 |
| active implementation | #33 |
| heparin lmwh | #33 |
| low probability | #33 |
| additional tests | #33 |
| prophylaxis vte | #33 |
| subcutaneous male | #33 |
| pulmonary angiogram | #33 |
| activation factors | #33 |
| thromboembolism young | #33 |
| apixaban treatment | #33 |
| rhirudin | #33 |
| chapter patients | #33 |
| warfarin risks | #33 |
| cancer patients diagnosis | #33 |
| unitage | #33 |
| deficiency protein | #34 |
| warfarin adult | #34 |
| 3 months treatment | #34 |
| control trials | #34 |
| vte thrombophilia | #34 |
| grade 1a | #34 |
| compare efficacy | #34 |
| thrombosis lower | #34 |
| 590 | #34 |
| 10 95 | #34 |
| phytonadione | #34 |
| anticoagulant | #34 |
| subsegmental pulmonary embolism | #34 |
| hemorrhage heparin humans | #34 |
| bilateral venography | #34 |
| pregnancy loss women | #34 |
| reocclusion patients | #34 |
| plasmin alpha | #34 |
| 9241 | #34 |
| lmwh unfractionated heparin | #34 |
| vte compared | #34 |
| apcsr | #34 |
| patients efficiency | #35 |
| activation coagulation | #35 |
| embolism | #35 |
| anticoagulants benzimidazoles | #35 |
| statin association | #35 |
| prevention model | #35 |
| neoplasms venous | #35 |
| 36 95 | #35 |
| risk members | #35 |
| pph blood loss | #35 |
| radiologists diagnosis | #35 |
| rviia | #35 |
| enoxaparin prevention | #35 |
| weekly subcutaneous | #35 |
| surgery hip | #35 |
| lung scanning | #35 |
| viii levels | #36 |
| inherited risk factors | #36 |
| treatment acute vte | #36 |
| venous thromboembolism dabigatran | #36 |
| acute symptomatic | #36 |
| novoseven | #36 |
| studies echocardiography | #36 |
| dose reduction patients | #36 |
| regular monitoring | #36 |
| catheterrelated infection | #36 |
| thrombophilia venous | #36 |
| iii antithrombin | #36 |
| 1698 | #36 |
| venous thromboembolic disease | #36 |
| riskbenefit | #36 |
| hellp patients | #36 |
| fibrinogen depletion | #36 |
| 4139 | #36 |
| 287 patients | #36 |
| factors travel | #36 |
| levels coagulation | #36 |
| fibrinolytic activation | #36 |
| peripheral endovascular | #36 |
| warfarin 95 | #37 |
| factors thrombophilia | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| tat complexes | #37 |
| anticoagulants prevention | #37 |
| recombinant hirudin | #37 |
| vte increased | #37 |
| cumulative incidence vte | #37 |
| screening occult | #37 |
| perelated mortality | #37 |
| genotype 95 | #37 |
| ototoxicity nephrotoxicity | #37 |
| suspected venous | #37 |
| lwmh | #37 |
| thrombosis humans | #37 |
| risk factors pts | #37 |
| venography | #37 |
| magellan | #37 |
| excluding | #37 |
| ctpa patients | #37 |
| bagsvaerd | #37 |
| outcome composite | #37 |
| prophylactic heparin | #37 |
| pad studies | #37 |
| risk venous thrombosis | #37 |
| anticoagulant action | #37 |
| congenital deficiencies | #38 |
| recurrence day | #38 |
| catheterrelated thrombosis | #38 |
| restenosis reocclusion | #38 |
| 10 total | #38 |
| vte bleeding | #38 |
| vte cancer patients | #38 |
| 3306 | #38 |
| anticoagulants female humans | #38 |
| patients ddimer levels | #38 |
| rivaroxaban placebo | #38 |
| age recurrence | #38 |
| 2835 | #38 |
| sensitivity biomarkers | #38 |
| nonmajor bleeding | #38 |
| submassive pulmonary | #38 |
| doac lmwh | #38 |
| fetal loss women | #38 |
| coagulation protein | #38 |
| specificity patients | #39 |
| compression stocking | #39 |
| incidence cancer | #39 |
| systemic inflammatory responses | #39 |
| septic syndrome | #39 |
| continued treatment | #39 |
| submassive | #39 |
| time compression | #39 |
| fibrin fibrinogen | #39 |
| doacs | #39 |
| embolus | #39 |
| low molecular weight | #39 |
| 277 patients | #39 |
| enoxaparin placebo | #39 |
| heparins lmwhs | #39 |
| diagnostic prediction | #39 |
| subcutaneous intention | #39 |
| incidence patients | #39 |
| superficial vein thrombosis | #39 |
| children familial hypercholesterolemia | #39 |
| patients normal | #40 |
| fviiic | #40 |
| bleeding | #40 |
| clotting activation | #40 |
| tfmp | #40 |
| pemb | #40 |
| common femoral vein | #40 |
| standardized definition | #40 |
| activatable fibrinolysis | #40 |
| episode venous thromboembolism | #40 |
| thrombinantithrombin complexes | #40 |
| anticoagulant therapy | #40 |
| endotoxininduced | #40 |
| anticoagulation therapy patients | #40 |
| ambulatory cancer | #40 |
| therapeutic dosages | #40 |
| grade 1a patients | #40 |
| international clinical | #40 |
| arterial vascular | #40 |
| dalteparin treatment | #40 |
| day 6 months | #40 |
| lowmolecularweight heparins | #41 |
| cancer lmwh | #41 |
| endotoxin induced | #41 |
| placebo 6 months | #41 |
| submassive pulmonary embolism | #41 |
| anticoagulated patients | #41 |
| risk recurrent vte | #41 |
| heparin therapy | #41 |
| 7268 | #41 |
| dabigatran etexilate | #41 |
| lung scintigraphy | #41 |
| 95 genotype | #41 |
| calf vein thrombosis | #41 |
| pentasaccharides | #41 |
| triage tests | #41 |
| prophylaxis venous | #42 |
| cell extravasation | #42 |
| type graft | #42 |
| patients prospective | #42 |
| anticoagulation risk | #42 |
| netilmicin | #42 |
| 8101 | #42 |
| major contributor | #42 |
| neoplasms thrombosis | #42 |
| stroke thrombosis | #42 |
| standardization committee | #42 |
| patients silent | #42 |
| thrombosis administration | #42 |
| patients vasopressors | #42 |
| 543 patients | #43 |
| post‐thrombotic syndrome | #43 |
| heparin risk | #43 |
| ischemic events | #43 |
| rtap | #43 |
| patients vte risk | #43 |
| venous thrombosis thrombophilia | #43 |
| initial treatment | #43 |
| draft document | #43 |
| fetal loss | #43 |
| cancer adjusted | #43 |
| probability patients | #43 |
| venous thromboembolism vte | #43 |
| vkas patients | #43 |
| warfarin anticoagulants | #43 |
| monthly incidence | #43 |
| protein sepsis | #44 |
| expert physicians | #44 |
| restoration euthyroidism | #44 |
| experimental venous thrombosis | #44 |
| enoxaparin risk | #44 |
| uedvt patients | #44 |
| nonvka oral anticoagulants | #44 |
| mild hyperhomocysteinaemia | #44 |
| 20 30 | #44 |
| edoxaban therapy | #44 |
| efficiency models | #44 |
| 95 pulmonary embolism | #44 |
| 10–14 | #44 |
| recurrent vte 95 | #44 |
| patients tinzaparin | #44 |
| indications patients | #44 |
| role coagulation | #44 |
| rate venous | #44 |
| factors thromboembolism | #44 |
| dose adjusted | #45 |
| oral direct | #45 |
| dvt patients | #45 |
| 95 warfarin | #45 |
| wells score | #45 |
| fondaparinux patients | #45 |
| dose lmwh | #45 |
| venous thrombotic | #45 |
| treated warfarin | #45 |
| years algorithm | #45 |
| revascularisation procedures | #45 |
| patients bnp | #45 |
| coumarin therapy | #45 |
| coagulation activation | #45 |
| healthcare settings | #46 |
| daily rivaroxaban | #46 |
| management venous | #46 |
| stroke risk assessment | #46 |
| ssc isth | #46 |
| extended duration | #46 |
| percent confidence | #46 |
| bleeding rivaroxaban | #46 |
| major bleeding placebo | #46 |
| patients unprovoked vte | #46 |
| day levels | #46 |
| ruling | #46 |
| pioped | #46 |
| standard therapy | #46 |
| hospital outpatients | #46 |
| treatment model | #46 |
| prothrombin fragment f1 | #46 |
| abtpo | #46 |
| mechanical prophylaxis | #47 |
| ambulatory anticoagulants | #47 |
| central venous lines | #47 |
| roccurve | #47 |
| plasma ddimer levels | #47 |
| mutation pregnancy | #47 |
| episode vte | #47 |
| boehringer ingelheim | #47 |
| outcome vitamin | #47 |
| new oral anticoagulant | #47 |
| iiia receptors | #47 |
| male methimazole | #47 |
| bristol myers squibb | #47 |
| patients pulmonary | #48 |
| rivaroxaban compared | #48 |
| elevated plasma levels | #48 |
| small studies | #48 |
| recurrence venous thromboembolism | #48 |
| fondaparinux heparin | #48 |
| daiichi | #48 |
| patients acute dvt | #48 |
| thromboprophylactic | #48 |
| thrombotic burden | #48 |
| diagnosis physicians | #48 |
| subcommittee | #48 |
| travel risk | #48 |
| factors rivaroxaban | #48 |
| risk recurrent | #48 |
| intermediate risk risk | #48 |
| women aspirin | #49 |
| levels protein | #49 |
| enoxaparin | #49 |
| calf vein | #49 |
| vte diagnosis | #49 |
| factor viii deficiency | #49 |
| rivaroxaban prevention | #49 |
| lowmolecularweight heparin lmwh | #49 |
| cardiac surgery mortality | #50 |
| buller | #50 |
| dvt diagnosis | #50 |
| vitamink antagonists | #50 |
| transient risk factor | #50 |
| thromboembolism aged | #50 |
| incidence venous thromboembolism | #50 |
| outpatient therapy | #50 |
| atria patients | #50 |
| acute respiratory insufficiency | #50 |
| nonselective betablockers | #50 |
| prospective diagnostic | #50 |
| treatment threshold | #50 |
| etexilate | #50 |
| intensity treatment | #50 |
| factor vte | #51 |
| patients 11 | #51 |
| discrimination model | #51 |
| tomography pulmonary | #51 |
| acenocoumarol | #51 |
| strategies treatment | #51 |
| 95 apixaban | #51 |
| previous survey | #51 |
| normal perfusion | #51 |
| effects coagulation | #51 |
| global disease | #51 |
| protein deficiencies | #51 |
| 1·12 | #52 |
| apixaban vte | #52 |
| inhibitors heparin | #52 |
| free thyroxine ft4 | #52 |
| svt patients | #52 |
| 3 month | #52 |
| vte major bleeding | #52 |
| patients comorbid conditions | #52 |
| pdvt | #52 |
| risk venous thromboembolism | #52 |
| hematologic malignancies patients | #52 |
| lmwh fondaparinux | #52 |
| doacs vka | #52 |
| unnecessarily | #52 |
| lung scans | #52 |
| versus enoxaparin | #53 |
| thrombophilic factors | #53 |
| warfarintreated patients | #53 |
| cross study | #53 |
| 1522 | #53 |
| suspected venous thromboembolism | #53 |
| patients initially | #53 |
| postthrombotic syndrome | #53 |
| preference patients | #53 |
| thromboembolism prevention | #53 |
| absolute risks | #53 |
| reported incidence | #53 |
| 479 patients | #53 |
| hemostatic balance | #53 |
| 40 daily | #53 |
| vte mortality | #54 |
| thromboembolism death | #54 |
| patients obese | #54 |
| pai1 levels patients | #54 |
| familial thrombophilia | #54 |
| chads2 cha2ds2vasc | #54 |
| bled score | #54 |
| 378 patients | #54 |
| prethrombotic | #54 |
| male pulmonary embolism | #54 |
| patients incidence | #54 |
| antithrombotic drug | #54 |
| 034 | #54 |
| 2537 | #54 |
| endocrine disorders | #54 |
| major bleeds | #54 |
| acquired risk factors | #54 |
| long term risk | #55 |
| methods randomized | #55 |
| rivaroxaban | #55 |
| unfractionated heparin ufh | #55 |
| compared lmwh | #55 |
| unfractionated heparin | #55 |
| nondeficient | #55 |
| legs patients | #55 |
| biological pan | #55 |
| insurances | #55 |
| proximal extent | #55 |
| anticoagulants arthroplasty replacement | #55 |
| treatment thresholds | #55 |
| dosereduction | #55 |
| enoxaparin rivaroxaban | #56 |
| 20210a | #56 |
| major bleeding apixaban | #56 |
| seventh accp conference | #56 |
| physicians guidelines | #56 |
| vte death | #56 |
| level mortality | #56 |
| venous outflow obstruction | #56 |
| risk major bleeding | #56 |
| tromboembólica | #56 |
| deficiency prevalence | #56 |
| vitamin warfarin | #56 |
| vasopressors | #56 |
| preeclampsia hellp syndrome | #56 |
| time event | #56 |
| enoxaparin patients | #56 |
| reduced capacity | #56 |
| inr values | #56 |
| weight heparins | #56 |
| subsegmental pulmonary | #57 |
| ctscan | #57 |
| inhibitors female humans | #57 |
| risk factors vte | #57 |
| levels survival | #57 |
| calf dvt | #57 |
| antithrombin iii heparin | #57 |
| clinical models | #57 |
| pharmo | #58 |
| unfractionated heparin patients | #58 |
| fibrinolysis humans | #58 |
| lowmolecular weight heparin | #58 |
| ruled | #58 |
| inhibitors female | #58 |
| doacs patients | #58 |
| malignancy mortality | #58 |
| spiral computed | #58 |
| thrombin activatable | #58 |
| heterozygous factor | #59 |
| clot lysis time | #59 |
| thrombosis aged | #59 |
| risk vte | #59 |
| direct oral | #59 |
| acute venous thromboembolism | #59 |
| warfarin treatment | #59 |
| risk periods | #59 |
| incidence symptomatic | #59 |
| aventis | #59 |
| safety warfarin | #59 |
| bias trial | #59 |
| risk factors sensitivity | #59 |
| factor generation | #59 |
| mutation prothrombin | #59 |
| pulmonary embolism 95 | #60 |
| prevalence pulmonary | #60 |
| constans | #60 |
| 079 95 | #60 |
| pediatric venous thromboembolism | #60 |
| hemorrhage humans | #60 |
| awareness risk factors | #60 |
| acute pulmonary embolism | #60 |
| target inr | #60 |
| anticoagulants treatment | #60 |
| fixeddose | #60 |
| atrial fibrillation metaanalysis | #60 |
| women difference | #60 |
| benzimidazoles dabigatran | #61 |
| tests prevalence | #61 |
| hypocoagulable | #61 |
| month surgery | #61 |
| association protein | #61 |
| perfusion ventilation | #61 |
| dvt 95 | #61 |
| amuse | #61 |
| 3633 | #61 |
| long‐term treatment | #61 |
| rosendaal | #61 |
| free thyroxine | #61 |
| cdr score | #61 |
| 273 patients | #62 |
| general practitioners patients | #62 |
| human endotoxemia | #62 |
| post thrombotic | #62 |
| activated partial | #62 |
| combined contraceptives oral | #62 |
| patients administration | #62 |
| informatizado | #62 |
| procoagulant state | #62 |
| protein fibrinogen | #62 |
| 250 patients | #62 |
| ttr patients | #62 |
| symptoms dvt | #63 |
| management anticoagulation | #63 |
| rivaroxaban lmwh | #63 |
| venous thromboembolisms | #63 |
| injection endotoxin | #63 |
| cvrs | #63 |
| women mutations | #63 |
| smoking smoking cessation | #63 |
| common odds ratio | #63 |
| factor leiden risk | #63 |
| treatment network | #63 |
| 33 women | #63 |
| physicians predictive | #63 |
| quantitative test | #63 |
| revised geneva score | #63 |
| vte thromboprophylaxis | #63 |
| selfadjustment | #64 |
| heparin fondaparinux | #64 |
| blinded trial | #64 |
| acute pulmonary | #64 |
| thrombophilic risk | #64 |
| postthrombotic | #64 |
| decision rules | #64 |
| cancer noncancer patients | #64 |
| bleeding events patients | #64 |
| patients aortic valve | #64 |
| dvts | #64 |
| vkas treatment | #64 |
| superficial vein | #64 |
| oral thrombin | #64 |
| factor inhibitors | #64 |
| prior vte | #64 |
| fvl vte | #65 |
| ultrasonograms | #65 |
| prothrombin g20210a mutation | #65 |
| accuracy diagnostic tests | #65 |
| prevalence abnormalities | #65 |
| treatment pad | #65 |
| stroke thromboembolism | #65 |
| 95 bleeding | #66 |
| risk factor thrombosis | #66 |
| newer anticoagulants | #66 |
| dvt sensitivity | #66 |
| rapid triage | #66 |
| axa | #66 |
| 0 points | #66 |
| death classification | #66 |
| elfa | #66 |
| statin therapy risk | #66 |
| female heparin | #66 |
| patients tertiles | #67 |
| standard therapy patients | #67 |
| rate major | #67 |
| apixaban | #67 |
| 1127 | #67 |
| patients factor | #67 |
| atrial fibrillation stroke | #67 |
| 3594 | #68 |
| patients benefits | #68 |
| patients bnp levels | #68 |
| academic medical centre | #68 |
| coagulation fibrinolysis | #68 |
| perioperative blood | #68 |
| ranging study | #68 |
| fibrinolytic | #68 |
| 05 95 | #68 |
| 1894 | #68 |
| 20210g | #68 |
| thrombosis blood | #69 |
| plasma interleukin | #69 |
| justify | #69 |
| postphlebitic | #69 |
| heparin ufh | #69 |
| recurrent thrombosis patients | #69 |
| suspected | #69 |
| ionis | #69 |
| enfermedad tromboembólica | #69 |
| certoparin | #69 |
| test patients | #70 |
| ischemic events patients | #70 |
| cutoff levels | #70 |
| major bleeding complications | #70 |
| rivaroxaban treatment | #70 |
| thrombosis recurrence | #70 |
| withhold | #70 |
| 8190 | #70 |
| patients protein | #70 |
| α2ap | #70 |
| fixed dose | #70 |
| vwfrco | #70 |
| mantelhaenszel | #70 |
| aged predictive | #70 |
| gramnegative sepsis | #70 |
| elevated cardiac | #70 |
| asymptomatic atherosclerosis | #71 |
| tests prospective | #71 |
| clopidogrel placebo | #71 |
| topic costs | #71 |
| vte vka | #71 |
| unfractionated | #71 |
| plasminogen plg | #71 |
| thromboprophylaxis | #71 |
| levels vwf | #71 |
| diagnostic sensitivity specificity | #71 |
| activation prothrombin | #72 |
| viia factor | #72 |
| versus vitamin | #72 |
| trifurcation | #72 |
| ddimer values | #72 |
| hf studies | #72 |
| complications hematologic | #72 |
| patients lmwh | #72 |
| overt hypothyroidism | #72 |
| elevated factor | #72 |
| antithrombin iii iii | #72 |
| new anticoagulant | #72 |
| pooled rate | #72 |
| reversal agent | #73 |
| analysis diagnostic | #73 |
| noacs | #73 |
| tomography spiral | #73 |
| 12 months 95 | #73 |
| soluble fibrin | #73 |
| ingelheim | #73 |
| ddimer measurement | #73 |
| prolongations | #73 |
| experimental metastasis | #74 |
| prethrombotic state | #74 |
| longterm risk | #74 |
| 1732 | #74 |
| 2550 | #74 |
| female hemorrhage | #74 |
| proteins patients | #74 |
| 2124 | #74 |
| carriers | #74 |
| dvt study | #74 |
| suspected dvt | #74 |
| 5395 | #74 |
| study selection | #74 |
| soluble thrombomodulin | #74 |
| postoperative dvt | #75 |
| thrombolytic therapy patients | #75 |
| selective factor | #75 |
| incidence bleeding events | #75 |
| 2904 | #75 |
| carotid femoral arteries | #75 |
| 8492 | #75 |
| retrospective follow | #75 |
| 1334 | #75 |
| oral combined contraceptives | #76 |
| tests primary | #76 |
| factor xii deficiency | #76 |
| combined contraceptives | #76 |
| duration thromboprophylaxis | #76 |
| early time | #76 |
| risk thrombosis | #76 |
| angiography ctpa | #76 |
| extended anticoagulation | #76 |
| social aspects | #77 |
| patients secondary | #77 |
| boehringer | #77 |
| thrombosis pregnancy | #77 |
| p023 | #77 |
| individual patient | #77 |
| ipg | #78 |
| arterial thromboembolism | #78 |
| elevated dimer | #78 |
| 20 daily | #78 |
| unprovoked | #78 |
| women thrombophilia | #78 |
| arterial wall thickness | #78 |
| female fibrinolysis | #78 |
| limulus test | #79 |
| 2486 | #79 |
| efficacy agents | #79 |
| factor adult | #79 |
| vkas | #79 |
| humans pulmonary | #79 |
| suspected acute | #79 |
| time therapeutic | #79 |
| topic heparin | #79 |
| vte fvl | #79 |
| vte rate | #80 |
| patient data | #80 |
| suspected cancer | #80 |
| sspe patients | #80 |
| subhazard ratio | #80 |
| 95 05 | #80 |
| heterozygous deficiency | #80 |
| validation models | #80 |
| alife | #80 |
| thromboembolism incidence | #80 |
| bleeding mortality | #80 |
| daily bid | #80 |
| prothrombin complex concentrate | #81 |
| systemic inflammatory | #81 |
| topic risk | #81 |
| weitz | #81 |
| outpatient basis | #81 |
| lmwh vte | #81 |
| knee arthroplasty patients | #81 |
| walking distance | #81 |
| vascular events | #81 |
| test evaluation | #81 |
| symptomatic carriers | #82 |
| crnmb | #82 |
| prospective validation | #82 |
| 50 micrograms | #82 |
| posthoc analysis | #82 |
| timeperiods | #82 |
| placebo women | #82 |
| heparin prevention | #82 |
| thrombosis incidence | #82 |
| 3month followup | #82 |
| mammography patients | #82 |
| clinical sign | #82 |
| thrombosis thrombophilia | #82 |
| common practice | #82 |
| thrombolytic drugs | #82 |
| inhibitor dabigatran | #83 |
| bistro | #83 |
| patients thrombi | #83 |
| 2213 | #83 |
| 287 | #83 |
| bleeding women | #83 |
| elective coronary | #83 |
| dimer patients | #83 |
| duration therapy | #84 |
| normotensive patients | #84 |
| prophylactic dose | #84 |
| healthcare setting | #84 |
| inhibitor rivaroxaban | #84 |
| screening humans | #84 |
| inherited thrombophilia | #84 |
| heparin treatment | #84 |
| diagnostic outcome | #84 |
| normal levels | #85 |
| asymptomatic dvt | #85 |
| antithrombin iii protein | #85 |
| endotoxins | #85 |
| thrombosis svt | #85 |
| peripheral vascular diseases | #85 |
| venous thrombosis patients | #85 |
| anticoagulants antiphospholipid | #85 |
| venovenous hemofiltration | #86 |
| 4576 | #86 |
| elevated ddimer levels | #86 |
| 75 microg | #86 |
| dabigatran vka | #86 |
| 10⁶ | #86 |
| rhapc | #86 |
| major bleeding warfarin | #86 |
| ≤50 | #87 |
| clinical impact | #87 |
| patients 28 | #87 |
| vidas | #87 |
| 95 100 | #87 |
| avws | #87 |
| contact activation | #87 |
| post‐hoc analysis | #87 |
| obstetric patients | #87 |
| acute venous | #87 |
| treatment incidence | #88 |
| treatment statins | #88 |
| lmwhs | #88 |
| washout period | #88 |
| 4 points | #88 |
| venographic | #88 |
| cdr | #88 |
| aged multicenter | #88 |
| 3319 | #88 |
| activation factor | #88 |
| internist | #88 |
| unexplained recurrent | #89 |
| rates major bleeding | #89 |
| beta blockers | #89 |
| safety noacs | #89 |
| ventilation lung | #89 |
| reversal strategies | #89 |
| costs patient | #89 |
| cytokine release | #89 |
| severe hf | #89 |
| anticoagulants dabigatran | #89 |
| stroke bleeding | #89 |
| smoking incidence | #89 |
| vte venous thromboembolism | #89 |
| ddimer | #89 |
| matisse | #89 |
| adequate treatment | #89 |
| tests test | #89 |
| outweighs | #90 |
| popliteal vein | #90 |
| new patients | #90 |
| vka dabigatran | #90 |
| thrombophilic risk factors | #90 |
| primary thromboprophylaxis | #90 |
| fibrinolytic factors | #90 |
| 2293 | #90 |
| venous thrombosis risk | #90 |
| pediatric venous | #90 |
| thromboembolism pregnancy | #91 |
| pyridines pyridones | #91 |
| 20210 | #91 |
| 60 95 | #91 |
| thrombosis women | #91 |
| cdrs | #91 |
| anticoagulants doacs | #91 |
| perfusion ratio | #91 |
| inconvenience | #91 |
| agents hemorrhage | #91 |
| combined clinical | #92 |
| single intravenous | #92 |
| thrombotic disease | #92 |
| prophylaxis incidence | #92 |
| direct thrombin inhibitors | #93 |
| scenario analyses | #93 |
| incidence knee | #93 |
| 95 years | #93 |
| rivaroxaban edoxaban | #93 |
| anticoagulation reversal | #93 |
| compression patients | #93 |
| children vte | #94 |
| test result | #94 |
| hf severity | #94 |
| 125 patients | #94 |
| 1027 | #94 |
| vte surgery | #94 |
| atherogenic lipid | #94 |
| patients symptomatic | #94 |
| heparins | #94 |
| direct oral anticoagulant | #95 |
| viia rfviia | #95 |
| european consensus statement | #95 |
| 2 levels | #95 |
| fondaparinux treatment | #96 |
| 6 12 months | #96 |
| efficacy rivaroxaban | #96 |
| xii deficiency | #96 |
| risk symptomatic | #96 |
| symptomatic vte | #96 |
| randomised crossover study | #96 |
| ddimer level | #96 |
| doacs risk | #97 |
| abnormal perfusion | #97 |
| studies evaluated | #97 |
| haemophilia patients | #97 |
| symptomatic pulmonary embolism | #97 |
| pyrazoles pyridones | #97 |
| tpa release | #97 |
| fibrin generation | #97 |
| difference rates | #97 |
| invasive testing | #97 |
| pregnancy postpartum period | #98 |
| 2875 | #98 |
| simplify | #98 |
| 16slice | #98 |
| hypercoagulable | #98 |
| essential thrombocythaemia | #98 |
| supervised exercise therapy | #98 |
| activated protein apc | #98 |
| major bleed | #98 |
| unselected | #99 |
| 2·0 | #99 |
| risk arterial | #99 |
| perfusion scintigraphy | #99 |
| acute dvt | #99 |
| probast | #99 |
| hirudin | #99 |
| lmwh warfarin | #99 |
| increasing levels | #100 |
| prevention recurrent | #100 |
| previews | #100 |
| patient groups | #100 |
| 3 trials | #100 |
| 1116 | #100 |
| gbd 2010 | #100 |
| doubleblind trial | #100 |
| warfarin patients | #100 |
| fatty foods | #100 |
| factor vii factor | #101 |
| factor viia | #101 |
| morpholines | #101 |
| aptts | #101 |
| 40 microg | #102 |
| alternative diagnosis | #102 |
| pts patients | #102 |
| low pretest probability | #102 |
| enoxaparin fondaparinux | #102 |
| 265 patients | #102 |
| venous thromboembolism women | #102 |
| pregnancy puerperium | #103 |
| adjudicated | #103 |
| endogenous thrombin | #103 |
| therapeutic consequences | #103 |
| 338 | #103 |
| arthroscopic anterior | #103 |
| cteph patients | #103 |
| doppler method | #103 |
| partial restoration | #104 |
| fibrin degradation products | #104 |
| term treatment | #104 |
| recurrence women | #104 |
| antithrombin iii | #104 |
| heparin pregnancy | #104 |
| assay variation | #104 |
| separate analyses | #104 |
| diagnostic imaging humans | #104 |
| apparent increase | #104 |
| absolute increase | #104 |
| oral factor | #104 |
| conventional therapy patients | #105 |
| 1089 | #105 |
| 7 children | #105 |
| embryo loss | #105 |
| elevated levels | #106 |
| thrombosis age | #106 |
| hospitalized patients hf | #106 |
| 314 | #106 |
| 2479 | #106 |
| thromboprophylaxis patients | #106 |
| thrombophilia | #106 |
| essentials | #106 |
| chest ray | #106 |
| study total | #106 |
| fibrinolytic systems | #106 |
| blind double | #106 |
| definition classification | #107 |
| topic recurrence | #107 |
| simplified version | #107 |
| ddimer levels | #107 |
| survival cancer patients | #107 |
| vte risk | #107 |
| thromboembolic | #107 |
| specific subgroups | #108 |
| post thrombotic syndrome | #108 |
| noncancer patients | #108 |
| grade 1c | #108 |
| cardiovascular death stroke | #108 |
| human volunteers | #108 |
| patients cancer | #108 |
| synthetic pentasaccharide | #109 |
| 1235 | #109 |
| anticoagulants cohort | #109 |
| evaluation studies | #109 |
| viia | #109 |
| 039 | #109 |
| thrombin antithrombin | #109 |
| factor mutation | #109 |
| embolism treatment | #109 |
| 500μg | #109 |
| routine coagulation | #109 |
| vka doac | #110 |
| antiplasmin | #110 |
| thrombosis treated | #110 |
| subsequent pregnancy | #110 |
| primary safety | #110 |
| inferiority trial | #110 |
| cancer activity | #110 |
| embolism quality | #110 |
| predefined | #111 |
| negative predictive 100 | #111 |
| siset | #111 |
| anticoagulants biomarkers | #111 |
| treatment risk factors | #111 |
| humans intermittent | #111 |
| obstetric complications | #111 |
| comparison control | #111 |
| patients ventricular dysfunction | #112 |
| rivaroxaban enoxaparin | #112 |
| recurrence treatment | #112 |
| thromboembolic diseases | #112 |
| epidemiology risk factors | #112 |
| efficacy prevention | #112 |
| publication anticoagulants | #112 |
| risk rivaroxaban | #112 |
| emergency situations | #112 |
| chromogenic | #112 |
| patients 70 | #112 |
| topic guidelines | #112 |
| metabolic response | #113 |
| inappropriate treatment | #113 |
| heterozygous carriers | #113 |
| lmwh risk | #113 |
| nonionic contrast | #113 |
| patients nephrotoxicity | #113 |
| dialysers | #114 |
| postphlebitic syndrome | #114 |
| study centre | #114 |
| total knee replacement | #114 |
| patients intermediate | #114 |
| cancerassociated vte | #114 |
| 0·0 | #114 |
| global public | #115 |
| positive predictive values | #115 |
| fibrinogen vwf | #115 |
| patients recurrent | #115 |
| hyperhomocysteinaemia | #115 |
| 393 | #115 |
| vte data | #116 |
| women severe preeclampsia | #116 |
| topic dabigatran | #116 |
| life treatment | #116 |
| heparin warfarin | #116 |
| reference standard | #116 |
| major bleeding 95 | #116 |
| computed tomography patients | #116 |
| agents heparin | #116 |
| anticoagulants arthroplasty | #116 |
| effects tnf | #116 |
| 2460 | #117 |
| protein resistance | #117 |
| vte complications | #117 |
| protein inhibitor pci | #117 |
| women caesarean | #117 |
| arthroscopies | #117 |
| vte children | #117 |
| fibrinolytic parameters | #117 |
| proximal dvt | #118 |
| autopsyconfirmed | #118 |
| 2744 | #118 |
| arterial thrombosis patients | #118 |
| patients extensive | #118 |
| 4118 | #118 |
| patients doac | #119 |
| humans leg | #119 |
| compression stockings | #119 |
| compared warfarin | #119 |
| incidence pulmonary embolism | #119 |
| risk thromboembolism | #120 |
| months follow | #120 |
| dabigatran factor | #120 |
| acquired deficiency | #120 |
| lactoferrin leukocyte | #120 |
| healthy humans | #120 |
| rivaroxaban patients | #120 |
| thrombosis study | #120 |
| previous vte | #120 |
| mortality diseases | #120 |
| thrombocytopenia thrombosis | #121 |
| patients prostatic cancer | #121 |
| oral hormonal | #122 |
| anti factor | #122 |
| patients 6 | #122 |
| fatal pulmonary embolism | #122 |
| studies venous | #122 |
| 100 patients | #123 |
| heparin hirudin | #123 |
| minor bleeding | #123 |
| early dynamics | #123 |
| venous thromboembolism pregnancy | #123 |
| placebo standard | #123 |
| acute infection | #123 |
| factor xia | #123 |
| heparin | #123 |
| thrombophilia pregnancy | #124 |
| statin risk | #124 |
| treatment data | #124 |
| atherogenic lipid profile | #124 |
| vte lmwh | #124 |
| ft4 levels | #124 |
| association level | #124 |
| incidence thrombosis | #125 |
| nonsignificantly | #125 |
| puerperal disorders | #125 |
| fibrinolysis inhibitor | #125 |
| intravenous heparin | #125 |
| thromboembolism recurrence | #125 |
| bayer | #125 |
| skin perfusion | #125 |
| diseases mortality | #125 |
| peripheral arterial disease | #125 |
| elevated liver enzymes | #125 |
| treatment indication | #125 |
| upper extremity | #126 |
| doacs treatment | #126 |
| distal dvt | #126 |
| unacceptably | #127 |
| patients permanent | #127 |
| occurrence vte | #127 |
| marder | #127 |
| patients ventilation | #127 |
| performance scores | #127 |
| thromboprophylaxis lmwh | #127 |
| direct factor | #128 |
| prevention | #128 |
| development vte | #128 |
| 50 age | #128 |
| treatment months | #128 |
| patients conventional therapy | #128 |
| resistance apc | #128 |
| venous thromboembolism risk | #128 |
| mortality cancer patients | #129 |
| 060 | #129 |
| elevated biomarkers | #129 |
| 1041 | #129 |
| riete registry | #129 |
| ctrough | #129 |
| 220 | #130 |
| plaster cast | #130 |
| day 10 | #130 |
| hospital discharge records | #130 |
| 194 patients | #130 |
| patients episode | #130 |
| anticoagulants antithrombins | #130 |
| internists | #130 |
| 05 patients | #131 |
| pooled incidence | #131 |
| long‐term clinical outcomes | #131 |
| linear interpolation | #131 |
| obviating | #131 |
| tests specificity | #131 |
| hoc analysis | #132 |
| postpartum period women | #132 |
| rivaroxaban versus | #132 |
| hypocoagulability | #132 |
| avidin | #133 |
| direct inhibitors | #133 |
| cha2ds2vasc | #133 |
| 80 anticoagulants | #133 |
| fxa inhibitors | #133 |
| enoxaparin treatment | #133 |
| started | #133 |
| risk pad | #134 |
| pulmonary angiography patients | #134 |
| instituted | #134 |
| embolism acute | #134 |
| selectin levels | #134 |
| rco vwf | #134 |
| anticoagulant prophylaxis | #135 |
| bnp concentration | #135 |
| activator plasminogen | #135 |
| prevalence dvt | #135 |
| east asian patients | #136 |
| months anticoagulation | #136 |
| thrombotic syndrome | #136 |
| followup patients | #136 |
| clinical prediction | #136 |
| apixaban edoxaban | #136 |
| severe pph | #136 |
| 0056 | #136 |
| diagnostic work | #137 |
| 2283 | #137 |
| factor prothrombin | #137 |
| point‐of‐care | #137 |
| sequential application | #137 |
| phase 3 trials | #137 |
| 99 patients | #137 |
| acquired thrombophilia | #137 |
| intravascular coagulation dic | #138 |
| enhanced factor | #138 |
| studies mortality | #138 |
| national guidelines | #138 |
| antidote | #138 |
| complete inhibition | #138 |
| bleeding warfarin | #138 |
| 95 major bleeding | #139 |
| 3 weeks | #139 |
| factor viii factor | #139 |
| risk fatal | #139 |
| reproducibility risk | #139 |
| 2465 | #139 |
| patients comparison | #139 |
| direct inhibitor | #139 |
| oral anticoagulant treatment | #139 |
| vwf rco | #140 |
| dvt incidence | #140 |
| 0114 | #140 |
| 20 iu | #140 |
| distal deep | #140 |
| 80 cohort | #140 |
| ottawa | #140 |
| human activated | #140 |
| 12 95 | #140 |
| thromboembolic disorders | #141 |
| pharmacy records | #141 |
| antidotes | #141 |
| thrombin potential | #142 |
| carriership | #142 |
| warfarin administration | #143 |
| jugular veins | #143 |
| escherichia humans | #143 |
| geneva | #143 |
| active malignancy | #143 |
| ischaemic events | #143 |
| treatment pulmonary | #143 |
| points 95 | #143 |
| topic practice patterns | #144 |
| compared treatment | #144 |
| pregnancy female humans | #144 |
| fatal pulmonary | #144 |
| doac treatment | #144 |
| management vte | #144 |
| postoperative venous | #144 |
| filters venous | #145 |
| dose rivaroxaban | #145 |
| patient populations | #145 |
| referred patients | #145 |
| thrombosis model | #145 |
| hyperthyroxinemia | #145 |
| serial testing | #145 |
| derived microvesicles | #146 |
| months treatment | #146 |
| protein factor | #146 |
| death cancer patients | #146 |
| personal fees | #147 |
| tissue factor pathway | #147 |
| long‐acting | #148 |
| 10 years patients | #148 |
| partial thromboplastin | #148 |
| acute medical illness | #148 |
| 2076 | #148 |
| rebuttal | #148 |
| antithrombotic drugs | #148 |
| embolism diagnosis | #148 |
| intention treat | #148 |
| individual patient data | #149 |
| diagnostic score | #149 |
| relevant publications | #149 |
| vte hospitalization | #149 |
| 0·45 | #149 |
| thrombocyte | #149 |
| procoagulant | #149 |
| risk subgroups | #149 |
| dimer level | #150 |
| coagulation dic | #151 |
| humans injections | #151 |
| enoxaparin unfractionated heparin | #151 |
| additional imaging | #151 |
| longterm treatment | #152 |
| bleeding patients | #152 |
| continuous venovenous | #152 |
| patient eligibility | #152 |
| patients primary outcome | #152 |
| extracorporeal circuit | #153 |
| point systems | #153 |
| cardiopulmonary bypass surgery | #153 |
| hypercoagulable state | #153 |
| thrombosis prevention | #153 |
| bleeding scores | #154 |
| dimer levels | #154 |
| angioplasty patients | #154 |
| thrombosis factor | #154 |
| direct thrombin | #154 |
| activity mortality | #154 |
| active cancer | #154 |
| states venous | #155 |
| fiia | #155 |
| tomography patients | #155 |
| drug factor | #155 |
| warfarin apixaban | #155 |
| thromboembolic event | #155 |
| curve sensitivity | #155 |
| coagulant activity | #156 |
| 09 | #156 |
| patients gastrointestinal | #156 |
| daily oral | #156 |
| vte treatment | #156 |
| stockings | #156 |
| enoxaparin dose | #156 |
| recurrent symptoms | #156 |
| fvl | #156 |
| prophylaxis patients | #157 |
| increased thrombin | #157 |
| cross‐sectional survey | #157 |
| hemodynamically | #157 |
| underlying malignancy | #158 |
| dfl | #158 |
| 2126 | #158 |
| months chemotherapy | #158 |
| duration anticoagulation | #158 |
| 97 | #158 |
| increased risk thrombosis | #159 |
| adjusted relative risk | #159 |
| plasma dimer | #160 |
| 145 patients | #160 |
| thrombotic disorders | #160 |
| guidelines prevention | #160 |
| antithrombotic efficacy | #160 |
| children fh | #160 |
| 120 minutes | #160 |
| schering | #160 |
| prophylactics | #161 |
| pvo | #161 |
| antagonists patients | #161 |
| lysine analogues | #162 |
| patients imaging | #162 |
| incidence vte | #162 |
| 2206 | #162 |
| women time | #162 |
| coagulation blood | #163 |
| rates vte | #163 |
| strain gauge | #163 |
| 198 patients | #163 |
| increased plasma levels | #163 |
| factors bleeding | #163 |
| venous thrombus | #163 |
| imaging test | #163 |
| lmwh therapy | #163 |
| age comorbidity | #164 |
| 028 | #164 |
| observer variability | #164 |
| justified | #164 |
| inborn humans | #164 |
| subhazard | #165 |
| mutation factor | #165 |
| patients enoxaparin | #165 |
| relatives patients | #165 |
| stockings compression | #166 |
| management venous thromboembolism | #166 |
| pravastatin therapy | #166 |
| viii factor | #166 |
| strategies patients | #166 |
| microvascular thrombosis | #166 |
| phlebography | #166 |
| ankle brachial abi | #167 |
| thrombin venous | #167 |
| recurrent thrombosis | #167 |
| 3658 | #167 |
| warfarin | #168 |
| treatment 3 months | #168 |
| cstatistics | #168 |
| double heterozygosity | #168 |
| current clinical practice | #168 |
| recurrent acute | #168 |
| syndrome pts | #168 |
| cvcs | #168 |
| risk profile | #169 |
| fold increased | #169 |
| postthrombotic syndrome pts | #169 |
| preexistent | #169 |
| patients infections | #169 |
| therapeutic range | #169 |
| 3 12 | #169 |
| heavy menstrual bleeding | #170 |
| thrombosis cancer | #170 |
| postoperative blood loss | #170 |
| interobserver agreement | #170 |
| cart patients | #170 |
| adamts‐13 | #171 |
| 57 years | #171 |
| venous thrombotic events | #171 |
| recombinant factor | #171 |
| aged algorithms | #171 |
| pulmonology | #172 |
| antifibrinolytic | #172 |
| clinical trials patients | #172 |
| lmw heparin | #172 |
| vaginal bleeding | #172 |
| patients blood transfusion | #172 |
| risk factors patients | #172 |
| pulmonary | #173 |
| inr | #173 |
| bleeds | #173 |
| hospitalized medical patients | #173 |
| patients initial | #174 |
| laboratory monitoring | #174 |
| clinically bleeding | #174 |
| bleeding tendency | #174 |
| arterial occlusions | #174 |
| reocclusion | #175 |
| vte common | #175 |
| data control | #175 |
| fragment 1 | #175 |
| arterial venous | #175 |
| prothrombin | #177 |
| picotamide | #177 |
| mitsubishi | #177 |
| short‐ | #178 |
| hyperthyroidism hypothyroidism | #178 |
| 122 | #178 |
| aspirin ticlopidine | #178 |
| intention analysis | #178 |
| concomitance | #179 |
| oral female humans | #179 |
| vte event | #179 |
| noninferior | #179 |
| baseline day | #179 |
| thromboplastin time | #180 |
| isth | #180 |
| patients deficiency | #180 |
| referral bias | #180 |
| ventilation perfusion | #180 |
| additional risk factors | #180 |
| aged partial | #181 |
| acute episode | #182 |
| antithrombin | #182 |
| testing patients | #182 |
| painkillers | #182 |
| 2–4 | #183 |
| patients major | #183 |
| hyperhomocysteinemic | #183 |
| biological variation | #183 |
| incidental | #184 |
| risk bleeding | #184 |
| subsequent diagnosis | #184 |
| treat analysis | #184 |
| n110 | #184 |
| coagulation factors | #184 |
| pregnancy vte | #184 |
| antithrombin iii atiii | #184 |
| thromboinflammation | #184 |
| 4150 | #184 |
| prognosis pulmonary | #184 |
| vte age | #185 |
| deficient patients | #185 |
| live birth rate | #186 |
| symptomatic | #186 |
| hemostatic effects | #186 |
| patients thromboprophylaxis | #186 |
| studies heparin | #186 |
| anticoagulated | #186 |
| brain natriuretic | #186 |
| patients intensive units | #186 |
| antifibrinolytic agents | #187 |
| safety apixaban | #187 |
| risk composite | #187 |
| cutoff level | #187 |
| patients haemophilia | #187 |
| doacs vkas | #188 |
| humans international | #188 |
| prevalence cancer | #188 |
| ratio inr | #188 |
| spontaneous rupture | #188 |
| absolute rate | #188 |
| 926 | #188 |
| willebrand factor antigen | #189 |
| patients netherlands | #189 |
| heparin administration | #189 |
| fibrinolysis | #189 |
| blood loss patients | #189 |
| 64slice | #189 |
| clinical validity | #189 |
| viia female | #189 |
| riete | #189 |
| thrombosis patients | #190 |
| ccus | #190 |
| anticoagulant drugs | #190 |
| ischemic event | #190 |
| current views | #190 |
| gogh | #191 |
| acute thrombosis | #191 |
| attending physicians | #191 |
| 07 | #191 |
| venous outflow | #191 |
| score patients | #191 |
| 1495 | #192 |
| stroke systemic | #192 |
| 058 | #192 |
| endothelial cell activation | #193 |
| coagulation assays | #193 |
| prothrombin activation | #194 |
| 070 | #194 |
| heparin patients | #194 |
| anticoagulation | #194 |
| blood coagulation | #194 |
| antixa levels | #195 |
| target range | #195 |
| risk major | #195 |
| 65 months | #195 |
| antagonist treatment | #195 |
| recurrent ischemic events | #195 |
| complications cardiovascular | #196 |
| abnormal test | #196 |
| 29 95 | #196 |
| coagulation status | #196 |
| difference treatment | #198 |
| vii rfviia | #198 |
| vwf adamts13 | #198 |
| treatment groups patients | #198 |
| ate | #198 |
| sew2871 | #198 |
| patient diagnosis | #199 |
| cachectin | #199 |
| coagulation monitoring | #199 |
| incidence cardiovascular events | #200 |
| screening patients | #200 |
| patients 12 months | #200 |
| obese controls | #200 |
| thrombin factor | #201 |
| patients abnormal | #201 |
| vte incidence | #201 |
| validation sets | #201 |
| thromboembolic disease | #201 |
| arterial thrombosis | #202 |
| johnson | #202 |
| 17 95 | #202 |
| peritoneovenous | #202 |
| induced activation | #203 |
| heparin dose | #203 |
| worldwide survey | #203 |
| symptomatic pad | #203 |
| invitees | #203 |
| levonorgestrel | #204 |
| antithrombotic agents | #204 |
| stroke systemic embolism | #205 |
| extended thromboprophylaxis | #205 |
| 0 95 | #205 |
| low incidence | #205 |
| period time | #205 |
| thrombophilia risk | #205 |
| fgt | #206 |
| data synthesis | #206 |
| patients anticoagulant therapy | #206 |
| venous ultrasonography | #206 |
| varese | #206 |
| 06 | #207 |
| desogestrel | #207 |
| cardiologist | #207 |
| death female humans | #207 |
| systematic review studies | #207 |
| imt patients | #207 |
| objectively | #207 |
| fviii | #207 |
| algorithms anticoagulants | #207 |
| methods consecutive | #207 |
| platelet activation patients | #207 |
| bleeding compared | #208 |
| patients hypothyroidism | #208 |
| thrombocythaemia | #208 |
| deficiency risk | #209 |
| free protein | #209 |
| tgt | #210 |
| women frequency | #210 |
| antixa activity | #210 |
| hirudins | #210 |
| ioxaglate | #211 |
| stocking | #211 |
| toxaemia | #211 |
| systemic embolism patients | #211 |
| anticoagulation management | #212 |
| atrial fibrillation study | #212 |
| plasminogen activator activity | #213 |
| heparitin sulfate | #213 |
| topic practice | #214 |
| dabigatran dose | #214 |
| correct interpretation | #214 |
| standard duration | #215 |
| factors vte | #215 |
| current developments | #215 |
| thrombin inhibition | #215 |
| studies rivaroxaban | #215 |
| duplex venous | #216 |
| betatg | #216 |
| warfarin stroke | #216 |
| deamino | #216 |
| community hospital | #216 |
| mildest | #217 |
| undergoing total | #217 |
| obviates | #217 |
| studies difference | #217 |
| diagnostic algorithm | #217 |
| npv 100 | #218 |
| conclusive evidence | #218 |
| cstatistic | #218 |
| g20210a | #218 |
| plasminogen activator inhibitor | #218 |
| deamino arginine | #219 |
| cancer | #219 |
| 077 95 | #219 |
| patients cart | #219 |
| techniques female | #220 |
| data extraction | #220 |
| vii factor | #220 |
| hip replacement surgery | #220 |
| viii female | #220 |
| postoperative vte | #221 |
| hmvec | #221 |
| preventive measures | #221 |
| healthy human subjects | #221 |
| heparin humans | #221 |
| proximally | #222 |
| vte events | #222 |
| apc resistance | #222 |
| substantial proportion | #223 |
| 1541 | #223 |
| 1 january | #223 |
| pulmonologists | #223 |
| engl | #223 |
| protein pathway | #224 |
| subsequent cancer | #224 |
| thromboendarterectomy | #224 |
| topic factor | #224 |
| org | #225 |
| neoplasms prospective | #225 |
| balloon coronary anticoagulants | #225 |
| kruskalwallis | #225 |
| thrombosis warfarin | #225 |
| extremity amputation | #226 |
| vascular events patients | #226 |
| inr monitoring | #226 |
| 0·67 | #226 |
| 16 95 | #226 |
| acute medical | #227 |
| haemostasis | #227 |
| tests diagnosis | #227 |
| 35 ± | #227 |
| mild hyperhomocysteinemia | #228 |
| ipe | #228 |
| residual thrombus | #229 |
| dalteparin | #229 |
| scant | #229 |
| cgp | #229 |
| 037 | #230 |
| advocated | #230 |
| equinox | #231 |
| patients discontinuation | #231 |
| thiazoles | #231 |
| major orthopaedic surgery | #231 |
| habitual abortion | #231 |
| urosepsis | #231 |
| ft4 | #231 |
| 6 studies | #231 |
| resource utilisation | #231 |
| severe preeclampsia | #231 |
| aspirin dipyridamole | #232 |
| patients warfarin | #232 |
| surgical embolectomy | #233 |
| recurrence risk factors | #233 |
| dimer | #233 |
| humans netherlands | #233 |
| endogenous thrombin potential | #233 |
| cancer prevalence | #233 |
| anticoagulant effects | #233 |
| effective alternative | #234 |
| graduated compression | #235 |
| doac | #235 |
| prothrombotic state | #235 |
| humans meta | #236 |
| venous thromboembolic events | #236 |
| brain natriuretic peptide | #236 |
| treatment continuation | #237 |
| oral anticoagulants | #237 |
| myocardial infarction 95 | #237 |
| patients vkas | #238 |
| 009 | #238 |
| predictive tests | #238 |
| 6500 | #238 |
| rational approach | #239 |
| anticoagulants aspirin | #239 |
| factor viii fviii | #239 |
| crossover study | #239 |
| factor tnf | #239 |
| arterial venous thrombosis | #240 |
| patients initial treatment | #240 |
| 045 | #241 |
| aspirin heparin | #241 |
| hip knee arthroplasty | #241 |
| bleeding incidence | #242 |
| time therapeutic range | #242 |
| prothrombin fragment | #243 |
| pivotal trials | #243 |
| patients intermittent claudication | #243 |
| iohexol | #244 |
| vte risk factors | #245 |
| n89 | #245 |
| thrombogenesis | #246 |
| children neonates | #246 |
| vte cases | #246 |
| casecontrol | #246 |
| lipoproteina levels | #247 |
| warfarin aged | #247 |
| antithrombotic | #247 |
| 23 95 | #247 |
| treatment compared | #248 |
| committees | #248 |
| anti activity | #248 |
| coronary anticoagulants | #248 |
| patients solid tumours | #248 |
| score risk | #249 |
| multiple comorbidities | #249 |
| bleeding rates | #249 |
| diagnostic models | #249 |
| fv leiden | #250 |
| ischemic strokes | #250 |
| ioxaglic | #250 |
| protein risk | #250 |
| finalized | #251 |
| patients contraindications | #251 |
| microthrombosis | #251 |
| 8595 | #251 |
| vkas doacs | #252 |
| somit | #252 |
| simplification | #252 |
| incidence | #253 |
| thrombin thrombosis | #253 |
| agents anticoagulants | #254 |
| treatment duration | #254 |
| fibrinolytic activity | #255 |
| palga | #255 |
| activation humans | #256 |
| haul | #256 |
| medea | #256 |
| activity assay | #257 |
| cost‐effectiveness | #257 |
| q24h | #257 |
| bleeding risk | #257 |
| continuous intravenous | #257 |
| clinical utility | #257 |
| patient subgroups | #258 |
| fibrin degradation | #258 |
| ctpa | #258 |
| unpublished data | #259 |
| 30 50 | #259 |
| sspe | #260 |
| dvt risk | #260 |
| noncarriers | #261 |
| thrombus size | #261 |
| heparin dosing | #261 |
| toxicosis | #261 |
| patients hospitalization | #262 |
| optimal duration | #263 |
| risk pulmonary | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| pbac | #267 |
| einstein | #267 |
| endotoxaemia | #268 |
| statins risk | #268 |
| randomised cross | #269 |
| malignancy patients | #269 |
| propeptide | #269 |
| lysis time | #269 |
| relation time | #269 |
| versus aspirin | #269 |
| single test | #270 |
| protein patients | #270 |
| exclusion | #270 |
| discontinuing | #270 |
| thrombosis inflammation | #271 |
| platelet serotonin | #271 |
| hormonal replacement therapy | #271 |
| orthopaedic patients | #271 |
| 3·0 | #271 |
| protein apc | #271 |
| clopidogrel ticlopidine | #272 |
| vte recurrence | #272 |
| patients combination | #272 |
| bleeding patient | #272 |
| groups levels | #272 |
| efficacy analysis | #273 |
| ankle brachial | #273 |
| months 12 | #274 |
| cleavage sites | #274 |
| risk levels | #274 |
| prevalence pad | #274 |
| international normalized | #275 |
| parenteral nutrition patients | #275 |
| performance score | #275 |
| fourth quartile | #276 |
| antithrombotic agent | #276 |
| time aptt | #277 |
| smoking hypertension | #277 |
| normalized ratio | #278 |
| dose reduction | #278 |
| imaging sensitivity | #278 |
| rco | #279 |
| blood test | #279 |
| aptt | #279 |
| exclusion criteria | #280 |
| intracranial hemorrhage patients | #280 |
| propositi | #280 |
| partial thromboplastin time | #280 |
| obviate | #280 |
| hospitalized medical | #280 |
| patients presence | #281 |
| diagnostic test | #282 |
| thromboplastin | #282 |
| diagnostic sensitivity | #283 |
| neutrophil degranulation | #283 |
| puerperal | #283 |
| thyroid diseases | #283 |
| presentation patients | #283 |
| animals anticoagulants | #284 |
| outpatient treatment | #284 |
| test characteristics | #284 |
| noninferiority margin | #284 |
| favor | #284 |
| departments | #284 |
| major orthopaedic | #285 |
| gentamicin treatment | #286 |
| 2630 | #286 |
| patients apixaban | #286 |
| plasma bnp | #286 |
| levels measured | #287 |
| clinically | #287 |
| disseminated intravascular | #287 |
| subdistribution | #287 |
| patients pancreatic cancer | #287 |
| md patients | #288 |
| premature atherosclerosis | #288 |
| 227 | #288 |
| oral combined | #288 |
| substantiation | #289 |
| cvt patients | #289 |
| vte rates | #289 |
| vte women | #289 |
| clot lysis | #289 |
| thrombin time | #290 |
| n59 | #290 |
| 0·50 | #290 |
| 016 | #291 |
| carriers mutation | #291 |
| extracted data | #291 |
| current clinical | #291 |
| oral contraceptives | #291 |
| 1603 | #292 |
| activator inhibitor | #292 |
| willebrand disease vwd | #292 |
| 2 studies | #292 |
| patients dabigatran | #293 |
| pentasaccharide | #293 |
| plasmin activity | #293 |
| adverse outcome patients | #293 |
| 1000 personyears | #293 |
| tissuetype plasminogen activator | #294 |
| lower extremities | #294 |
| patients rivaroxaban | #294 |
| cardiac troponin ctnt | #294 |
| scenario analysis | #295 |
| extremity dvt | #295 |
| 1025 | #295 |
| peripheral vascular | #296 |
| coagulation factor viii | #296 |
| classified | #296 |
| routine monitoring | #297 |
| observer agreement | #297 |
| specificity npv | #298 |
| episode patients | #298 |
| recurrent miscarriage | #298 |
| thrombocytes | #298 |
| patients inr | #299 |
| inferiority | #300 |
| heparitin | #301 |
| 041 | #301 |
| aged neoplasms | #302 |
| toxemia | #302 |
| subclinical thyroid dysfunction | #302 |
| thromboglobulin | #302 |
| 155 patients | #302 |
| absolute difference | #304 |
| 1214 | #304 |
| rivaroxaban dabigatran | #305 |
| prophylactic administration | #306 |
| medline embase | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| thrombotic | #310 |
| surgery day | #310 |
| vte pregnancy | #310 |
| hematologic pregnancy | #310 |
| patients 100 | #311 |
| clinical presentation | #311 |
| percentage points | #311 |
| antithrombins blood | #311 |
| 105 patients | #311 |
| leg male | #312 |
| 598 | #312 |
| hereditary thrombophilia | #313 |
| vte 95 | #313 |
| obesity risk factor | #313 |
| negative reactions | #313 |
| diagnosis | #314 |
| postpartum haemorrhage | #315 |
| funding | #315 |
| puerperium | #315 |
| cardiologists | #315 |
| heparin aspirin | #315 |
| apixaban versus | #316 |
| therapeutic dose | #316 |
| patients followup | #317 |
| adjudicators | #317 |
| 0·92 | #318 |
| deciding | #318 |
| safety outcomes | #319 |
| failure rates | #319 |
| decision model | #319 |
| catheter thrombosis | #320 |
| influenza infections | #320 |
| 1731 | #320 |
| combined administration | #320 |
| bnp levels | #320 |
| patients pregnancy | #320 |
| ventricular dysfunction patients | #321 |
| additional data | #322 |
| difference risk | #322 |
| patients noacs | #322 |
| intermediate phenotype | #322 |
| peripheral arterial | #324 |
| inrs | #324 |
| glaxosmithkline | #324 |
| convincing evidence | #325 |
| mortality odds ratio | #325 |
| mechanical heart valves | #326 |
| pulmonary embolus | #326 |
| blood coagulation factor | #326 |
| 122 patients | #326 |
| clinical | #327 |
| surgery trauma | #327 |
| association vte | #329 |
| vitamin administration | #331 |
| thrombotic event | #331 |
| incidence bleeding | #331 |
| pregnancy outcome women | #331 |
| new oral | #332 |
| n69 | #333 |
| analysis trials | #333 |
| embase databases | #333 |
| 95 percent | #333 |
| incidences | #334 |
| 95 confidence limits | #334 |
| complicate | #334 |
| minor effects | #334 |
| fibrillation benzimidazoles | #335 |
| rationale design | #335 |
| patients healthy volunteers | #335 |
| pulmonary perfusion | #336 |
| septicaemia | #336 |
| central venous catheter | #336 |
| 035 | #337 |
| 065 | #337 |
| recurrent | #337 |
| 2 points | #337 |
| plethysmographic | #337 |
| total hip replacement | #337 |
| aged netherlands | #338 |
| fatal bleeding | #338 |
| outpatient management | #338 |
| coagulation abnormalities | #338 |
| prospective clinical study | #339 |
| noacs warfarin | #339 |
| placebo trials | #339 |
| antithrombotic effects | #340 |
| 024 | #340 |
| patients 12 | #340 |
| activatable | #341 |
| 217 | #341 |
| coagulation markers | #341 |
| noac patients | #342 |
| knee arthroscopy | #342 |
| pretest | #344 |
| patients covid19 infection | #344 |
| rfviia | #345 |
| splanchnic vein thrombosis | #345 |
| antithrombotic strategies | #345 |
| vte prevention | #345 |
| diagnosis vte | #346 |
| embolisms | #346 |
| patients thrombosis | #347 |
| activated protein resistance | #347 |
| 073 | #347 |
| 044 | #348 |
| cochrane central | #348 |
| 2575 | #349 |
| chads2 | #349 |
| bsf | #349 |
| randomized studies | #350 |
| brain predictive | #350 |
| trousseau | #350 |
| tafia | #350 |
| factor viii | #351 |
| versus warfarin | #351 |
| 013 | #351 |
| selection bias | #352 |
| factor activation | #352 |
| dermatan sulphate | #352 |
| anticoagulants noacs | #352 |
| oral anticoagulant therapy | #353 |
| 1590 | #353 |
| relative efficacy | #353 |
| vein | #353 |
| 5075 | #353 |
| aged pulmonary | #354 |
| international normalized ratio | #354 |
| patients gp | #355 |
| studies diagnostic accuracy | #355 |
| protein deficiency | #356 |
| post hoc | #357 |
| tests prospective studies | #357 |
| intestinal microbiome | #357 |
| categorised | #357 |
| 127 patients | #358 |
| sucra | #360 |
| pilots | #360 |
| intermittent claudication | #361 |
| treatment risk | #362 |
| consensus agreement | #362 |
| anticoagulation patients | #364 |
| conventional therapy | #365 |
| humans risk | #365 |
| bleeding rate | #366 |
| topic female | #366 |
| prediction models | #367 |
| time recurrence | #368 |
| infrainguinal | #368 |
| patients 3 | #368 |
| thrombin inhibitor | #369 |
| patients acl reconstruction | #370 |
| influenza infection | #370 |
| 6week | #370 |
| endotoxin infusion | #371 |
| venous stasis | #371 |
| 055 | #372 |
| 803 | #372 |
| recombinant activated | #373 |
| aprotinin blood | #373 |
| clinical suspicion | #373 |
| patients svt | #373 |
| knee surgery | #373 |
| patients scores | #374 |
| helical computed tomography | #374 |
| human cytomegalovirus infection | #374 |
| subcutaneous | #375 |
| hmb | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| stroke venous | #380 |
| contraceptives oral | #380 |
| tafi | #381 |
| ethinyloestradiol | #381 |
| antitnf | #382 |
| prefilter | #383 |
| multivariate regression analysis | #384 |
| reassessed | #384 |
| 0·8 | #384 |
| standardized questionnaire | #384 |
| thromboembolic complications | #384 |
| systemic activation | #385 |
| alpha2m | #385 |
| conference proceedings | #386 |
| surrogate outcome | #386 |
| bleeding events | #386 |
| cumulative incidences | #387 |
| sensitivity npv | #387 |
| antithrombins | #387 |
| delegates | #388 |
| major orthopedic | #388 |
| 880 | #389 |
| systemic embolism | #389 |
| safety rivaroxaban | #389 |
| referred | #389 |
| tinzaparin | #390 |
| apixaban warfarin | #390 |
| vitt | #390 |
| abi | #391 |
| postop | #391 |
| comparison patients | #391 |
| biosis | #391 |
| drug prescription | #391 |
| increased bleeding | #391 |
| topic female humans | #392 |
| patients chest | #392 |
| time presentation | #392 |
| factors thrombosis | #393 |
| kappa values | #393 |
| clinical score | #394 |
| pulmonary emboli | #394 |
| background patients | #394 |
| injections intravenous | #394 |
| 007 | #395 |
| popliteal | #396 |
| bleeding event | #396 |
| 95 12 | #396 |
| 665 | #397 |
| replacement surgery | #397 |
| embolic events | #397 |
| factors factor | #397 |
| hirudins humans | #397 |
| risk score patients | #399 |
| heparin induced | #400 |
| risk factors asthma | #400 |
| patients risk | #400 |
| echography | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| increased risk vte | #403 |
| controversy | #403 |
| dabigatran | #403 |
| massive pulmonary embolism | #405 |
| 2215 | #406 |
| treatment patient | #406 |
| 075 | #406 |
| thrombolytic agents | #406 |
| factor levels | #408 |
| oral anticoagulant | #408 |
| biologic effects | #410 |
| patients assigned | #411 |
| fviii levels | #411 |
| noacs patients | #411 |
| safety combination | #411 |
| transfusion patients | #412 |
| 20 microg | #412 |
| major risk factor | #412 |
| euthyroidism | #414 |
| maastricht | #414 |
| coagulation patients | #414 |
| xii | #415 |
| aged odds | #415 |
| hypocortisolism | #415 |
| pai1 levels | #416 |
| intravascular coagulation | #416 |
| deserve | #416 |
| dose heparin | #416 |
| comparable | #417 |
| 95 10 | #417 |
| data risk | #417 |
| 95 | #418 |
| carotid femoral | #418 |
| pretest probability | #418 |
| risk factors thrombosis | #419 |
| 269 | #419 |
| dermatan | #419 |
| xia | #420 |
| ototoxicity | #420 |
| fibrillation risk | #421 |
| tests radiography | #422 |
| fibrillation clinical | #422 |
| 2850 | #422 |
| 1989 | #422 |
| fibrinolysin | #423 |
| fviia | #424 |
| subanalysis | #424 |
| prevalence patients | #425 |
| cancer cohort | #426 |
| randomised double | #426 |
| adjunct | #426 |
| fii | #426 |
| consecutive | #427 |
| activated factor | #427 |
| conferences | #428 |
| daily practice | #428 |
| plg | #428 |
| excessive bleeding | #428 |
| idiopathic myelofibrosis | #429 |
| patients testing | #429 |
| daily clinical practice | #429 |
| prolactin levels | #429 |
| undergoing elective | #429 |
| 1904 | #430 |
| heparinoids | #431 |
| rule | #431 |
| bleeding complications | #431 |
| 04 | #432 |
| incidence length | #433 |
| outpatients | #433 |
| ncb | #434 |
| patients systematic review | #434 |
| firstdegree relatives patients | #436 |
| blood cultures | #436 |
| 059 | #437 |
| bolus injection | #437 |
| proven | #439 |
| dose adjustment | #439 |
| composite point | #439 |
| prostatic cancer | #439 |
| women compared | #439 |
| concomitant medications | #441 |
| highrisk populations | #441 |
| rate vte | #442 |
| 074 | #442 |
| standard therapies | #444 |
| –control study | #444 |
| prespecified | #445 |
| febrile patients | #446 |
| patients atrial fibrillation | #446 |
| female fibrinolytic | #447 |
| hellp | #449 |
| utrecht | #449 |
| 58 | #449 |
| patients parenteral nutrition | #449 |
| 3 12 months | #450 |
| prevalence distribution | #450 |
| category | #451 |
| stigmatisation | #451 |
| pipecolic | #452 |
| noninvasive tests | #453 |
| fatal disease | #453 |
| thrombin generation | #453 |
| aspirin risk | #453 |
| portal blood | #454 |
| placebo day | #454 |
| factor xii | #454 |
| 30 40 | #454 |
| microthrombi | #455 |
| 026 | #455 |
| 12week | #455 |
| dichotomized | #456 |
| fviii vwf | #456 |
| onwards | #457 |
| squibb | #457 |
| dicumarol | #457 |
| iii complexes | #458 |
| hazard ratio 95 | #458 |
| anti levels | #458 |
| recommend | #460 |
| plasma lipoprotein | #460 |
| svt | #460 |
| factor fxa | #461 |
| gastrointestinal cancer | #461 |
| curve biomarkers | #462 |
| expert consensus document | #462 |
| hip arthroplasty replacement | #462 |
| haemolysis | #463 |
| guidelines patients | #463 |
| gp iib | #464 |
| patients values | #464 |
| studies ultrasonography | #464 |
| month follow | #465 |
| cancerassociated thrombosis | #466 |
| diabetes stroke | #466 |
| accuracy detection | #467 |
| thrombin formation | #467 |
| patients nsaids | #468 |
| intimamedia thickness | #468 |
| prophylaxis | #468 |
| bmi≥30 | #469 |
| eligible studies | #469 |
| teaching hospitals | #469 |
| hemihepatectomy | #470 |
| 077 | #470 |
| roc analysis | #470 |
| test probability | #470 |
| inr patients | #470 |
| placebo recipients | #471 |
| prophylactic anticoagulation | #472 |
| case control study | #472 |
| hypercoagulability | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| plethysmograph | #475 |
| heterozygote humans | #475 |
| intermittent pneumatic | #475 |
| patients heparin | #475 |
| 15 95 | #475 |
| endotoxemia | #475 |
| atria | #477 |
| patients score | #479 |
| haemophiliacs | #479 |
| 08 | #479 |
| versus standard | #480 |
| acutely | #481 |
| thrombosis cvt | #481 |
| hit patients | #481 |
| transportability | #482 |
| advisory | #482 |
| postoperative blood | #482 |
| 1162 | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| diagnostic efficacy | #485 |
| patients hematologic malignancies | #485 |
| awaited | #486 |
| secondary prophylaxis | #487 |
| composite scores | #487 |
| travel | #488 |
| silent | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| p00007 | #493 |
| new therapy | #493 |
| hemophilic | #493 |
| treatment period | #493 |
| pan troglodytes | #493 |
| residual risk | #493 |
| vcf | #494 |
| activated protein | #495 |
| dose oral | #496 |
| favour | #496 |
| heterozygote | #496 |
| replacement hip arthroplasty | #496 |
| topic risk factors | #497 |
| 271 | #497 |
| blockages | #498 |
| risk factors stroke | #498 |
| willebrand disease | #498 |
| discriminative ability | #498 |
| hip knee | #501 |
| ptp | #502 |
| nri | #502 |
| deficiencies | #503 |
| ft4 tsh | #503 |
| subcategories | #503 |
| rapid decrease | #504 |
| complications pulmonary | #505 |
| nondiagnostic | #505 |
| 1107 | #505 |
| patients referred | #505 |
| 310 | #506 |
| net clinical | #506 |
| oftentimes | #507 |
| day surgery | #507 |
| nonionic | #507 |
| inhibitors rivaroxaban | #508 |
| 13 95 | #509 |
| aminocaproates | #509 |
| guidelines diagnosis | #509 |
| coagulation tests | #509 |
| contraceptives | #509 |
| thrombosis animals | #510 |
| angiography patients | #510 |
| new oral anticoagulants | #510 |
| degradation products | #510 |
| viii fviii | #511 |
| 019 | #512 |
| epiphenomenon | #512 |
| serial | #513 |
| highintensity | #514 |
| interim analysis | #514 |
| 056 | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| sensitivity diagnosis | #518 |
| thrombophilia thrombosis | #518 |
| bleeding outcomes | #518 |
| protein antithrombin | #518 |
| thrombotic diseases | #518 |
| groups treatment | #519 |
| treatment cancer patients | #519 |
| study sensitivity | #520 |
| 1599 | #521 |
| 8090 | #521 |
| duration intensity | #521 |
| warfarin therapy | #524 |
| fixed doses | #525 |
| general practitioner | #525 |
| 062 | #527 |
| cancer age | #528 |
| cindices | #528 |
| 051 | #529 |
| convincing | #529 |
| 378 | #529 |
| 923 | #529 |
| health female | #530 |
| fatal | #530 |
| humans postoperative | #531 |
| medically patients | #531 |
| thrombosis hemostasis | #531 |
| betaalanine | #531 |
| 068 | #532 |
| thrombosis risk | #532 |
| ≥50 years | #532 |
| intensive units icu | #532 |
| therapy cancer | #534 |
| factor thrombin | #534 |
| 730 | #536 |
| factor pathway | #537 |
| 449 | #538 |
| patients idiopathic | #538 |
| humans neoplasms | #538 |
| concise | #539 |
| cbo | #539 |
| ddavp | #539 |
| comprehensive search | #539 |
| diagnostic accuracy studies | #540 |
| clinical review | #540 |
| diagnosis acute | #540 |
| 234 | #543 |
| thrombotic risk | #543 |
| conventional treatment | #543 |
| vascular obstruction | #543 |
| patients eligible | #543 |
| bleeding episodes | #543 |
| jak2 mutation | #544 |
| 00 | #544 |
| pad abi | #544 |
| coagulative | #544 |
| v617f | #545 |
| prospective cohort study | #545 |
| hellp syndrome | #545 |
| perc | #545 |
| screening strategies | #546 |
| association statin | #546 |
| prothrombin complex | #547 |
| bureau | #547 |
| primary | #548 |
| 95 difference | #549 |
| adequate | #549 |
| overt | #549 |
| platelet inhibitors | #550 |
| cancer type | #550 |
| 1103 | #550 |
| reviewers | #550 |
| conduction anesthesia | #550 |
| percent patients | #550 |
| management bleeding | #552 |
| studies sensitivity | #552 |
| careful | #552 |
| amsterdam | #552 |
| day patients | #552 |
| 500 patients | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| 66 patients | #558 |
| vivo treatment | #558 |
| factor vii | #558 |
| orthopedic surgery | #559 |
| bleeding time | #559 |
| limulus | #561 |
| risk development | #563 |
| patients transfusion | #563 |
| board directors | #563 |
| female humans tests | #563 |
| appears | #564 |
| hip replacement | #564 |
| anamnesis | #564 |
| hyperfibrinolysis | #565 |
| increasing risk | #565 |
| solid tumours | #566 |
| cardiac troponins | #566 |
| withholding | #566 |
| patients 2 years | #568 |
| n46 | #568 |
| roc curves | #568 |
| levothyroxine | #571 |
| alpha1antitrypsin | #571 |
| aggravation | #572 |
| ctnt | #573 |
| revascularization procedures | #574 |
| menstrual bleeding | #574 |
| cutoff point | #574 |
| women proportion | #575 |
| major bleedings | #575 |
| subcutaneously | #575 |
| progression cancer | #577 |
| patients vka | #578 |
| endothelial barrier | #578 |
| endotoxin | #579 |
| pharma | #579 |
| thiophenes | #579 |
| diagnostic tools | #580 |
| notice | #580 |
| 99 | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| unselected patients | #584 |
| dummy | #584 |
| coagulation disorders | #585 |
| 094 | #585 |
| chondroitin sulfates | #586 |
| feasibility safety | #588 |
| major orthopedic surgery | #588 |
| helminth proteins | #589 |
| reversal agents | #590 |
| thrombophilias | #590 |
| healthy human | #590 |
| malignancy | #590 |
| beta alanine | #590 |
| conventional management | #592 |
| massive pulmonary | #592 |
| doppler ultrasound | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| patency rates | #597 |
| severe bleeding | #597 |
| replacement knee | #597 |
| ldf | #597 |
| major hemorrhage | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| loss surgical | #600 |
| tests sensitivity | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| events occurred | #604 |
| clinical characteristics patients | #604 |
| comorbid conditions | #604 |
| diagnostic studies | #606 |
| initial increase | #607 |
| activated coagulation | #607 |
| patients antibodies | #607 |
| 0·3 | #607 |
| treatment acute | #608 |
| pfizer | #609 |
| tissue factor | #609 |
| arbitrage | #609 |
| benefit risk | #610 |
| 100 years | #610 |
| patients death | #610 |
| airline | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| patients bariatric surgery | #615 |
| leg | #615 |
| reluctant | #615 |
| complications risk | #616 |
| treatment rivaroxaban | #617 |
| arterial disease | #617 |
| 467 | #618 |
| stroke atrial fibrillation | #618 |
| occurred | #618 |
| fh patients | #620 |
| compared placebo | #620 |
| advisory committees | #621 |
| patients elevated | #621 |
| 1002 | #622 |
| thrombocytopenia hit | #623 |
| sgs | #623 |
| thyrotoxic | #623 |
| cochrane central register | #625 |
| peptide bnp | #625 |
| stopped | #626 |
| topic practice guidelines | #626 |
| stroke warfarin | #627 |
| women risk factors | #628 |
| 66 | #628 |
| 5000 | #628 |
| warfarin risk | #628 |
| physical training | #629 |
| human subjects | #629 |
| diagnostic algorithms | #629 |
| referral patients | #629 |
| sanofi | #630 |
| absolute | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| uneventful | #635 |
| outweigh | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 95 allcause mortality | #640 |
| 14 95 | #640 |
| study quality | #641 |
| proceedings | #641 |
| 3050 | #642 |
| predictive performance | #642 |
| threatening bleeding | #643 |
| neutrophilia | #643 |
| association mortality | #647 |
| primary outcome measure | #647 |
| statin treatment | #648 |
| studies efficacy | #648 |
| necessitating | #648 |
| 036 | #651 |
| thrombolysis patients | #651 |
| fixed | #651 |
| troglodytes | #652 |
| organisations | #652 |
| fxa | #653 |
| hemorrhagic stroke | #653 |
| 127 | #655 |
| patients review | #657 |
| coronary stent implantation | #659 |
| bleeding death | #659 |
| 69 | #659 |
| haematoma | #660 |
| coagulation proteins | #661 |
| tertiles | #661 |
| physical examination | #661 |
| clinical presentations | #662 |
| haemophilia | #662 |
| 1028 | #663 |
| 95 studies | #663 |
| long term treatment | #664 |
| provoked | #664 |
| sepsis shock | #665 |
| deep | #666 |
| phase iii studies | #666 |
| patients completed | #667 |
| presence patients | #667 |
| guideline adherence | #667 |
| onethird | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| elevated plasma | #673 |
| patients cteph | #673 |
| hospitalization hf | #674 |
| managing | #674 |
| clotting factors | #675 |
| il6 levels | #675 |
| inhibitor 1 | #675 |
| prothrombotic | #676 |
| highincome countries | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| medicine humans | #681 |
| pulmonary endarterectomy | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| patients bleeding | #692 |
| ambulatory patients | #692 |
| activator pa | #693 |
| graduated | #693 |
| myocardial infarctions | #693 |
| precise mechanisms | #694 |
| composite outcome | #694 |
| intracranial bleeding | #694 |
| administer | #694 |
| 1718 | #695 |
| stroke prevention patients | #696 |
| combined oral contraceptives | #696 |
| moyamoya | #696 |
| ratio male | #698 |
| participant data | #698 |
| difference 95 | #698 |
| compression devices | #700 |
| episode | #700 |
| prothrombin gene | #702 |
| therapeutic management | #702 |
| diagnostic errors | #702 |
| patients confirmed | #703 |
| surgery risk | #703 |
| veins venous | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| directors | #709 |
| clinical expression | #709 |
| starters | #711 |
| gastrointestinal bleeding | #712 |
| gynaecology | #712 |
| 048 | #712 |
| medical patients | #712 |
| radionuclide imaging | #713 |
| 1098 | #714 |
| rate death | #714 |
| neurosurgical patients | #714 |
| intravenous bolus | #715 |
| menstrual period | #716 |
| rivaroxaban stroke | #716 |
| cancer groups | #717 |
| adequately | #717 |
| solid cancer | #718 |
| 10 30 | #718 |
| falsely | #718 |
| plasminogen | #719 |
| reagent kits | #719 |
| pulmonary medicine | #720 |
| nordisk | #721 |
| accp | #721 |
| pyrazoles pyridines | #721 |
| clinical judgment | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| abnormal | #726 |
| follow period | #726 |
| gentamicins | #727 |
| 59 patients | #727 |
| orthopaedic surgery | #728 |
| diagnostic therapeutic | #728 |
| diagnostic tests | #730 |
| gentamicin | #732 |
| leeches | #732 |
| tumor necrosis factor | #733 |
| oral contraception | #733 |
| relative risk 95 | #734 |
| hull | #735 |
| patients levels | #735 |
| disease pad | #735 |
| clinical prediction rule | #736 |
| tests retrospective studies | #736 |
| atrial fibrillation risk | #736 |
| post hoc analysis | #739 |
| 6 12 | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| unclear | #742 |
| early pregnancy loss | #742 |
| 040 | #742 |
| topic predictive | #743 |
| betathromboglobulin | #744 |
| molecular weight | #744 |
| illness time factors | #744 |
| 285 | #746 |
| etp | #746 |
| antithrombin activity | #746 |
| patients 50 years | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| advisable | #754 |
| fibrin formation | #754 |
| primary patients | #755 |
| 95 risk factors | #756 |
| hf risk | #756 |
| 95 combination | #756 |
| pneumatic compression | #756 |
| answer | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| loe | #759 |
| 85 | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| 435 | #763 |
| proportion women | #763 |
| cprs | #764 |
| start treatment | #764 |
| hip surgery | #765 |
| risk pregnancy | #767 |
| aspirin clopidogrel | #767 |
| 689 | #767 |
| 732 | #768 |
| method drug | #769 |
| relevant | #770 |
| groups patients | #770 |
| 566 | #770 |
| baseline values | #772 |
| graft patency | #772 |
| patients criteria | #773 |
| bmi patients | #774 |
| subcutaneous injections | #774 |
| 1·5 | #776 |
| 992 | #777 |
| dose warfarin | #778 |
| study groups | #778 |
| patients 65 years | #778 |
| dose intravenous | #778 |
| miscarriage | #779 |
| patients hyperthyroidism | #780 |
| plasmin generation | #780 |
| 066 | #780 |
| thromboembolism prophylaxis | #780 |
| age ≥ | #782 |
| factor ixa | #785 |
| onefifth | #785 |
| abnormalities patients | #786 |
| topic disease models | #787 |
| cteph | #787 |
| general practitioners | #787 |
| 100 personyears | #787 |
| polypharmacy | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| recombinant tissue | #793 |
| mechanical heart | #793 |
| risk factors risk | #795 |
| 047 | #795 |
| inactivators | #795 |
| patency | #796 |
| patient years | #796 |
| eligible | #797 |
| studies prevalence | #797 |
| netherlands | #797 |
| lupus anticoagulant | #798 |
| femoropopliteal | #798 |
| theme | #799 |
| estrogen therapy | #799 |
| patients lower | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| randomized patients | #804 |
| subclinical | #804 |
| anticoagulant agents | #805 |
| microvesicles | #805 |
| fibrillation blood | #806 |
| adverse outcomes patients | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| efficacy patients | #809 |
| hypertension cteph | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| flights | #816 |
| factor vwf | #816 |
| 0·4 | #818 |
| vehicle control | #820 |
| health predictive | #820 |
| irrespective | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| prevention patients | #823 |
| reduction mortality | #823 |
| single administration | #824 |
| coc | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| gp | #828 |
| cardioembolic stroke | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| 93 | #833 |
| antithrombotic treatment | #833 |
| myers | #833 |
| abortion habitual | #835 |
| plough | #836 |
| oral adult | #836 |
| noac | #837 |
| versus placebo | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| 49 | #846 |
| antithrombotic therapy | #846 |
| 072 | #847 |
| multidetector row | #847 |
| advise | #848 |
| recurrence risk | #849 |
| caesarean | #850 |
| patients diagnosis | #850 |
| area roc curve | #852 |
| pre‐eclampsia | #853 |
| reference method | #853 |
| 30 patients | #853 |
| advanced prostate | #854 |
| clopidogrel aspirin | #855 |
| fibrin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| 6 month | #870 |
| pyridones | #870 |
| longterm clinical outcomes | #872 |
| individual participant | #872 |
| tasman | #873 |
| favoring | #873 |
| targeted inhibition | #874 |
| imaging reproducibility | #874 |
| thromboembolic pulmonary | #874 |
| plasminogen activation | #875 |
| titles | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| risk thromboembolic | #878 |
| dabigatran rivaroxaban | #878 |
| anticoagulants atrial | #879 |
| 57 | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| male mexico | #894 |
| 084 | #894 |
| domiciliary | #894 |
| p011 | #896 |
| loading dose | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| 064 | #908 |
| factor activity | #908 |
| subcutaneous administration | #909 |
| documented | #911 |
| patients clinical trials | #911 |
| haemostatic | #912 |
| initially | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| haemodialysis patients | #916 |
| combined approach | #916 |
| 317 | #917 |
| 022 | #918 |
| thromboembolic events | #918 |
| chronic thromboembolic | #919 |
| standard patients | #920 |
| randomeffects model | #920 |
| antagonist oral | #920 |
| ultrasound examination | #921 |
| optimal dose | #921 |
| loss patients | #921 |
| practise | #923 |
| estimate male | #923 |
| multifactorial disease | #925 |
| study medication | #925 |
| total hip | #926 |
| safer | #928 |
| 902 | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| treatment placebo | #934 |
| wording | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| 60 patients | #938 |
| subgroup patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| stroke atrial | #944 |
| echocardiographically | #944 |
| women preeclampsia | #944 |
| emboli | #945 |
| predictive values | #946 |
| ssc | #946 |
| anticoagulation treatment | #947 |
| extensive disease | #948 |
| knee replacement | #948 |
| diagnostic | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| dic | #956 |
| registro | #956 |
| cancer humans | #956 |
| network metaanalysis | #956 |
| reassuring | #957 |
| venous insufficiency | #957 |
| efficacy | #958 |
| day1 | #958 |
| combined oral | #961 |
| retropubic | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| reference lists | #966 |
| inhibitor1 | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| risk allcause mortality | #973 |
| prevalence characteristics | #973 |
| antiplatelet | #973 |
| hoc | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| female fibrinogen | #976 |
| vascular humans | #976 |
| fvii | #978 |
| false negative | #979 |
| 071 | #980 |
| onset aged aged | #980 |
| 50 100 | #980 |
| early gestation | #984 |
| 426 | #986 |
| prophylactic treatment | #987 |
| randomised trials | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| rises | #991 |
| missed | #991 |
| academic medical center | #992 |
| seminar | #992 |
| counteracted | #993 |
| normal lung | #993 |
| treatment bleeding | #994 |
| 226 | #999 |
| aged | #999 |
| thromboembolic risk | #1000 |
| justification | #1000 |
| lower extremity | #1000 |
| tissue type | #1001 |
| parenteral administration | #1002 |
| rivaroxaban apixaban | #1002 |
| eclamptic | #1003 |
| extended | #1005 |
| interleukin 6 | #1005 |
| hyperprolactinaemia | #1005 |
| pyridines | #1006 |
| orthosis | #1007 |
| easier | #1007 |
| 50 patients | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| ticlopidine | #1018 |
| pounds | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| years risk | #1023 |
| cha2ds2 vasc | #1023 |
| humans randomized | #1024 |
| international prospective | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| decision analysis | #1030 |
| firstdegree relatives | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| risk hemorrhage | #1033 |
| cardiovascular event | #1033 |
| relatives | #1033 |
| 052 | #1035 |
| male netherlands | #1037 |
| graft occlusion | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| vwf levels | #1047 |
| patients severe asthma | #1047 |
| patients massive | #1050 |
| examiner | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| mean±sd | #1054 |
| 221 | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| 179 | #1060 |
| coagulant | #1060 |
| birth rate | #1060 |
| pad | #1061 |
| 610 | #1061 |
| published literature | #1062 |
| primary data | #1062 |
| false | #1064 |
| 150 | #1065 |
| prekallikrein | #1065 |
| 00008 | #1066 |
| live birth | #1066 |
| 101 | #1066 |
| cut | #1067 |
| lysosphingolipid | #1067 |
| pmol | #1068 |
| 95 increased risk | #1070 |
| register controlled | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| laboratory diagnosis | #1074 |
| thorax | #1074 |
| systematic search | #1078 |
| advocate | #1080 |
| 063 | #1080 |
| drawbacks | #1082 |
| f1 | #1087 |
| longterm therapy | #1087 |
| bandages | #1089 |
| clarifications | #1095 |
| stopping | #1095 |
| diagnostic utility | #1096 |
| idarucizumab | #1096 |
| mandated | #1096 |
| 083 | #1099 |
| 1223 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| clinical protocols | #1107 |
| peptide brain | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| haemodialysis | #1116 |
| bypass grafts | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| probands | #1123 |
| resistance factor | #1123 |
| new developments | #1124 |
| advised | #1125 |
| new perspectives | #1126 |
| 445 | #1126 |
| cip | #1127 |
| heparininduced thrombocytopenia | #1127 |
| patients pad | #1128 |
| judged | #1132 |
| discretion | #1132 |
| ≤10 | #1133 |
| statistic | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| 635 | #1141 |
| superior efficacy | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| roc curve | #1150 |
| refusal | #1150 |
| medical records | #1151 |
| medline | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| blood loss | #1156 |
| patients influenza | #1156 |
| anticoagulation therapy | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| bristol | #1163 |
| published guidelines | #1163 |
| viii | #1164 |
| intermittent | #1164 |
| stable angina | #1164 |
| safety concerns | #1164 |
| hyperhomocysteinemia | #1164 |
| age 65 years | #1165 |
| thromboembolism risk | #1165 |
| angiogram | #1167 |
| glucocorticoid treatment | #1172 |
| atherosclerotic disease | #1172 |
| crossover design | #1172 |
| perioperative bleeding | #1172 |
| occlusive diseases | #1173 |
| practice guideline | #1173 |
| 5 years patients | #1176 |
| macroglobulin | #1176 |
| findings patients | #1178 |
| analysis studies | #1178 |
| 79 | #1179 |
| concealed | #1181 |
| conceive | #1181 |
| hospitalized patients | #1182 |
| unaware | #1182 |
| patients obesity | #1182 |
| combined therapy | #1186 |
| conclusive | #1186 |
| degree relatives | #1189 |
| occult | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| cardiotonic agents | #1199 |
| mandate | #1199 |
| international society | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| quantitative trait locus | #1204 |
| 015 | #1204 |
| categorized | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| pph | #1214 |
| multicenter randomized | #1214 |
| 103 | #1218 |
| patient treatment | #1221 |
| warranted | #1221 |
| scores patients | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| 64 patients | #1224 |
| peak levels | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| blind | #1227 |
| sixfold | #1227 |
| consensus guidelines | #1228 |
| metabolic syndrome patients | #1228 |
| radionuclide | #1229 |
| peptide hydrolases | #1229 |
| trial background | #1229 |
| 65 patients | #1230 |
| rules | #1232 |
| doubles | #1232 |
| aspirin | #1234 |
| milliliter | #1238 |
| coronary angiography patients | #1238 |
| postoperative hemorrhage | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| ml1 | #1252 |
| subgroups | #1252 |
| matter lesions | #1252 |
| artery pulmonary | #1254 |
| extensive | #1257 |
| oral vitamin | #1257 |
| search strategy | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| visiting | #1266 |
| entity | #1266 |
| troponins | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| equally | #1274 |
| intensive patients | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| statin users | #1281 |
| routine screening | #1281 |
| 75 years | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| janssen | #1295 |
| scan | #1295 |
| perfusion defects | #1295 |
| predictive | #1297 |
| hemofiltration | #1297 |
| insufficiently | #1298 |
| low prevalence | #1299 |
| cardiovascular complications | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| 61 | #1303 |
| pf4 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| cyproterone | #1312 |
| apoa | #1312 |
| 1st | #1312 |
| risk difference | #1312 |
| adamts13 activity | #1313 |
| current strategies | #1314 |
| 0·7 | #1314 |
| tests severity | #1314 |
| claudication | #1316 |
| atrial fibrillation | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| glycoprotein gpiib | #1325 |
| lipoproteina | #1325 |
| patients coronavirus disease | #1326 |
| beneficial | #1329 |
| vascular diseases | #1329 |
| antibodies monoclonal antibodies | #1329 |
| thyroid disorders | #1330 |
| plasminogen activators | #1330 |
| low moderate | #1330 |
| 77 | #1331 |
| coagulation cascade | #1331 |
| 6 months patients | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| venous catheters | #1342 |
| likelihood ratio | #1342 |
| 91 | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| antitrypsin | #1347 |
| surgical trauma | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| 15 patients | #1359 |
| experimental model | #1359 |
| allcause mortality 95 | #1359 |
| limb salvage | #1363 |
| arsenal | #1363 |
| vwf | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| 224 | #1385 |
| noninferiority | #1385 |
| dl1 | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| patients control subjects | #1400 |
| record linkage | #1400 |
| antisense oligonucleotide | #1402 |
| 82 | #1402 |
| equipoise | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| patients advanced cancer | #1405 |
| 1886 | #1405 |
| pregnancy loss | #1406 |
| obese patients | #1406 |
| categories | #1408 |
| 515 | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| thrombotic complications | #1419 |
| 7 weeks | #1419 |
| 3 6 | #1419 |
| 6 weeks | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| university hospitals | #1422 |
| followup data | #1422 |
| daily | #1424 |
| 061 | #1424 |
| ≥55 | #1424 |
| eightfold | #1425 |
| 080 | #1427 |
| randomised controlled trials | #1427 |
| rgs | #1430 |
| casecontrol study | #1430 |
| outcome pregnancy | #1438 |
| 096 | #1439 |
| imaging radiopharmaceuticals | #1439 |
| principal | #1443 |
| 78 | #1443 |
| 1123 | #1445 |
| drug levels | #1446 |
| outcome studies | #1446 |
| weight bmi | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| population patients | #1454 |
| confusion | #1454 |
| platelet factor | #1455 |
| aged blood | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| actual | #1466 |
| funded | #1466 |
| avoided | #1468 |
| 0·9 | #1468 |
| 26 patients | #1469 |
| heart failure hf | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| prevalences | #1473 |
| 1215 | #1473 |
| centrally | #1474 |
| probability | #1477 |
| systemic infection | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| cushing syndrome | #1485 |
| analysis randomized | #1485 |
| methodologic | #1486 |
| phase iii trials | #1486 |
| general practice | #1491 |
| procoagulant activity | #1495 |
| patients control | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| adverse outcome | #1514 |
| growing body | #1514 |
| proximal | #1516 |
| patients 10 | #1520 |
| ganz | #1520 |
| pregnancy postpartum | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| thrombotic events | #1527 |
| contraindicated | #1527 |
| score | #1529 |
| time study | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| live births | #1552 |
| patients severe sepsis | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| pfa | #1564 |
| enfermedad | #1564 |
| iii topic | #1565 |
| topic | #1566 |
| treatment prevention | #1566 |
| hyperlipoproteinemia type | #1568 |
| deficient | #1568 |
| 95ci | #1568 |
| cushings syndrome | #1568 |
| aged biomarkers | #1571 |
| plasminogen activator | #1575 |
| 36 | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| cocs | #1586 |
| activation markers | #1586 |
| study entry | #1586 |
| thyroid dysfunction | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| 1·1 | #1594 |
| total mortality | #1594 |
| translates | #1597 |
| placebo | #1598 |
| noncancer | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| 162 | #1613 |
| general surgery | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| prospective cohort studies | #1616 |
| tests reproducibility | #1616 |
| postpartum period | #1616 |
| positive effects | #1616 |
| factors tomography | #1616 |
| 155 | #1618 |
| perinatal outcome | #1618 |
| cvd patients | #1619 |
| imaging tomography | #1619 |
| female hemostasis | #1619 |
| proportion | #1620 |
| 12month followup | #1621 |
| uncertain | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| pa patients | #1632 |
| venous disease | #1632 |
| incidentally | #1632 |
| fresh frozen plasma | #1633 |
| clinical patients | #1633 |
| study outcomes | #1639 |
| double | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| ctni | #1644 |
| stroke prevention | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| dorsiflexion | #1651 |
| 997 | #1651 |
| ≤4 | #1652 |
| 35 years | #1652 |
| thrombin activity | #1653 |
| studies data | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| disease adult | #1670 |
| homocysteine levels | #1670 |
| thrombi | #1674 |
| daily dosing | #1676 |
| inpatient treatment | #1676 |
| plasma level | #1677 |
| deficiency | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| unreliable | #1686 |
| steroidal anti | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| yielded | #1712 |
| 033 | #1712 |
| intravenous | #1715 |
| hemorheology | #1715 |
| bronchospasm | #1720 |
| hematologic malignancies | #1720 |
| mb | #1721 |
| female femoral | #1721 |
| diagnostic evaluation | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| 107 | #1726 |
| conference | #1726 |
| derived microparticles | #1729 |
| 021 | #1730 |
| volunteer | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| clinical scores | #1735 |
| east asian | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| patients ventricular | #1745 |
| 691 | #1745 |
| table | #1745 |
| profession | #1746 |
| risk cardiovascular events | #1747 |
| hyperinsulinaemia | #1747 |
| apc | #1749 |
| turp | #1749 |
| replacement | #1750 |
| pselectin | #1750 |
| homozygosity | #1750 |
| 128 | #1752 |
| 133 | #1753 |
| intracranial hemorrhages | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| audiometry | #1760 |
| treatment recommendations | #1760 |
| assessor | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| fx | #1764 |
| human insulin | #1764 |
| duplicate | #1769 |
| initial management | #1770 |
| hemorrhage | #1770 |
| arteriosclerosis | #1770 |
| 2 6 | #1774 |
| allcause death | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| clinical consequences | #1790 |
| selfmanagement | #1790 |
| reid | #1793 |
| microparticle | #1793 |
| vascular surgical | #1794 |
| cardiac troponin | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| 020 | #1802 |
| aggregation inhibitors | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| slc6a4 | #1812 |
| tumor necrosis | #1812 |
| 95 specificity | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| economic evaluation | #1819 |
| conjoint | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| screening middle | #1825 |
| preference | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| compressibility | #1837 |
| definite | #1837 |
| cushing | #1838 |
| kaplanmeier estimate | #1838 |
| severe sepsis | #1839 |
| central venous | #1842 |
| 1 week | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| explanations | #1852 |
| hydroxyethyl starch | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| shrs | #1892 |
| diagnostic techniques | #1892 |
| thromboses | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 067 | #1897 |
| 5 10 | #1897 |
| contraindications | #1900 |
| diagnostic testing | #1901 |
| tnf | #1901 |
| extremity | #1901 |
| clt | #1905 |
| induced thrombocytopenia | #1906 |
| plaster | #1906 |
| hazard ratio | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| referral | #1910 |
| efficacy treatment | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 793 | #1920 |
| 13 patients | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| 868 | #1923 |
| stroke 95 | #1923 |
| biotin | #1924 |
| 55 years | #1924 |
| trials patients | #1926 |
| venous pressure | #1926 |
| μg | #1927 |
| intracranial hemorrhage | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| nonfatal | #1934 |
| glucocorticoid | #1934 |
| relative risks | #1935 |
| 3months | #1935 |
| acute | #1936 |
| 17 | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| femoral vein | #1950 |
| safety effectiveness | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| observer | #1962 |
| investigators | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| 48 hours | #1973 |
| surgical blood | #1973 |
| fibrin clot | #1973 |
| potent inhibitor | #1976 |
| renewed | #1976 |
| topic clinical trials | #1978 |
| 771 | #1981 |
| hyperaldosteronism | #1981 |
| specificity ultrasonography | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| 1·0 | #1986 |
| treatment cancer | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| prospero | #1992 |
| 018 | #1992 |
| drug drug therapy | #1994 |
| cmax | #1994 |
| cvt | #1995 |
| computerized | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| transient increase | #2000 |
| 3 months patients | #2000 |
| autopsy | #2000 |
| clinical severity | #2000 |
| 53 | #2003 |
| 7 patients | #2006 |
| pneumonia patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| mongrel | #2017 |
| angina unstable | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| 097 | #2033 |
| patients lung | #2033 |
| pertechnetate | #2036 |
| medical record | #2041 |
| costs cost | #2041 |
| undergoing major | #2042 |
| abstracts | #2042 |
| questioned | #2043 |
| prediction rule | #2045 |
| thrice | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| quartiles | #2051 |
| superior vena cava | #2051 |
| inadequately | #2052 |
| pregnancy trimester | #2053 |
| 277 | #2053 |
| controversial | #2055 |
| adherence guidelines | #2056 |
| stent implantation | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| requested | #2063 |
| varies | #2063 |
| clinical indications | #2064 |
| biological neoplasms | #2064 |
| hemostatics | #2070 |
| 188 | #2074 |
| mcnemar | #2074 |
| national institute | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| bypasses | #2087 |
| media thickness | #2087 |
| 03 | #2089 |
| versions | #2091 |
| 114 | #2092 |
| square distribution | #2092 |
| tissue plasminogen | #2093 |
| reference range | #2099 |
| preformed | #2099 |
| 038 | #2100 |
| desmopressin | #2101 |
| lifetime risk | #2101 |
| 59 | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| substantial | #2109 |
| 1966 | #2109 |
| 031 | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| unnecessary | #2118 |
| independently | #2118 |
| exists | #2119 |
| initial | #2119 |
| development validation | #2120 |
| 11 | #2122 |
| clinicaltrialsgov | #2122 |
| coronary stent | #2122 |
| acl reconstruction | #2125 |
| original | #2125 |
| topic surveys | #2127 |
| patients cardiovascular disease | #2127 |
| chose | #2129 |
| controlled | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| congress | #2134 |
| protamines | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| clot | #2145 |
| live | #2145 |
| bodyweight | #2146 |
| professionals | #2146 |
| pancreatic cancer patients | #2157 |
| oestrogens | #2160 |
| committee | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| 674 | #2183 |
| advanced cancer | #2183 |
| 2 × | #2185 |
| fifty | #2185 |
| giant cell arteritis | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| increased patients | #2205 |
| pravastatin | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| diagnosis differential | #2212 |
| neutrophil elastase | #2212 |
| doubled | #2213 |
| pao2 | #2219 |
| 364 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| differential female | #2225 |
| 94 | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| clots | #2257 |
| hivinfected patients | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| stroke aged | #2265 |
| hyperthyroidism | #2265 |
| 12 | #2266 |
| 6 months | #2267 |
| metaanalysis | #2267 |
| patients developed | #2273 |
| reverses | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| based case | #2284 |
| setting | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| tests | #2314 |
| metaanalysis studies | #2314 |
| initial therapy | #2316 |
| nephelometry | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| humans myocardial | #2324 |
| method female | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| inhibitor | #2344 |
| lacked | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| risk bias | #2375 |
| 099 | #2375 |
| patients active | #2376 |
| predictable | #2377 |
| hemostasis | #2377 |
| enrolling | #2379 |
| acute coronary syndromes | #2379 |
| 187 | #2381 |
| dosing regimen | #2382 |
| anticardiolipin | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| patients liver cirrhosis | #2401 |
| 757 | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| postinjection | #2413 |
| periodicals | #2413 |
| protein | #2413 |
| risk estimates | #2414 |
| 22 | #2415 |
| sphingosine1 | #2415 |
| internal medicine | #2424 |
| study drug | #2424 |
| 32 | #2425 |
| guidelines | #2426 |
| sensitivity 100 | #2426 |
| 0048 | #2430 |
| legs | #2430 |
| coagulants | #2430 |
| 002 | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| prolonging | #2434 |
| ptca | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| 719 | #2448 |
| turbidimetry | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| therapy acute | #2468 |
| nephrotoxic | #2468 |
| 477 | #2469 |
| comprised | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| cancer population | #2476 |
| current review | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| pathway inhibitor | #2485 |
| 648 | #2485 |
| treatment efficacy | #2489 |
| 829 | #2490 |
| 1015 | #2490 |
| chest | #2493 |
| duration | #2493 |
| 25 | #2495 |
| 616 | #2503 |
| illness tomography | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| drug female humans | #2516 |
| 479 | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| neutrophil extracellular traps | #2521 |
| 463 | #2521 |
| 152 | #2523 |
| accurate diagnosis | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 164 | #2537 |
| 874 | #2537 |
| 0046 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| hydroxyethyl | #2560 |
| hours | #2560 |
| haematology | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| kits | #2574 |
| humans logistic | #2574 |
| 73 | #2574 |
| prevalence | #2575 |
| pill | #2575 |
| translate | #2577 |
| patients total | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| 591 | #2585 |
| efficacious | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| manifest | #2605 |
| burden disease | #2605 |
| metaregression | #2606 |
| parenteral | #2606 |
| patients 2 | #2608 |
| fatal outcome | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| cost analysis | #2620 |
| aviation | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| trials rcts | #2635 |
| chondroitin | #2635 |
| coincided | #2635 |
| 10 day | #2637 |
| 345 | #2641 |
| attractive | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| benzimidazoles | #2662 |
| c677 | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| 516 | #2683 |
| outcome ultrasonography | #2683 |
| iii | #2685 |
| initial dose | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| 594 | #2691 |
| aso | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| management strategies | #2732 |
| dose low | #2732 |
| cart | #2736 |
| 595 | #2737 |
| 427 | #2739 |
| classifications | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| 848 | #2746 |
| predetermined | #2746 |
| baseline characteristics | #2747 |
| patients asthma | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| 143 | #2768 |
| management acute | #2768 |
| confounded | #2769 |
| antithyroid | #2772 |
| expert consensus | #2772 |
| alpha animals | #2772 |
| active control | #2775 |
| thrombomodulin | #2776 |
| inpatient | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| consecutive series | #2802 |
| 402 | #2802 |
| cirrhosis patients | #2805 |
| reaching | #2805 |
| international | #2809 |
| standardized | #2811 |
| secondary | #2811 |
| embolic | #2812 |
| 406 | #2813 |
| follow studies | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| bid | #2826 |
| antiplatelet drugs | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| contacting | #2835 |
| recurrence rate | #2835 |
| ketoprostaglandin | #2836 |
| helminth | #2836 |
| crossover | #2839 |
| kruskal | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| iii trials | #2852 |
| doppler ultrasonography | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| post discharge | #2857 |
| new treatment | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| excessive | #2880 |
| trimester pregnancy | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| systematic review metaanalysis | #2897 |
| 21 | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| severe asthma | #2903 |
| slight | #2903 |
| feasible | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| lowrisk patients | #2917 |
| leading death | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| 993 | #2928 |
| proportions | #2928 |
| clear | #2932 |
| risk stratification patients | #2934 |
| 2400 | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 270 | #2960 |
| 010 | #2960 |
| 20 | #2961 |
| exercise therapy | #2962 |
| followup | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| lecture | #2984 |
| declare | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| pneumatic | #2991 |
| point | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| factors surveys | #3015 |
| antigen levels | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| early recognition | #3025 |
| nested case | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 419 | #3040 |
| 50 years | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| 80 | #3063 |
| nomogram | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| 2 4 | #3076 |
| subsequently | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| angioplasty | #3088 |
| chronic renal failure | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| trimester | #3110 |
| benchmark | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| lifelong | #3122 |
| wallis | #3122 |
| oac | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 136 | #3134 |
| 12 months | #3134 |
| meta‐analysis | #3137 |
| 082 | #3142 |
| levels risk | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| 507 | #3153 |
| idiopathic | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| diethylstilbestrol | #3194 |
| pregnancy women | #3194 |
| pacientes | #3197 |
| 945 | #3198 |
| plasmin | #3198 |
| therapy risk | #3199 |
| tenth | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| cancer types | #3219 |
| suggested | #3219 |
| intravenous infusion | #3223 |
| 153 | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| recombinant | #3241 |
| meetings | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| bivalirudin | #3251 |
| 198 | #3251 |
| hypothyroid | #3253 |
| 29 | #3253 |
| judgement | #3255 |
| scoring | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| tumor markers | #3289 |
| coumarin | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| 465 | #3330 |
| reduces | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| cerebrovascular disease | #3344 |
| inpatients | #3344 |
| evaluating | #3349 |
| 362 | #3349 |
| spontaneous abortion | #3354 |
| diagnosing | #3354 |
| 273 | #3355 |
| common complication | #3356 |
| diagnosis cancer | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| 301 | #3379 |
| humans lower | #3379 |
| concluded | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| calf | #3389 |
| function patients | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| acute treatment | #3403 |
| tunica | #3403 |
| 553 | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| randomisation | #3419 |
| preventive | #3419 |
| surgical patients | #3420 |
| hypothesised | #3420 |
| study risk | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| prevalence incidence | #3452 |
| 168 | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| 34 | #3470 |
| differ | #3470 |
| intensive chemotherapy | #3471 |
| patients receive | #3472 |
| pregnancy complications | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| cancer metastasis | #3485 |
| antiphospholipid | #3485 |
| increased morbidity | #3486 |
| asymptomatic | #3487 |
| lower leg | #3487 |
| personyears | #3490 |
| paradox | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| hemorrhagic complications | #3506 |
| treat | #3506 |
| inhibitors | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| confirmed | #3522 |
| discusses | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| human cytomegalovirus | #3533 |
| lupus | #3533 |
| areas covered | #3537 |
| guidance | #3541 |
| societies | #3541 |
| 113 | #3544 |
| gastro | #3551 |
| current practice | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| prognosis prospective | #3596 |
| necessity | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| platelet function | #3619 |
| treated | #3619 |
| interval | #3622 |
| platelet activation | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| q3 | #3629 |
| kappa | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| undergo | #3642 |
| bypass surgery | #3642 |
| homozygote | #3642 |
| p006 | #3645 |
| externally | #3645 |
| occlusions | #3646 |
| 1960 | #3649 |
| 30 | #3649 |
| interindividual variability | #3651 |
| fibrillation | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| optimal management | #3671 |
| outcome administration | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| drug monitoring | #3721 |
| diagnostic process | #3721 |
| pharmacodynamics | #3725 |
| inhibitors humans | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| effective | #3739 |
| humans intracranial | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| deterioration | #3754 |
| randomised | #3754 |
| objectives | #3759 |
| subgroup analyses | #3762 |
| 8 patients | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| computed ultrasonography | #3774 |
| clinicians patients | #3774 |
| inherited | #3775 |
| interpretable | #3778 |
| 517 | #3778 |
| 483 | #3782 |
| thyroid hormones | #3789 |
| aminoglycosides | #3789 |
| total knee arthroplasty | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| vessel wall | #3804 |
| compelling | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| patients lung cancer | #3815 |
| 330 | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| meeting | #3856 |
| irs | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| acquired resistance | #3860 |
| review data | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| cancer survival | #3884 |
| optimisation | #3884 |
| record | #3885 |
| sensitivity | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| 184 | #3890 |
| difference | #3890 |
| 351 | #3890 |
| 10000 | #3902 |
| halflives | #3903 |
| methylamines | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| angiography | #3915 |
| specificity tomography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| 405 | #3946 |
| case fatality | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| p004 | #3961 |
| dichotomy | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| risk cancer | #3970 |
| uncontrolled | #3970 |
| austrian | #3971 |
| behalf | #3971 |
| cardiovascular events | #3972 |
| data studies | #3975 |
| 2nd | #3975 |
| quality assurance | #3980 |
| pregnancy | #3982 |
| 986 | #3982 |
| continuous infusion | #3983 |
| flying | #3986 |
| unstable | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| introduction | #4045 |
| 296 | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| bariatric | #4077 |
| pcc | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| natriuretic peptide | #4089 |
| oligosaccharides | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| cutoff | #4099 |
| activation | #4099 |
| indications | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| 008 | #4137 |
| withdrawn | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| 2030 | #4171 |
| patients prostate cancer | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 485 | #4212 |
| 411 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 121 | #4226 |
| 289 | #4226 |
| trough | #4229 |
| p0005 | #4230 |
| crosssectional analysis | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| patients mortality | #4242 |
| cox regression | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 102 | #4340 |
| 455 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| managed | #4350 |
| potential risk factors | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| rapid | #4383 |
| minutes | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| concurrently | #4394 |
| slice | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| bowel diseases | #4407 |
| negative | #4407 |
| 71 | #4407 |
| general | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| lacking | #4417 |
| splanchnic | #4417 |
| immunoassays | #4419 |
| dose aspirin | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| 192 | #4459 |
| vascular surgery | #4459 |
| proband | #4461 |
| cytomegalovirus infection | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| cd18 | #4486 |
| clinical manifestations | #4486 |
| inadequate | #4487 |
| pancreatic cancer | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| comprises | #4503 |
| activation platelet | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| cerebrovascular disorders | #4571 |
| calculating | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| attenuating | #4594 |
| preserves | #4594 |
| eventually | #4595 |
| gradual | #4595 |
| simplified | #4596 |
| 204 | #4596 |
| 4000 | #4601 |
| 4 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| acetylsalicylic acid | #4613 |
| vii | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| risks benefits | #4640 |
| hospital costs | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| habitual | #4658 |
| 003 | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| myelofibrosis | #4670 |
| 171 | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| fh | #4680 |
| day | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| unchanged | #4698 |
| ranging | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| baseline patients | #4775 |
| chronic renal | #4775 |
| acute coronary | #4784 |
| scheduled | #4785 |
| 44 | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| definition | #4861 |
| acl | #4861 |
| efficiency | #4869 |
| gpiib | #4870 |
| nonvalvular atrial fibrillation | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| total | #4891 |
| antiplatelet therapy | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| preparations | #4906 |
| tests prognosis | #4906 |
| served | #4910 |
| chlamydophila | #4913 |
| fmd | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| manufacturers | #4976 |
| dose | #4976 |
| albeit | #4982 |
| orthopedics | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| references | #5006 |
| 389 | #5006 |
| epoprostenol | #5009 |
| reminder | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| 156 | #5040 |
| screening test | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| evaluable | #5089 |
| regarded | #5089 |
| relation | #5090 |
| hip fractures | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| bay | #5124 |
| vivo studies | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| ischaemic stroke | #5130 |
| 0018 | #5130 |
| 131 | #5131 |
| female | #5131 |
| transfused | #5134 |
| balancing | #5136 |
| contrast media | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| disagreement | #5157 |
| shortly | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| 11 patients | #5170 |
| predispose | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| articles | #5233 |
| emergencies | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| pooling | #5289 |
| 365 | #5289 |
| aware | #5300 |
| thrombus | #5301 |
| 36 patients | #5301 |
| atherogenesis | #5302 |
| urokinase | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| reagent | #5341 |
| acute ischemic stroke | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| schedule drug | #5363 |
| male | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| 247 | #5490 |
| occurrences | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| patient risk | #5497 |
| 260 | #5497 |
| discomfort | #5499 |
| continuing | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| limitation | #5539 |
| erythema | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| established | #5563 |
| receptor1 | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| 46 | #5573 |
| reduce risk | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| equivalent | #5598 |
| circulating levels | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| 80 years | #5644 |
| reclassification | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| milder | #5771 |
| semiquantitative | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| incidence rates | #5804 |
| mpo | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| aircraft | #5819 |
| 1000 | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| true | #5852 |
| atrial | #5852 |
| 088 | #5854 |
| attending | #5856 |
| 290 | #5857 |
| women pregnancy | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| reliable | #5894 |
| occurrence | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| aged platelet | #5928 |
| 22 patients | #5928 |
| graded | #5934 |
| revision | #5938 |
| premenopause | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| rcts | #5962 |
| 43 | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| topics | #6101 |
| type iii | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| generation | #6160 |
| ffa | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| terminated | #6228 |
| mortality morbidity | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| practitioners | #6273 |
| colleagues | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 63 | #6340 |
| 135 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| factor gene | #6405 |
| roche | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| accuracy | #6501 |
| peripheral artery disease | #6501 |
| cancer cell | #6502 |
| incidence risk | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| triiodothyronine | #6524 |
| washout | #6524 |
| 318 | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| cochrane | #6532 |
| increased incidence | #6532 |
| highrisk patients | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| exogenous | #6538 |
| bowel | #6538 |
| thirteen | #6540 |
| aspirin patients | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| pancreatic neoplasms | #6641 |
| genetic testing | #6641 |
| complications | #6650 |
| individual | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| hazard ratios | #6729 |
| recognised | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| 385 | #6766 |
| body temperature | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| 2 groups | #6780 |
| defined | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| reached | #6803 |
| premedication | #6803 |
| plasma proteins | #6807 |
| response relationship | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| adverse event | #6912 |
| disturbances | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| intensity | #6976 |
| 246 | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| 222 | #6995 |
| shock septic | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| computed | #7104 |
| betacoronavirus covid19 | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| 5year | #7204 |
| withdrawal | #7204 |
| acting | #7210 |
| cardiovascular disease cvd | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| vldl | #7250 |
| treatment children | #7250 |
| hematocrit | #7255 |
| retrospective cohort study | #7257 |
| 199 | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| modest | #7290 |
| sensitivity analysis | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| ischemic stroke | #7338 |
| pectoris | #7338 |
| interleukin6 | #7352 |
| 1c | #7352 |
| p0001 | #7356 |
| standardised | #7356 |
| myocardial infarction | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| angina | #7522 |
| urgently | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| cinahl | #7578 |
| 191 | #7578 |
| comorbid | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| epidemiological studies | #7647 |
| 29 patients | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| 18 | #7705 |
| medical conditions | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| 110 | #7802 |
| manufacturer | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| hormone replacement | #7828 |
| 31 patients | #7828 |
| label | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| academic | #7878 |
| tramadol | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| highrisk | #7939 |
| urogenital | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| 600 | #8051 |
| preventable | #8051 |
| medical | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| patients heart | #8120 |
| training | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| imaging studies | #8141 |
| investigational | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| confidence | #8204 |
| parenteral nutrition | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| renal function | #8228 |
| impairment | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lists | #8250 |
| lowest | #8250 |
| version | #8260 |
| activated | #8264 |
| 125i | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| postulated | #8338 |
| endothelium vascular | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| absence presence | #8382 |
| 2 years | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| 28 patients | #8415 |
| occur | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| transient ischemic | #8463 |
| procedures operative | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| covariate | #8501 |
| evaluate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| 146 | #8582 |
| adolescent | #8582 |
| row | #8590 |
| carotid arteries | #8596 |
| thirty | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| fish oil | #8624 |
| 15 years | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| 1 2 | #8723 |
| hold | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| endovascular | #8756 |
| practical | #8756 |
| cardiovascular | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| convenient | #8837 |
| hydroxymethylglutaryl | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| planned | #8914 |
| micrograms | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| proportional hazards | #8945 |
| signs symptoms | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| options | #9002 |
| patients placebo | #9002 |
| comprise | #9005 |
| chemoprevention | #9005 |
| societies medical | #9007 |
| clinical events | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| diagnose | #9080 |
| mps | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| time points | #9147 |
| valve prosthesis | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| dyspnea | #9230 |
| pci | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| illness surveys | #9264 |
| hazards | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| rabbit | #9286 |
| positive | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| p0004 | #9355 |
| patients negative | #9355 |
| preceded | #9376 |
| loss | #9378 |
| higher incidence | #9380 |
| 014 | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| kidney failure | #9638 |
| primary point | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| precise | #9817 |
| easily | #9817 |
| coa reductase | #9828 |
| nmol | #9828 |
| classification | #9836 |
| craniotomy | #9839 |
| 212 | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| nonhuman primates | #9871 |
| heterozygotes | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| degradation | #9941 |
| 2003 | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| casecontrol studies | #9997 |
| 12 hours | #9997 |
| pancreatic | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| protective | #10045 |
| obstacles | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| cell activation | #10199 |
| investigations | #10199 |
| cardiovascular risk factors | #10209 |
| clinical data | #10213 |
| medical therapy | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| blood transfusion | #10293 |
| hospitalization | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| dilution | #10336 |
| 032 | #10336 |
| 667 | #10337 |
| worldwide | #10337 |
| aorta | #10352 |
| greatly | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| p0003 | #10408 |
| outcome measures | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| circulation | #10432 |
| reductase inhibitors | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| patients age | #10461 |
| priority | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| increased prevalence | #10489 |
| activity levels | #10489 |
| 1991 | #10491 |
| style | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| ray | #10570 |
| patients moderate | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| antisense | #10583 |
| recurrences | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| microvascular | #10605 |
| 159 | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| held | #10674 |
| concerned | #10674 |
| pulmonary vascular | #10690 |
| term | #10697 |
| discriminate | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| diagnoses | #10903 |
| airways | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| neutropenia | #11057 |
| ischemic | #11057 |
| ethical | #11062 |
| summarizes | #11062 |
| attained | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| inability | #11108 |
| location | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| humans kidney | #11281 |
| cerebrovascular | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| placebo treatment | #11533 |
| occlusion | #11533 |
| outflow | #11542 |
| multicenter study | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| younger patients | #11624 |
| baseline | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| dietary intake | #12057 |
| thirds | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| lung | #12208 |
| causality | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| inflammatory response | #12409 |
| switzerland | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| requires | #12540 |
| guide | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| prostatic | #12708 |
| 45 | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| oral administration | #13041 |
| instance | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| escalation | #13107 |
| cancer risk | #13107 |
| physical | #13112 |
| vomiting | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| pulmonary hypertension | #13563 |
| accurate | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| competence | #13708 |
| vascular | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| explanation | #13773 |
| pelvic | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| risk death | #14033 |
| members | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| situations | #14084 |
| focus | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| 6 patients | #14391 |
| min1 | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| renal insufficiency | #14637 |
| statistics | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| independent predictor | #14787 |
| validity | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| copd | #15201 |
| decrease | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| drug | #15278 |
| disorders | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| women age | #15474 |
| randomised controlled trial | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| examination | #15813 |
| effectively | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| discuss | #15997 |
| severely | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| prevented | #16513 |
| develop | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| cooperative | #17262 |
| lung neoplasms | #17262 |
| estimated | #17274 |
| acute phase | #17288 |
| largest | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| ventricular function | #18296 |
| metastases | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| gestational | #20050 |
| 2002 | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| elisa | #20562 |
| persistent | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| attenuated | #21137 |
| operative | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| 139 | #21894 |
| majority | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| naive | #23767 |
| adverse | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| commonly | #27411 |
| mass bmi | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
运行报告 | |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| 闻名 Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL-Index: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| 闻名 Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| 闻名 Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL-Index: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| 闻名 Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL-Index: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| 闻名 Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL-Index: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| 闻名 Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| 闻名 Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL-Index: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| 闻名 Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL-Index: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| 闻名 Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL-Index: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| 闻名 Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL-Index: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| 闻名 Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL-Index: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| 闻名 Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| 闻名 Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL-Index: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| 闻名 Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
关键人物 Pulmonary Embolism
世界顶级科尔斯
Harry Roger Büller:专家影响
哪个概念Harry Roger Büller具有直接影响:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:KOL的影响
与其他作者的工作有关的概念for which Harry Roger Büller 有影响力:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
这是您的个人资料吗？ 要求您的个人资料 复制URL 嵌入到您的个人资料的链接 |